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I. Abbreviations 
 
Amino acids:    Nucleotides: 
A Ala Alanine  A Adenosine 
R Arg Arginine  T Thymidine 
N Asn Asparagine  G Guanosine 
D Asp Aspartate  C Cytidine 
C Cys Cysteine    
Q Gln Glutamine    
E Glu Glutamate    
G Gly Glycine    
H His Histidine    
I Ile Isoleucine    
L Leu Leucine    
K Lys Lysine    
M Met Methionine    
F Phe Phenylalanine    
P Pro Proline    
S Ser Serine    
T Thr Threonine    
W Trp Tryptophan    
Y Tyr Tyrosine    
V Val Valine    
 
Abbreviations: 
A Absorption  Dab Disabled 
aa Amino acid  dd double distilled (ultrapure) 
Aβ Amyloid-β peptide   dll-G4 distalless-Gal4 
AD Alzheimer’s disease  Dly Dally-like 
ADAM A Disintegrin and Metalloprotease  HBS Hepes buffered saline 
ap-G4 apterous-Gal4  Hepes (N-2-Hydroxyethyl)-
piperazin-N'-(2-
ethansulfonic acid) 
APLP Amyloid precursor like protein  HRP Horseradish peroxidase 
APP Amyloid precursor protein  hs-Flp heat shock-Flip 
APS Ammonium peroxodisulfate  IgG Immunoglobuline 
BCA Bicinchinonic acid  IPTG Isopropyl-β-D-
Thiogalactoside 
bp base pair  kb Kilobase 
BSA Bovine serum albumine  kDa Kilodalton 
Ci Curie  LB Luria-Bertani medium 
CTF C-terminal fragment  MEM Minimum Essential 
Medium 
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MES 2-Morpholinoethane-sulfonic 
acid 
 SP Signal peptide 
min Minute  ss single stranded DNA/RNA 
MOPS 3-(N-morpholino)propane-
sulfonic acid 
 TAE Tris acetate EDTA buffer 
NFTs Neurofibrillary Tangles   TBS Tris buffered saline 
Nmb Numb  TBST Tris buffered saline with 
Tween 20 
Nmbl Numb-like  TE Tris-EDTA buffer 
NP-40 Nonidet P-40  TMEDA N, N, N', N'-Tetramethyl-
ethylendiamine 
OD Optical density  TMD Transmembrane domain 
PAGE Polyacrylamide gel 
electrophoresis 
 Tris Tris-(Hydroxymethyl)-
aminomethane 
PBS Phosphate buffered saline  Tween 20 Polyoxyethylensorbitan-
monolaurate 
PCR Polymerase chain reaction  U Enzyme units 
Pers. 
comm. 
Personal communication  UAS upstream activating 
sequence 
PFA Paraformaldehyde  3´UTR 3-prime untranslated 
region 
P.I. Preimmune serum  5´ UTR 5-prime untranslated 
region 
PLL Poly-L-Lysine  rpm Rotations per minute 
PMSF Phenylmethylsulfonylfluoride  UV Ultraviolet light 
PS Presenilin  V Volt  
RNA Ribonucleic acid  vg-G4 vestigial-Gal4 
RT room temperature  v/v Volume per volume 
s second  Wg Wingless 
S2 Schneider cells  w/o without 
SD Standard deviation  wt Wild type 
SDS Sodium dodecylsulfate  w/v Weight per volume 
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II. Summary 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting 
cognitive functions of the brain, and is pathologically characterized by extracellular 
Amyloid plaques and intracellular neurofibrillary tangles are the main pathological 
features of AD. Amyloid-β (Aβ), the main protein constituent of Amyloid plaques, is 
derived from the Amyloid Precursor Protein (APP) by proteolytic processing. APP is a 
type I transmembrane protein, which resembles a cell surface receptor, and consists 
of a large ectodomain and a short cytoplasmic tail. While Aβ generation from APP is 
well investigated, the physiological function of APP is still incompletely understood. 
Nevertheless, a diverse set of APP functions has been proposed, including cell-cell 
and cell-matrix interactions and intracellular signalling. 
In this study, the cell adhesion properties of APP and its mammalian paralogues, 
APLP1 and APLP2, were investigated in vivo and in vitro. Using Drosophila 
melanogaster as a model system, it has been shown that expression of APP, APLP1, 
or APLP2 in the Drosophila wing leads to cell adhesion defects, which was evident 
from detached cell layers and incomplete wing development. It was further revealed 
that the induced, so called blistered wing phenotype depends on the extracellular 
domain and membrane anchoring of APP, and the phenotype is additionally 
modulated by proteolytic conversion of APP. Interestingly, the most pronounced 
defects in wing development were caused by overexpression of APLP2, which were 
shown to be caused by interference of APLP2 with Wingless signaling via genetic 
interaction with the Drosophila Glypican Dally. Furthermore, using the Drosophila 
model organism, genetic interactions of the APP intracellular domain with two novel 
putative interaction partners, Numb and Disabled-2, were identified. The interacting 
domain of APP was mapped, and binding was verified by biochemical analysis. 
The results obtained with the Drosophila model system for cell adhesion properties of 
APP family proteins were extended to an in vitro cell aggregation assay, where APP, 
APLP1, or APLP2 were shown to mediate homo- and heterotypic cell interaction. The 
intercellular interaction of APP family proteins is highly specific, as a mutant of APP 
lacking the extracellular domain failed to promote cell clustering. These data strongly 
suggest that APP family proteins form trans-dimers and contribute to cellular 
interactions via formation of homo- and heterotypic, trans-cellular complexes. 
Interestingly, the in vivo phenotype strength induced by APP family proteins in 
Drosophila correlates with the cell aggregation data, suggesting that trans-cellular 
interaction of APP family proteins is crucial for both phenomena. Additionally, APLP1 
and APLP2 were shown to mediate cellular uptake of their corresponding secreted 
fragments, supporting a hitherto not observed receptor-like function. Moreover, a 
genetic interdependence and molecular interaction of APP and APLP1 in synaptically 
enriched membrane compartments was found in this study, corroborating a functional 
role for APP family proteins in the connectivity of pre- and postsynaptic membranes. 
Taken together, previously not described homo- and hetero-trans-dimerization of 
APP family proteins seems to be involved in cell adhesion and represents an 
important feature required for their physiological function.  
 Zusammenfassung 
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III. Zusammenfassung 
 
Alzheimer ist die am häufigsten auftretende neurodegenerative Erkrankung und führt 
zum zunehmenden Verlust kognitiver Fähigkeiten. Pathologisch ist die Krankheit 
durch extrazelluläre Amyloide Plaques und intrazelluläre Neurofibrillenbündel (NFTs) 
charakterisiert, welche als Ablagerungen im Gehirn auftreten. Der 
Hauptproteinbestandteil der Plaques ist das Amyloid-β (Aβ) Peptid, welches durch 
proteolytische Spaltung des Vorläuferproteins APP („Amyloid Precursor Protein“) 
entsteht. APP ist ein Typ I Transmembranprotein mit Ähnlichkeit zu 
Zelloberflächenrezeptoren, und besteht aus einer großen extrazellulären, einer 
Transmembran- und einer kurzen zytoplasmatischen Domäne. Obwohl die Aβ-
Entstehung aus APP und dessen pathologische Relevanz sehr gut untersucht sind, 
ist die physiologische Funktion von APP weitgehend unbekannt. 
In dieser Arbeit wurden die Eigenschaften von APP und den humanen Paralogen, 
APLP1 und APLP2, in Bezug auf Zelladhäsion untersucht. Hierzu wurde zum einen 
die Fruchtfliege Drosophila melanogaster als Modellsystem benutzt. Es wurde 
gezeigt, dass die Expression von APP, APLP1 und APLP2 während der 
Flügelentwicklung zu Zelladhäsionsdefekten führt. Dies konnte durch unvollständige 
Flügelentwicklung und Blasenbildung („blistered wing“ Phänotyp) durch Verlust von 
Zelladhäsion beobachtet werden. Es konnte weiterhin gezeigt werden, dass die 
Ektodomäne und die Membranverankerung von APP zur Erzeugung des Phänotyps 
notwendig sind. Außerdem wurden die Zelladhäsionsdefekte durch eine 
Prozessierungs-defiziente APP Mutante (APP-M596I/F615P) deutlich verstärkt. Für 
APLP2 konnte gezeigt werden, dass es während der Flügelentwicklung mit dem 
Wingless-Signalweg interferiert, indem es mit dem Zelloberflächen-Glypican Dally 
interagiert. Basierend auf genetischen Interaktionsanalysen in Drosophila, konnte 
nachfolgend in vitro und in vivo gezeigt werden, dass die Adapterproteine Numb und 
Disabled-2 an das zytoplasmatische NPTY-Motiv der APP Genfamilie binden 
können.  
Die Zelladhäsionseigenschaften der APP Gen-Familie  wurden zum anderen auch in 
einem zellulären System untersucht. Durch Zellaggregation konnte gezeigt werden, 
dass APP, APLP1 und APLP2 homo- und heterophil interagieren können. Diese 
Ergebnisse lassen auf eine spezifische und direkte interzelluläre trans-Dimerisierung 
der APP Genfamillie schließen, da ein APP Konstrukt ohne Ektodomäne keine 
Zellaggregation verursachte. Auffälligerweise korreliert die Stärke des 
Zelladhäsionsphänotyps in Drosophila mit den Zellaggregationseigenschaften der 
APP Genfamillie, was auf einen Zusammenhang beider Phänomene mit der trans-
Interaktion von APP, APLP1 und APLP2 hindeutet. Weiterhin wurde eine 
Rezeptorfunktion für APLP1 und APLP2 beschrieben, da beide Proteine die zelluläre 
Aufnahme ihrer eigenen sekretorischen Fragmente vermitteln. Im Mausmodell wurde 
die Interaktion zwischen APP und APLP1 bestätigt, und es konnte eine Interaktion 
der beiden Proteine in synaptischen Kompartimenten gezeigt werden. Da zudem die 
APLP1 Proteinmenge in APP „knock out“-Mäusen erhöht ist, kann auf eine 
gemeinsame Funktion während der Synaptogenese geschlossen werden.  
Zusammenfassend stellt die hier erstmalig beschriebene homo- und hetero-trans-
Dimerisierung der APP Genfamillie eine wichtigen funktionelle Eigenschaft dieser 
Proteine dar, welche für Zelladhäsion physiologisch relevant sein könnte. 
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1 Introduction 
1.1 Alzheimer’s disease 
Alois Alzheimer was the first to link the pathology with the disease severely affecting 
cognitive functions of the brain (Alzheimer 1907) that later was named after its 
discoverer, Alzheimer’s disease (AD). AD leads to progressive loss of cognitive brain 
functions, deterioration of the patient’s personality, and finally to the death of the 
patient. The main pathological features of AD are neurodegeneration, extracellular 
deposition of Amyloid plaques and vascular Amyloid, and formation of intracellular 
Neurofibrillary Tangles (NFTs) (reviewed in Selkoe 2002). The era of molecular 
biology research in AD started with the identification of the main constituent of 
vascular Amyloid and of Amyloid Plaques, that was shown to consist of a protein 
fragment with 40-42 amino acids termed Amyloid-β (Aβ40-42) (Glenner et al. 1984; 
Masters et al. 1985). Soon after, paired helical filaments (PHFs), which are 
composed of a hyperphosphorylated form of the microtubule-binding protein Tau, 
were identified as the main component of NFTs (Grundke-Iqbal et al. 1986; Kosik et 
al. 1986; Wolozin et al. 1986). Both, Aβ and Tau, have been extensively investigated 
in the following.  
In studies on genetic inheritance of AD (familiar AD, FAD), several mutations were 
discovered in genes involved in Aβ production, which in general lead to an earlier 
age of onset. FAD Mutations were found in the app, and presenilin 1 and 2 genes, all 
of which are directly involved in the generation of Aβ (reviewed in Annaert et al. 
2002). The main effect of mutations in these genes is the overproduction of Aβ42, 
which was shown to be especially prone to aggregation (Suzuki et al. 1994). 
Recently, evidence for a direct correlation of Aβ42 production and the age of disease 
onset has been elucidated for FAD mutations of presenilin 1 (Marco Düring, pers. 
comm.). The progression of AD also correlates very well with the formation of 
tangles, indicating a direct involvement of NFTs in the disease process (Delacourte 
et al. 2000). Interestingly, mutations in the tau gene are not associated with FAD, but 
cause frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-
17) instead (Lee et al. 2001). 
In the course of AD, disturbed Calcium homeostasis (reviewed in Mattson et al. 
2003), oxidative stress, and reactive gliosis are observed, and might play a major 
role in the disease process (reviewed in Small et al. 2001). Moreover, numerous 
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studies found Aβ to be toxic to neurons and to induce apoptosis. Although some 
researchers now believe that oligomeric Aβ42 is the crucial agent causing the 
disease (reviewed in Selkoe 2002), the precise molecular mechanism leading to AD 
is still unknown. Until recently, it was also unclear, whether Tau 
hyperphosphorylation and tangle formation is cause or effect of Aβ production and 
deposition, or vice versa. In the meantime, elegant studies in mouse model systems 
have shown that Aβ42 injection in the brain of Tau P301L transgenic mice can induce 
formation of PHFs (Gotz et al. 2001), which puts Aβ in the front.  
Recent therapeutic strategies (reviewed in Janus 2003) are aiming at preventing Aβ 
generation by inhibition of APP cleavage (reviewed in Dewachter et al. 2002), 
degradation of Aβ with enzymes like IDE (Qiu et al. 1998; Vekrellis et al. 2000), or 
immunization (Schenk et al. 1999), either with humanized antibodies against 
oligomeric Aβ42, or active immunization with preaggregated Aβ peptides. Some of 
these efforts have already shown promising results (Hock et al. 2002; Hock et al. 
2003), but no applicable therapy is available so far. 
1.2 Structure, expression, and processing of the Amyloid Precursor Protein 
family 
Research in the field of AD was strongly stimulated by the discovery and cloning of a 
protein precursor to Aβ, the Amyloid Precursor Protein (APP) (Kang et al. 1987). APP 
is encoded by 18 exons, of which exons 7, 8, and 15 are alternatively spliced. All 
eight variants have been shown to exist in vivo and expression of the different splice 
variants is developmentally regulated (Sandbrink et al. 1997). 
APP resembles a ubiquitously expressed cell surface receptor with a large 
ectodomain, a single transmembrane domain and a short cytoplasmic tail (Kitaguchi 
et al. 1988; Tanzi et al. 1988). The major expressed isoforms of APP consist of 695, 
751, or 770 amino acids, all of which are N- and O-glycosylated and transported to 
the cell surface through the secretory pathway (Weidemann et al. 1989). APP695 is 
predominantly expressed in neurons, while APP751 and 770 are the major species in 
peripheral tissues and glial cells (Sandbrink et al. 1994). Alternative splicing by 
omission of exon 15 generates a consensus sequence for chondroitin sulfate 
glycosaminoglycan (CS-GAG) modification, and the corresponding L-APP 
Proteoglycans have first been characterized to be expressed in Leukocytes, but are 
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also found in other peripheral cells, and to a minor extend in neurons (Sandbrink et 
al. 1993).  
 
   b 
1 9910 20 30 40 50 60 70 80(1)
---------------------MLPGLALLLLAAWTARALEVP--------TDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILAPP (1)
MGPASPAARGLSRRPGQPPLPLLLPLLLLLLRAQPAIGSLAGG-------SPGAAEAPGSAQVAGLCGRLTLHRDLRTGRWEPDPQRSRRCLRDPQRVLAPLP1 (1)
-----------MAATGTAAAAATGRLLLLLLVGLTAPALALAGYIEALAANAGTGFAVAEPQIAMFCGKLNMHVNIQTGKWEPDPTGTKSCFETKEEVLAPLP2 (1)  100 199110 120 130 140 150 160 170 180(100)
QYCQEVYPELQITNVVEANQPVTIQNWCKRGRK-QCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGAPP (71)
EYCRQMYPELQIARVEQATQAIPMERWCGGSRSGSCAHPHHQVVPFRCLPGEFVSEALLVPEGCRFLHQERMDQCESSTRRHQEAQEACSSQGLILHGSGAPLP1 (93)
QYCQEMYPELQITNVMEANQRVSIDNWCRRDKK-QCKSR--FVTPFKCLVGEFVSDVLLVPEKCQFFHKERMEVCENHQHWHTVVKEACLTQGMTLYSYGAPLP2 (89)  200 299210 220 230 240 250 260 270 280(200)
MLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEAT---APP(170)
MLLPCGSDRFRGVEYVCCPPPGTPDPSGTAVGDPSTRSWP---------------------PG-------SRVEGAEDEEEEESFPQPVDDYFVEPP---APLP1(193)
MLLPCGVDQFHGTEYVCCPQTKIIGSVSKEEEEEDEEEEEEEDEEEDYDVYKSEFPTEADLED---FTEAAVDEDDEDEEEGEEVVEDRDYYYDTFKGDDAPLP2(186)  300 399310 320 330 340 350 360 370 380(300)
---ERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKAPP(267)
-----------Q---------------AEEEEETVP---------P---------------PSS--------HTLAVVGKVTPTPRPTDG----------APLP1(262)
YNEENPTEPGSDGTMSDKEITHDVKAVCSQEAMTGPCRAVMPRWYFDLSKGKCVRFIYGGCGGNRNNFESEDYCMAVCKAMIPPTPLPTN----------APLP2(283)  
400 499410 420 430 440 450 460 470 480(400)
LPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAAPP(364)
-----------VDIYFGMPGEISEHEGFLRAKMDLEERRMRQINEVMREWAMADNQSKNLPKADRQALNEHFQSILQTLEEQVSGERQRLVETHATRVIAAPLP1(294)
----------DVDVYFETSADDNEHARFQKAKEQLEIRHRNRMDRVKKEWEEAELQAKNLPKAERQTLIQHFQAMVKALEKEAASEKQQLVETHLARVEAAPLP2(373)  500 599510 520 530 540 550 560 570 580(500)
MLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDAPP(464)
LINDQRRAALEGFLAALQADPPQAERVLLALRRYLRAEQKEQRHTLRHYQHVAAVDPEKAQQMRFQVHTHLQVIEERVNQSLGLLDQNPHLAQELRPQIQAPLP1(383)
MLNDRRRMALENYLAALQSDPPRPHRILQALRRYVRAENKDRLHTIRHYQHVLAVDPEKAAQMKSQVMTHLHVIEERRNQSLSLLYKVPYVAQEIQEEIDAPLP2(463)  600 699610 620 630 640 650 660 670 680(600)
ELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTAPP(564)
ELLHSEHLGPSELEAPAP-------GGSSEDKGGLQPPDSKDDTPMTLPKGSTEQDAASPE--------------------K--E--------KMNPLEQAPLP1(483)
ELLQ-EQRADMDQFTASISETPVDVRVSSEESEEIPPFHPFHPFPALPENEDTQPELYHPMKKGSGVGEQDGGLIGAEEKVINSK---NKVDENMVIDETAPLP2(563)  700 799710 720 730 740 750 760 770 780(700)
EEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLK-KKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYAPP(664)
YERKVNASVPRGFPFHSSEIQRDELAPAGTGVS--REAVSGLLIMGAGGGSLIVLSMLLLRRKKPYGAISHGVVEVDPMLTLEEQQLRELQRHGYENPTYAPLP1(546)
LDVKEMIFNAER--VGGLEEERESVGPLREDFSLSSSALIGLLVIAVAIATVIVISLVMLR-KRQYGTISHGIVEVDPMLTPEERHLNKMQNHGYENPTYAPLP2(659)  800 807(800)
KFFEQMQNAPP(763)
RFLEERP-APLP1(644)
KYLEQMQIAPLP2(756)  
Fig. 1.1: Schematic overview and sequence alignment of the human APP family. (a) Modular 
organization of APP family proteins consisting of a signal peptide (SP), a Cystein rich domain (CRD), 
an acidic region with Zn-/Cu-binding properties (Zn-/Cu-BD), a Kunitz-type protease inhibitor domain 
(KPI), the APP specific OX2 and Aβ domains, a carbohydrate domain (CHD), and the highly 
conserved intracellular domain (ID). Brackets indicate alternatively spliced regions. (b) Protein 
sequence alignment of APP770, APLP1, and APLP2-763. Identical (yellow), conserved (blue), or 
similar (green) amino acid residues are indicated. 
APP belongs to a large family of proteins conserved even as far as in the nematode 
C. elegans (APL-1) (Daigle et al. 1993), as well as in Drosophila melanogaster 
(APPL) (Rosen et al. 1989; Luo et al. 1990) and Xenopus laevis (xAPP) (Okado et al. 
1992). In mammals, two paralogues of APP were identified called Amyloid Precursor-
like Proteins, APLP1 and APLP2 (Wasco et al. 1992; Wasco et al. 1993). Both share 
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high sequence homology and similar protein domain organization with APP 
(reviewed in Bayer et al. 1999; Coulson et al. 2000). On the extracellular side, a 
Cystein rich domain (CRD) showing Heparin and Collagen binding properties, Zinc- 
and Copper binding domains (Zn/Cu-BD) within an acidic region, and a Carbohydrate 
domain are conserved (Fig. 1.1a). Moreover, the short intracellular domain exhibits 
the highest degree of conservation (Fig. 1.1a, b). APP and APLP2 also share an 
alternatively spliced Kunitz-type protease inhibitor (KPI) domain, while the OX-2 and 
the Aβ region are unique to APP. 
APLP1 is viewed as the ancestral member of the mammalian APP gene family, since 
it is closest to the invertebrate homologues (Coulson et al. 2000). APLP1 undergoes 
no alternative splicing and its expression is limited to neurons and some glial cell of 
the central nervous system (Lorent et al. 1995), which is also described for 
Drosophila APPL (Martin-Morris et al. 1990). APLP2 on the other hand, is 
alternatively spliced and expressed in a similar pattern as APP (Slunt et al. 1994). 
One notable difference between APP and APLP2 is that the major neuronal form of 
APLP2 with 763 amino acids contains the KPI domain (Sandbrink et al. 1997). 
In the mammalian brain, all APP family members are widely expressed in a similar 
pattern (Wasco et al. 1993; Lorent et al. 1995; Crain et al. 1996; McNamara et al. 
1998), although subcellular localization is different. Biochemical analyses have 
shown presynaptic enrichment for APP (Ferreira et al. 1993) and APLP2 (Lyckman et 
al. 1998), while APLP1 was found to be specifically localized to the postsynapse (Kim 
et al. 1995). 
APP is best investigated in regard to proteolytic generation of Aβ, which was found to 
be derived from its precursor during normal cellular metabolism (Haass et al. 1992; 
Seubert et al. 1993). In the amyloidogenic pathway, APP is cleaved by the β-site 
APP cleaving enzyme 1 (BACE1) (Hussain et al. 1999; Sinha et al. 1999; Vassar et 
al. 1999; Yan et al. 1999), resulting in the release of the soluble β-cleaved 
ectodomain (sAPPβ) (Fig. 1.2). Subsequently, the remaining C-terminal fragment is 
further processed by cleavages at the γ- and ε-sites within the transmembrane region 
(Weidemann et al. 2002), thus setting free the Aβ peptide and the intracellular 
domain (APPID). The γ-secretase complex, that consists of at least Presenilin, 
Nicastrin, Aph-1, and Pen-2 (Edbauer et al. 2003; Takasugi et al. 2003), is thought to 
be required for both, γ- and ε-cleavage. The mechanism of this unusual cleavage 
within a hydrophobic surrounding is still uncertain, but might be mediated by two 
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aspartic residues present within the transmembrane region of Presenilin (Wolfe et al. 
1999), which could execute a dual cleavage at the γ- and ε-sites (Schroeter et al. 
2003). Alternatively, APP is processed at the α-site, which precludes Aβ generation, 
and is therefore called the non-amyloidogenic pathway. Subsequently, proteolysis of 
the remaining α-C-terminal fragment by γ-secretase leads to the release of the APPID 
and a small, extracellular 3 kDa peptide (p3) (Fig. 1.2).  
 
Fig. 1.2: APP processing and comparison with Notch cleavage. APP is initially cleaved either at 
the α- or β-site releasing the large ectodomain (sAPPα/β) and a membrane retained C-terminal 
fragment (CTF) comprising 99 or 83 amino acids, respectively. The CTF is further processed by the γ-
secretase complex at the γ- and ε-cleavage sites, generating Aβ from C99 in the amyloidogenic 
pathway or p3 from C83 in the non-amyloidogenic pathway. Concomitantly, processing at the ε-site 
releases the intracellular domain of APP (ID). Notch processing reveals high similarity with APP. 
Initially, the mature Notch receptor is generated by Furin cleavage at the S1-site creating a 
heterodimer. After ligand interaction, S2-cleavage by a Metalloprotease is followed by possibly 
simultaneous processing at S3- and S4-sites by γ-secretase. The S3-cleaved Notch intracellular 
domain is further translocated to the nucleus. 
The protease activity responsible for α-cleavage is not clearly identified so far. 
Several members of the ADAM-Metalloprotease family (A Disintegrin and 
Metalloprotease family), prominently, MDC-9 (Koike et al. 1999), ADAM-10 (Lammich 
et al. 1999), and ADAM-17 (Buxbaum et al. 1998) are described to cleave APP, 
suggesting a redundant cleavage system. Processing represents another common 
feature of all APP family members, since recent evidence suggests that APLP1 and 
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APLP2 are cleaved by the same proteases as APP (Gu et al. 2001; Scheinfeld et al. 
2002; Walsh et al. 2003; Eggert et al. 2004).  
Interestingly, juxta- and intramembranous cleavage might be a universal signaling 
mechanism described as regulated intramembrane proteolysis (RIP) (Brown et al. 
2000). Quite a number of transmembrane proteins have been identified so far to be 
cleaved by Metalloproteases and the γ-secretase complex in a similar manner as 
APP family proteins (reviewed in De Strooper 2003). The most prominent example is 
the Notch receptor, a crucial mediator of cell fate decisions and boundary formation 
in development (reviewed in Selkoe et al. 2003). Notch is initially cleaved by a Furin-
like convertase at the S1-site, creating the heterodimeric, mature receptor. In 
contrast to α-cleavage of APP, S2-site cleavage of Notch by a Metalloprotease is 
only induced after ligand interaction (Delta, Jagged), which results in subsequent 
γ-secretase mediated processing at the S3- and S4-sites, similar to γ- and ε-cleavage 
of APP (Fig. 1.2). The released Notch intracellular domain is further translocated to 
the nucleus and can activate transcription of numerous developmentally important 
genes.  
1.3 Functions of APP family proteins 
Although APP has been a subject of extensive investigation for almost two decades, 
its physiological role has not been clearly defined yet. Many functions have been 
attributed to APP (summarized in (De Strooper et al. 2000; Annaert et al. 2002) and 
phenomenological investigations have supplied data for APP taking part in neuronal 
cell adhesion (Breen et al. 1991), neurite outgrowth (Allinquant et al. 1995; Qiu et al. 
1995), cell migration (Sabo et al. 2001), fibroblast growth (Ninomiya et al. 1993), and 
neural progenitor cell proliferation (Hayashi et al. 1994; Ohsawa et al. 2001; Caille et 
al. 2004). Further evidence for the notion that APP is involved in neurite outgrowth 
came from studies with APP -/- primary neuronal cultures exhibiting diminished 
neurite branching (Perez et al. 1997), and the observation that APP colocalizes with 
β1-integrin subunits in neurons (Storey et al. 1996; Yamazaki et al. 1997). However, 
the mechanism of how APP participates in these processes still remains enigmatic. 
Similarly, mouse genetic studies have not revealed a function for APP family proteins 
yet. APP knockout mice are viable and show only a mild phenotype, including 
reduced forelimb grip strength and locomotor activity (Muller et al. 1994; Zheng et al. 
1995; Li et al. 1996). Additionally, no neuronal phenotype could be observed in vivo, 
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suggesting that if APP has a crucial neuronal function, it is compensated by other 
proteins. Mouse knockouts of APLP1 or APLP2 are viable as well, while 
combinations of APLP2 -/- and APP -/- or APLP1 -/- are lethal shortly after birth. 
However, the reason for the lethality remains unknown so far (von Koch et al. 1997; 
Heber et al. 2000). Interestingly, APP and APLP1 double knockout mice are viable 
with no obvious phenotype (Heber et al. 2000) suggesting an essential function of 
APLP2 during development. These studies underline the functional redundancy of 
APP family proteins, but do not substantially support the in vitro evidence for cell 
adhesion and growth factor properties of APP, APLP1, and APLP2. 
Nevertheless, biochemical analyses have shown that APP exhibits properties of a 
cell adhesion protein, since it is strongly associated with extracellular matrix 
components (Small et al. 1992). Moreover, APP was shown to bind Heparin 
(Multhaup 1994; Multhaup et al. 1995; Williamson et al. 1995; Caceres et al. 1997; 
Clarris et al. 1997) and Collagen (Beher et al. 1996) with high affinity, and complexes 
with secreted Cerebroglycan could be isolated from rat brain (Williamson et al. 1996). 
The ectodomains of APP family proteins were also shown to bind Zinc (Bush et al. 
1994) and Copper (Simons et al. 2002), and APP is able to reduce bound Cu2+ to 
Cu+ (Multhaup et al. 1996).  
In the meantime, structural data of the N-terminal APP Heparin- (Rossjohn et al. 
1999) and Copper-binding domain (Barnham et al. 2003) are available, further 
corroborating a growth factor- or receptor-like function of APP. Recently, Fibulin-1 
(Ohsawa et al. 2001) and F-Spondin (Ho et al. 2004) have been reported to bind the 
APP ectodomain. In this context, it is of interest that APP forms cellular cis-Dimers 
(Scheuermann et al. 2001), which is reminiscent of classical receptor dimerization 
described for the EGF receptor (reviewed in Schlessinger 2002). APP-dimers could 
be crosslinked in cell lysates and dimerization seems to be mediated by the Collagen 
binding domain, and possibly also by the Carbohydrate domain (Beher et al. 1996; 
Scheuermann et al. 2001). However, it is unclear whether dimerization of APP is 
essential for ligand binding, and if dimerization could also occur between APP 
proteins present on adjacent cells.  
Another set of experimental evidence, concerning the function of APP family 
proteins, comes from studies on protein interaction with the highly conserved 
intracellular domain. The adaptor protein PAT1 binds to the basolateral sorting signal 
(BASS) of APP, and is described to influence APP processing (Zheng et al. 1998). 
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Interaction of APP with GO proteins in the brain has also been described (Nishimoto 
et al. 1993). Moreover, all APP family proteins share a common NPTY motif, which 
serves a double function. On the one hand, it is important for Clathrin mediated 
endocytosis from the cell surface (Koo et al. 1994; Perez et al. 1999), on the other 
hand it also represents the binding site for Phosphotyrosine-binding (PTB) domain 
containing proteins. PTB domains are functionally and evolutionary conserved 
modules, which play essential roles in signal transduction and protein transport (Borg 
et al. 1996). So far, Disabled-1 (Dab1) (Trommsdorff et al. 1998; Homayouni et al. 
1999; Howell et al. 1999), Shc (Russo et al. 2002; Tarr et al. 2002), JIP-1 (Matsuda 
et al. 2001; Scheinfeld et al. 2002), X11 (McLoughlin et al. 1996; Zhang et al. 1997; 
Tomita et al. 1999), and Fe65 (Fiore et al. 1995; Borg et al. 1996; McLoughlin et al. 
1996; Zambrano et al. 1997; Duilio et al. 1998; Trommsdorff et al. 1998) have been 
described to interact with the NPTY motif of at least one APP family member. Binding 
of some of these intracellular adaptor proteins also affects processing of APP. 
Prominently, X11 and Fe65 seem to have antagonizing effects. While X11 can 
stabilize the full length APP protein upon overexpression (Borg et al. 1998; Tomita et 
al. 1999; Mueller et al. 2000), Fe65 expression and binding seems to increase APP 
processing and secretion of Aβ (Sabo et al. 2001), suggesting both interaction 
partners can influence intracellular transport and function in a distinct way. 
Intriguingly, Fe65 and APP colocalize with β1-Integrins at focal complex adhesion 
sites, and increase cell motility upon overexpression (Sabo et al. 2001).  
An additional proposed function of the APPID implies nuclear translocation together 
with Fe65, where a complex of APPID, Fe65 and TIP60, a Histone-Acetyl-
Transferase, exhibits transcriptional activity (Cao et al. 2001). Similar results have 
been obtained for the APLP1 and APLP2 intracellular domains (Scheinfeld et al. 
2002; Walsh et al. 2003), while APP might additionally activate transcription in 
complex with JIP-1 (Scheinfeld et al. 2003). In vivo evidence for transcriptional 
activation of the kai1 gene by the APPID/Fe65/Tip60 complex corroborates a function 
of APP in nuclear signaling (Baek et al. 2002), although there is still some 
controversy in regard to nuclear translocation of the APPID (Kinoshita et al. 2002; Cao 
et al. 2004; Muresan et al. 2004).  
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1.4 Drosophila melanogaster as a model system for APP function and AD 
Animal model systems are of fundamental importance to understand physiological 
protein functions and disease mechanisms. Due to the well developed genetic 
methods and the availability of the complete genome sequence, Drosophila 
melanogaster is a powerful tool to elucidate protein functions and disease processes. 
Accordingly, Drosophila has already been used as a model system for several 
neurodegenerative diseases including human polyglutamine repeat diseases, 
Parkinson, Tauopathies, and Alzheimer’s disease (reviewed in Bonini et al. 2003). 
Major players in Alzheimer’s disease like the γ-secretase complex are highly 
conserved in Drosophila (Struhl et al. 1999; Ye et al. 1999; Struhl et al. 2000; Struhl 
et al. 2001; Guo et al. 2003; Takasugi et al. 2003). Moreover, questions about 
physiological properties of proteins can be addressed in the Drosophila system, due 
to the possibility to overexpress transgenes in a spatially and developmentally 
regulated manner. The gene of interest is generally cloned into a P-element vector, 
which allows chromosomal integration into the Drosophila genome by P-element 
mediated germ line transformation (Rubin et al. 1982; Spradling et al. 1982). This is 
achieved by co-injection of a Transposase and the P-element vector into w1118 
embryos. The w1118 strain carries a mutation in the white gene and therefore these 
flies have non-pigmented, white eyes. Transgenic flies of the F1 generation can 
afterwards easily be identified, due to the mini-white marker gene present on the P-
element vector leading to pigmented fly eyes, ranging from yellow to dark orange, 
depending on the site of integration.  
For transgene expression, an inducible system utilizing yeast Gal4 was developed 
(Brand et al. 1993), which prevents possible unwanted toxic effects due to 
constitutive transgene expression and allows timed and regulated overexpression. 
Many transgenic Gal4 driver lines have been created in the past, expressing Gal4 
under a variety of endogenous, tissue specific promotors. Crossing of a specific Gal4 
driver line with transgenic flies carrying the gene of interest and multiple copies of 
Gal4 responsive, upstream activating sequences (5x UAS) as a promoter, thus 
results in transgene expression in the same pattern as Gal4 (Fig. 1.3). This dual 
system allows a very detailed analysis of the impact of transgene overexpression on 
development. 
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Fig. 1.3: Gal4-inducible expression of transgenes in Drosophila in vivo. Flies carrying a 
transgene with five repeats of Gal4 responsive, upstream activating sequences (UAS) and a 
heatshock minimal promotor (hsp70) express the gene of interest after crossing with a line expressing 
Gal4 under a tissue specific promotor.  
For APP, the feasibility of such an approach has already been shown. Deletion of the 
endogenous APPL gene in Drosophila resulted in behavioral deficits in fast 
phototaxis and impaired axonal transport (Luo et al. 1992). Interestingly, 
overexpression of human APP or APPL can partially rescue the behavioral 
phenotype suggesting that APP functions are conserved from invertebrates to 
mammals and vice versa. Additionally, studies with APPL overexpressing transgenic 
lines have shown an influence on synaptogenesis at the neuromuscular junction 
(Torroja et al. 1999). APPL overexpression caused a strong increase in synaptic 
bouton numbers and changes in the synaptic structure, while APPL null mutants 
exhibited decreased bouton numbers, which strongly suggests a role for APPL in 
synaptogenesis (Torroja et al. 1999). Moreover, both deletion and overexpression of 
APPL leads to axonal transport deficits in larvae (Torroja et al. 1999), possibly due to 
impaired Kinesin mediated axonal transport (Gunawardena et al. 2001).  
Protein processing events seem to be conserved in Drosophila as well, since APPL 
is also processed in vivo (Torroja et al. 1996). However, no BACE homologue has 
been identified in flies. Nevertheless, it could be shown that a construct consisting of 
the Aβ-, the transmembrane region, and the intracellular domain of APP (SPA4CT), 
when expressed in Drosophila, leads to Aβ generation (Fossgreen et al. 1998). 
Similarly, overexpressed APP is also processed, resulting in the release of a larger 
Aβ-like fragment, which might induce neurotoxicity and neurodegeneration similar to 
Aβ (Greeve et al. 2004; Iijima et al. 2004). 
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Fig. 1.4: Drosophila wing structure and blistered wing phenotype (adapted from G. Merdes). 
The adult wing consists of single dorsal and ventral epithelial cell layers, which are held together by 
Integrin mediated cell adhesion. Interference with Integrin signaling leads to cell adhesion defects and 
detachment of dorsal and ventral cell layers evident from wing blistering. 
Overexpression of APP in the Drosophila wing induces a blistered wing phenotype by 
interfering with intercellular adhesion (Fossgreen et al. 1998). This effect was shown 
to depend on both, the intra- and extracellular domain of APP, since deletion 
constructs lacking either the C-terminal or N-terminal domain of APP induced no 
phenotype. This was the first direct evidence for a receptor-like function of APP, 
since an involvement of transmembrane signaling was suggested. The adult wing 
consists only of two epithelial cell sheets, which are held together exclusively by 
Integrin mediated adhesion (reviewed in Brown et al. 2000). Interference with Integrin 
signaling in the wing leads to detachment of the dorsal and ventral cell layer, leading 
to visible cell adhesion defects and blisters, which are sometimes filled with 
hemolymph (Fig. 1.4). Since colocalization of APP with β1-Integrin subunits has 
already been observed in neurons (Storey et al. 1996; Yamazaki et al. 1997), these 
findings suggest functional interaction of APP with Integrins. 
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2 Aim of this study 
To elucidate a physiological function of the neuronally expressed splice variants of 
human APP (695 aa), APLP1 (650 aa), and APLP2 (763 aa) in regard to cell 
adhesion, different in vivo and in vitro approaches should be applied.  
As already described, APP induced a blistered wing phenotype upon expression in 
Drosophila melanogaster, suggesting APP transmembrane signaling and 
interference of full length APP with Integrin-mediated cell adhesion (Fossgreen et al. 
1998). In this study, the corresponding APP extra- and intracellular motifs necessary 
for phenotype induction should be elucidated. For this purpose, the mapping of 
different domains, with a specific emphasis on the intracellular domain, should be 
carried out by generation of APP mutant constructs and transgenic flies. 
Furthermore, the in vivo analysis in Drosophila melanogaster should be extended to 
the APP family proteins APLP1 and APLP2, where properties of the APP paralogues 
in regard to cell adhesion should be investigated as well. Additionally, the influence of 
APP processing on the wing phenotype should be addressed by creating secretion 
deficient APP constructs, which should be tested in a cell culture system first. 
Afterwards, transgenic flies, generated for those mutant APP constructs showing the 
strongest reduction in cleavage efficiency, should be analyzed in vivo.  
In this context, intracellular adaptor proteins binding to APP should be investigated 
as well. Interaction partners like Fe65 (Sabo et al. 2001) and X11 (Borg et al. 1998; 
Tomita et al. 1999; Mueller et al. 2000) were shown to influence transport and 
processing of APP family proteins, and could thus modulate their cell adhesion 
function. Therefore, novel putative interaction proteins, found in the Drosophila 
system, should be analyzed biochemically by in vitro pulldown assays and 
coimmunoprecipitation. 
Furthermore, it has previously been shown that APP can dimerize in cells (Beher et 
al. 1996; Scheuermann et al. 2001). However, it is unclear whether dimerization of 
APP is essential for ligand binding, or if dimerization could also occur between APP 
proteins present on adjacent cells. Trans-cellular dimerization has been well 
described for different cell adhesion molecules (CAMs) like Cadherins and Nectins 
(reviewed in Takai et al. 2003). Cadherins for example, are transmembrane proteins, 
which are important Calcium dependent mediators of cell-cell adhesion in epithelial 
cells, but also involved in establishing synaptic connectivity. Different types of 
Cadherins like N-Cadherin or E-Cadherin preferentially show homophilic trans-
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dimerization, a mechanism that has been studied in detail (reviewed in Takai et al. 
2003). Since a role for APP in neuronal cell-cell adhesion has been suggested as 
well (Breen et al. 1991), the idea of trans-dimerization of APP family proteins similar 
to other CAMs is quite feasible. Therefore, a cellular assay to investigate intercellular 
ectodomain interaction of APP family proteins should be established. The results 
obtained for trans-interactions of APP family proteins should be further extended to 
the in vivo situation in mice. For this purpose, interaction of APP/APLPs should be 
analyzed in wild type and APP family knockout mice by coimmunoprecipitation, and 
synaptic localization and interaction of APP family proteins should be investigated in 
detail. 
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3 Results 
3.1 Functional analysis of APP in Drosophila melanogaster 
3.1.1 Generation and analysis of APP C-terminal deletion mutants 
Previous studies in Drosophila have shown that expression of APP in the Drosophila 
wing, interferes with cell adhesion leading to detachment of the epithelial cell layers 
and a so called wing blistering (Fossgreen et al. 1998; Yagi et al. 2000). It was 
reported that the ectodomain as well as the intracellular domain of APP are 
necessary for phenotype induction suggesting signal transduction via APP. Based on 
this evidence for transmembrane signaling of APP in the Drosophila wing, the motif 
within the APP C-terminus necessary for phenotype induction should be identified. 
For this purpose, deletion constructs mapping the C-terminal domain of APP were 
designed based on putative protein interaction motifs.  
 
Fig. 3.1: Schematic overview of the generated APP constructs. The APP695 sequence of the 
intracellular domain is shown on top and deleted or exchanged residues are highlighted. Deleted 
motifs are marked with lines and the generated APP constructs were named corresponding to the 
deleted motif or point mutation. For the APP∆CTGFP mutant, the green fluorescent protein (GFP) was 
fused to APP lacking the intracellular domain. 
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Several functional aspects of the APP intracellular domain were already known. The 
basolateral sorting sequence (BASS) was reported to regulate basolateral sorting in 
polarized MDCK cells (Haass et al. 1995), while the adjacent further C-terminal motif 
is supposed to interact with G0 proteins (Nishimoto et al. 1993). No interacting 
partner of the 668TPEER sequence is known yet, but it was shown by NMR analysis 
to contain a pre-ordered loop structure (Ramelot et al. 2000), and Thr-668 is 
specifically phosphorylated in neurons (Ando et al. 1999). Finally, the NPTY 
sequence was of special interest, since quite a number of Phosphotyrosine binding 
(PTB) domain proteins like Fe65 (Borg et al. 1996) and Dab1 (Trommsdorff et al. 
1998) have been found to interact with APP via this motif. The corresponding 
deletion constructs (APP∆BASS, APP∆G0, APP∆PEER, and APP∆NPTY) were 
generated by site directed mutagenesis of an N-terminally myc-tagged APPwt cDNA 
(Fig. 3.1). Due to its importance, additional point mutations (APPY862A, APPN684A, 
APPY687A), known to inhibit binding of PTB domain proteins like Dab1 (Howell et al. 
1999) and Fe65 (Borg et al. 1996), were created within the NPTY motif (Fig. 3.1). 
Moreover, a construct lacking the APP C-terminus except the BASS sequence (APP-
BASS∆CT), and APP without its entire intracellular domain fused to GFP (APP∆CT-
GFP), were generated to exclude possible motif redundancies in regard to phenotype 
induction, and to assure proper membrane anchoring, respectively.  
The mutant APP constructs were subcloned into the P-element vector pUAST and 
transgenic flies were generated by P-element induced germline transformation 
according to standard procedures (Rubin et al. 1982; Spradling et al. 1982).  
In order to screen for expression of the different APP mutant constructs and for 
selecting lines with similar expression levels as APPwt, the transgenic flies were 
crossed with a glass-Gal4 (gl-G4) driver line to induce transgene expression in the 
eye. Adult fly head homogenates were analyzed by SDS-PAGE and immunoblotting 
for APP with 22C11, and equal loading was confirmed by reprobing the membrane 
with an ELAV antibody (Fig. 3.2). Those transgenic lines exhibiting expression levels 
comparable to APPwt were chosen for further analysis.  
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Fig. 3.2: Western blot analysis of APP transgenic flies. Transgenic flies expressing APPwt and 
different APP mutants (as indicated) under the glass-Gal4 promoter. Extracts of 10 fly heads per lane 
were loaded and analyzed by SDS-PAGE and immunoblotted for APP with 22C11. Equal loading was 
confirmed with an anti-ELAV antibody. 
For this purpose, the different transgenic APP lines were analyzed in regard to wing 
phenotype induction by crossing with apterous-Gal4 (ap-Gal4) flies to induce 
expression in the dorsal compartment of the wing epithelium early in development.  
As described previously with other Gal4 driver lines (Fossgreen et al. 1998), APPwt 
expression induced a blistered wing phenotype, evident from detachment of the 
dorsal and ventral cell layers, while no major phenotype was observed in control flies 
(Fig. 3.3). Unexpectedly, all generated transgenic lines expressing mutant APP 
constructs were still able to induce a phenotype to a similar extend as APPwt 
(Fig. 3.3). Though some variation in phenotype strength was observed, possibly due 
to slightly different expression levels or other secondary effects, even complete 
truncation of the APP intracellular domain in APP∆CTGFP expressing lines did not 
abolish phenotype induction (Fig. 3.3). These findings led to the conclusion that the 
APP intracellular domain is dispensable for phenotype induction. However, there 
might be some influence on phenotype strength by the BASS sequence, given that 
APP∆BASS and also APP∆CTGFP expressing flies displayed a weaker phenotype 
compared to APPwt. Moreover, APP∆BASS expressing lines were the only to survive 
when the gene dosage of APP was increased (G. Merdes, pers. comm.).  
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Fig. 3.3: APP induced blistered wing phenotypes. Generated transgenic fly lines carrying APP 
deletion constructs described in Fig. 3.1 were crossed with ap-Gal4 lines at 28 °C, leading to 
expression in the dorsal wing compartment. Loss of cell adhesion is indicated by arrowheads.  
This would be consistent with basolateral sorting of APP in the Drosophila wing, as 
apically transported APP presumably cannot contribute to the phenotype. 
Nevertheless, membrane anchoring of APP is a prerequisite, since secreted APP 
(sAPP) did not induce a phenotype (G. Merdes, pers. comm.). Improper membrane 
retention or lower expression levels of the APP∆CT construct used in the study of 
Fossgreen and colleagues might have been the reason for not observing a 
phenotype.  
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3.1.2 Generation and analysis of secretion defective APP constructs 
Since membrane anchoring seemed to play an important role and APP was shown to 
be processed in Drosophila in vivo (Fossgreen et al. 1998), it was hypothesized that 
the phenotype might be influenced by processing. So far, no BACE equivalent was 
identified in Drosophila, but Metalloproteases with α-secretase-like properties (Lieber 
et al. 2002) and the γ-secretase complex are conserved (Takasugi et al. 2003). Since 
α- or β-cleavage is thought to be a prerequisite for γ-cleavage (Struhl et al. 2000), 
mutations at those sites aimed at inhibiting proteolysis should stabilize full length 
APP, and increase its potency to induce wing blisters in vivo. Several mutations at 
the α- and β-sites of APP were already shown to reduce cleavage efficiency (Sisodia 
1992; Citron et al. 1995). However, a complete inhibition of α-cleavage of APP is 
difficult to achieve, since α-secretase acts with low sequence specificity and a helical 
substrate conformation is supposedly the only requirement for efficient cleavage 
(Sisodia 1992). The APP point mutations described to have the strongest effect are 
single amino acid exchanges at V614G and F615P for α- (Sisodia 1992), and at 
M596I for β-cleavage (Citron et al. 1995). Equivalent constructs and additionally, 
combinations thereof were generated by site directed mutagenesis and cassette 
cloning with N-terminally myc-tagged APPwt cDNA as a template (see Fig. 3.4). To 
reduce α-cleavage efficiency by electrostatic repulsion, a further construct was 
generated by substituting eight amino acids at the α-cleavage site with Aspartates 
(APP-D8). Finally, APP constructs with larger deletions comprising the β-cleavage 
site (APPsd) or additionally, the extracellular region of the Aβ domain (APP∆F616, 
APP∆S622), were generated (Fig. 3.4). All constructs were subcloned into the 
pUAST vector and verified by sequencing. 
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Fig. 3.4: Overview of the generated APP secretion deficient constructs. The APP695 sequence 
of the Aβ region is shown on top and deleted or exchanged residues are highlighted. The generated 
APP constructs are schematically shown and the deleted motifs are marked with lines. Additionally, 
positions of α-, β-, and γ-cleavage sites are indicated. All APP constructs were named according to the 
deleted motifs or the APP sequence position and amino acid exchange by point mutation. 
To test whether the designed APP constructs are indeed less efficiently cleaved, 
expression and secretion was analyzed in cell culture. Since the processing effect 
should be tested in vivo afterwards, one criterion for the cell culture system was that 
it should resemble the in vivo situation in Drosophila as close as possible. Therefore, 
Schneider (S2) cells were chosen, in view of the fact that they express α- and γ-site 
cleaving enzymes (Fossgreen et al. 1998).  
To allow efficient use of the pUAST-APP plasmids in S2 cells, the same dual Gal4 
system used for transgene expression in vivo was utilized (Klueg et al. 2002). 
Therefore, Gal4 cDNA was PCR-amplified and cloned into a pMT-TOPO vector, thus 
allowing Cu2+-inducible high level expression of Gal4 under control of the 
Metallothionine promoter. 
S2 cells were transiently cotransfected with pMT-Gal4 and the different pUAST-APP 
constructs and expression of Gal4 and thus APP was induced 48 h after transfection 
with 500 µM CuSO4. The media were exchanged 16 h after induction and fresh 
media were added and conditioned for 3 h. Conditioned media were then cleared 
from cell debris, and sAPP was immunoprecipitated with antibody 22734. Likewise, 
cell lysates were prepared from the transfected cells and all samples were analyzed 
by SDS-PAGE and immunoblotted with 22C11. The experiment was repeated at 
least three times for all APP mutant constructs with APPwt as a control. 
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Fig. 3.5: Analysis of sAPP secretion from APP wt and mutant constructs. Cellular and medium-IP 
samples from transfected S2 cells (as indicated) were subjected to SDS-PAGE and immunoblotted 
with 22C11. Densitometric quantification of sAPP and cellular APP levels was performed, and 
secretion of sAPP was normalized to cellular APP levels. The ratio of sAPP secretion to APPwt was 
further normalized to one and relative ratios are shown for each construct analyzed (as indicated) 
(n≥3, ±SD). 
Quantification of sAPP secretion relative to cellular APPwt amounts revealed that 
APP∆F616 and APP∆S622 showed a significant reduction in sAPP generation, while 
APPsd led to a 1.5 fold stronger secretion. The strongest sAPP reduction of 60-70 % 
was observed for APP-D8 and APP-F615P/M596I. The V614G mutation in APP had 
no effect on secretion, and combinations with F615P or F615P/M596I did not alter 
their properties in regard to cleavage efficiency. Interestingly, the β-cleavage site 
mutation M596I also significantly affected sAPP generation strengthening the 
secretion defect of F615P, and especially of V614G. This result is somehow 
surprising, since no cleavage at this site would be expected in Drosophila due to the 
lack of a BACE homologue. Additionally, an APP/APLP2 chimeric construct was 
analyzed, where the APP Aβ- and ID-domains were substituted by the corresponding 
APLP2 region. This chimera has been used in previous studies and shown to induce 
a stronger phenotype compared to APPwt (Fossgreen et al. 1998). APP/APLP2 
displayed a significantly reduced secretion efficiency of about 80 %.  
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The generated secretion defective APP constructs were also investigated in COS-7 
cells to verify if the effects observed in S2 cells are comparable to a mammalian cell 
culture system. The observed reduction in secretion of the corresponding APP 
mutant constructs was very similar to S2 cells (data not shown), suggesting related 
cleavage preferences in the mammalian system and Drosophila. 
3.1.3 In vivo analysis of APP-M596I/F615P transgenic flies 
The influence of APP processing on phenotype strength in vivo was investigated in 
the following, since the APP/APLP2 chimeric construct exhibited significantly reduced 
secretion and concomitantly stronger phenotype transduction. If secretion deficiency 
indeed leads to increased phenotype strength in vivo, then a significant effect would 
be expected for APP-D8 and APP-M596I/F615P. Transgenic lines were generated 
with APPsd, APP∆F616, APP∆S622, and APP-M596I/F615P, due to their differences 
in secretion compared to APPwt. 
A complete analysis has so far been performed for APP-M596I/F615P. Several 
independent transgenic APP-M596I/F615P lines and APPwt flies were crossed with 
ap-G4 to analyze the wing phenotype, and additionally with glass-G4 to determine 
the expression levels. For expression analysis, the transgenic fly lines crossed with 
glass-G4 were subjected to SDS-PAGE, and immunoblotted with an antibody against 
the C-terminal domain of APP (CT-13) to visualize C-terminal fragments (CTFs), as 
well as full length APP. Reprobing with an anti-ELAV antibody was performed to 
normalize the expressed mutant transgenes to APPwt levels (Fig. 3.6a). Most APP-
M596I/F615P lines exhibited similar expression levels of full length APP compared to 
APPwt, while the amounts of cleaved CTFs were strongly reduced. Quantification of 
CTF levels of all tested lines showed a highly significant reduction of 65 % for the 
APP-M596I/F615P CTF compared to wild type (Fig. 3.6b). Interestingly, almost all 
tested lines of APP-M596I/F615P were able to induce far stronger phenotypes than 
APPwt (Fig. 3.6c). Wing development was massively disturbed and led to complete 
loss of adhesion between ventral and dorsal cell layers with incomplete unfolding of 
the wing, which was never observed for APPwt expressing flies under the same 
conditions. For example, the transgenic APP-M596I/F615P lines 4 and 12 displayed 
comparable expression to APPwt flies, but had a far higher impact on wing blistering 
(Fig. 3.6c). 
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Fig. 3.6: Expression and phenotype analysis of APP-M596I/F615P transgenic flies. (a) 
Expression of the different transgenic lines (as indicated) was determined by crossing with the 
glass-G4 driver line. Fly head homogenates of 10 fly heads per line were lysed in sample buffer, 
followed by SDS-PAGE analysis and immunoblotting with 2213. Signal intensities of full length and 
CTF bands were quantified densitometrically and normalized by reprobing with an αELAV antibody as 
a loading control. Signal intensities of the mutant full length APP and CTFs are shown relative to 
APPwt. (b) Relative, average CTF amount of the analyzed APP-M596I/F615Plines compared to 
APPwt. (n=8, ±SD); (c) w1118 control, APPwt, and APP-M596I/F615P transgenic flies were crossed 
with ap-G4 at 28 °C and assayed for wing blistering. Phenotypes for APPwt and APP-M596I/F615P 
line 4 and 12 are shown. 
Taken together, these results show that reduced processing of APP correlates 
directly with the strength of the blistered wing phenotype, suggesting that membrane 
retained, non-cleaved APP is interfering in the cell adhesion process of dorsal and 
ventral cell layers in the Drosophila wing. 
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3.2 Functional analysis of APLP2 in Drosophila melanogaster 
3.2.1 APLP2 induced wing notching 
The mammalian APP paralogues APLP1 and APLP2 are thought to have redundant 
functions, which can be deduced from comparable protein domain organization 
(Coulson et al. 2000) and mouse knockout studies (von Koch et al. 1997; Heber et al. 
2000). In order to analyze their properties regarding cell adhesion in comparison to 
APP in the Drosophila model system, transgenic flies expressing APLP1 and APLP2 
were generated. Intriguingly, both family members showed far stronger wing 
phenotypes than APP when crossed with ap-Gal4, leading to incompletely developed 
wing structures and increased pupal lethality (data not shown). Particularly, APLP2 
expression caused major abnormalities suggesting massive interference with cell 
adhesion, but due to the severity of the phenotype, it could not be classified.  
Therefore, Gal4 driver lines with different expression patterns in the wing were 
screened for displaying a specific phenotype with APLP2. Although some of the 
crossed lines showed cell adhesion defects as well, APLP2 expression rather 
induced wing margin notches than blisters. Especially, expression of APLP2 in the 
posterior wing compartment (engrailed-Gal4, en-G4), in the central wing pouch 
(distalless-Gal4, dll-Gal4), or at the wing margin (vestigial-Gal4, vg-G4), caused 
strong wing notching effects, and additionally, aberrant wing vein formation (Fig. 3.7). 
The induced phenotypes correspond with the expression pattern of APLP2 and are 
reminiscent of loss of function mutations in the Notch receptor and Wingless 
pathways. Both signaling pathways co-operate in wing patterning and are particularly 
important for dorsal-ventral boundary formation during wing development (Ng et al. 
1996; Milan et al. 2003). Loss of Wingless or Notch signaling leads to severe wing 
margin defects due to loss of the boundary signal suggesting that APLP2 expression 
is interfering with these developmental pathways. On the one hand, the APLP2 
phenotype could be due to interference with Notch-ligand interaction, processing or 
downstream events. On the other hand, disturbed Wingless distribution, secretion, or 
uptake would lead to similar effects. These possible mechanisms of APLP2 induced 
wing notching were addressed in the following. 
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Fig. 3.7: APLP2 expression in the Drosophila wing causes margin notches. (a) Classification of 
adult wing regions in hinge, anterior and posterior wing blade, wing margin including sensory bristles, 
and wing veins (b)w1118 control or APLP2 transgenic flies were crossed with en-G4 (posterior wing 
compartment expression), dll-G4 (wing pouch expression), or vg-G4 (wing margin expression), 
respectively. Observed wing phenotypes at the indicated temperatures are shown. 
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3.2.2 Analysis of dorsal-ventral boundary formation in larval imaginal wing 
discs expressing APLP2 
In order to investigate if Notch signaling is impaired due to APLP2 expression during 
development, the wing anlage of Drosophila larvae was examined. In imaginal discs, 
the precursor tissue in larvae, from which the wing develops, Wingless and Notch 
signaling are required for dorsal-ventral boundary (DVB) formation, to define the 
dorsal and ventral cell layers of the adult wing (Neumann et al. 1996). Notch 
signaling can be indirectly monitored by immunostaining of Cut. Cut is a homeobox-
containing transcription factor, whose expression is induced by Notch signaling 
exclusively at the DVB. (Micchelli et al. 1997). For this purpose, the effect of APLP2 
expression in the posterior wing disc compartment (en-G4) or the wing pouch (dll-G4) 
on DVB formation was analyzed by immunostaining of Cut in third instar wing discs. 
UAS-APLP2 transgenic flies were recombined with en-G4 to get stable lines 
expressing APLP2 in the posterior wing compartment during development. Several 
recombinant lines were generated and the one with the strongest phenotype was 
used in the following experiments (depicted as en-G4 APLP2). En-G4 APLP2 was 
crossed with UAS-EGFP flies to facilitate visualization of the transgene expressing 
domain. Additionally, UAS-EGFP and UAS-APLP2 were crossed with dll-G4 flies, 
since a strong wing notching effect was observed with this driver line as well (see 
Fig. 3.7). Immunohistochemical analysis of imaginal discs revealed that expression of 
APLP2 in the posterior part of the wing disc abrogated Cut expression, 
corresponding with the APLP2 pattern visualized by GFP (Fig. 3.8b). The wing discs 
additionally exhibited deformation of the posterior, APLP2 expressing compartment. 
Wild type wing discs in contrast, displayed normal DVB formation and 
compartmentalization (Fig. 3.8b). Similarly, expression of APLP2 under dll-Gal4 
control bisected the DVB in the wing pouch, where it was shown to have the highest 
expression visualized by αAPLP2 staining with CT-12. Again, the disc tissue 
appeared to be distorted, since the APLP2 expressing domain was condensed 
compared to wild type discs (Fig. 3.8c). These results suggest that APLP2 can 
interfere with Notch signaling at the DVB, and at the same time induce tissue 
deformation of the expression domains.   
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Fig. 3.8: APLP2 expression affects DVB formation in wing discs. (a) Schematic organization of a 
third instar imaginal wing disc. Compartmentalization is described by boundary formation along the 
anterior/posterior and dorsal/ventral axis. For visualization of the dorsal-ventral boundary (DVB), 
immunostaining with an αCut antibody was used. (b) Third instar wing discs from larvae, expressing 
GFP (en-G4xUAS-GFP) or GFP and APLP2 (en-G4 APLP2xUAS-GFP) in the posterior disc 
compartment, were immunostained with an αCut antibody to visualize the DVB. (c) Third instar wing 
discs from larvae expressing GFP (dll-G4xUAS-GFP) or APLP2 (dll-G4xUAS-APLP2) in the wing 
pouch were immunostained with an αCut antibody and CT-12 for APLP2 Cut immunostaining is also 
detected at the notum and hinge regions. Average projections of z-stack confocal sections are shown. 
Scale bar equals 30 µm. 
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3.2.3 Influence of mosaic expression of APLP2 on DVB formation and Notch 
signaling 
Despite the apparent effect of APLP2 on Cut expression and thus Notch signaling, it 
was still unclear whether APLP2 interfered by binding to a member of the Notch 
pathway itself, or possibly inhibited Notch processing by substrate competition for α- 
or γ-secretase. Moreover, the nature of the APLP2 induced effect still remained 
enigmatic, since it could not be clarified, at which time point during imaginal disc 
development DVB formation was inhibited, due to the early expression onset of 
en-G4.  
To address these questions, mosaic expression of APLP2 in wing discs was utilized 
to analyze if APLP2 expression at the DVB inhibits its formation and thus Notch 
signaling at later time points. For this purpose the Flp-Recombinase-FRT system was 
used, which allows statistical generation of expression clones during larval 
development (Duffy et al. 1998). In addition, GFP was coexpressed as a marker of 
APLP2 expressing clones. Imaginal discs of positive larvae were dissected and 
stained with αCut and αAPLP2 (CT-12) antibodies.  
When APLP2 expressing clones at the DVB were analyzed, it became evident that 
Cut expression was not affected and only slight distortions of the boundary signal 
could be detected (Fig. 3.9a). Generally, a very low efficiency of clone induction was 
observed when expressing APLP2, indicating that some clonal cells might be 
eliminated. These results suggested that APLP2 does not affect Notch signaling at 
the DVB directly, at least not if expressed at later developmental time points. 
Additionally, it was analyzed if APLP2 can compete with Notch for γ-secretase 
processing. Accordingly, S2-precleaved Notch (NS2) or the Notch intracellular domain 
(NID), were coexpressed with APLP2 in clones. NS2 clones alone efficiently induced 
ectopic Cut expression, since it is a direct γ-secretase substrate and the released NID 
can ectopically activate its target, Cut. Clonal coexpression of APLP2 did not 
abrogate this effect showing identical intensity of ectopic Cut immunostaining 
(Fig. 3.9b). Similarly, APLP2 did not interfere with NID induced ectopic Cut expression 
(Fig. 3.9b).  
These observations indicate that APLP2 does not interfere with γ-secretase 
processing or downstream events of Notch signaling. Notably, coexpression of 
UAS-BACE with en-G4 APLP2 rescued the wing notching phenotype (data not 
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shown). This result suggests that BACE can cleave APLP2 in vivo, and additionally 
argues against competition of APLP2 for endogenous α- or γ-secretase activity. 
 
Fig. 3.9: Clonal expression of APLP2 and Notch in imaginal wing discs. (a) APLP2 expressing 
clones are marked by GFP and immunostained with CT-12 (αAPLP2); the DVB was visualized with an 
αCut antibody. (b) Clonal expression of S2-cleaved Notch (NS2), NS2 and APLP2, or NIC and APLP2 
was induced by a heat shock 48h after egg laying. Expression clones are visualized by GFP and an 
αCut antibody was used to visualize the DVB and ectopic Notch activation. Average projections of z-
stack confocal sections are shown. Clones relevant for this analysis are highlighted by a surrounding 
dashed line. Scale bar equals 30 µm. 
In accordance with the observation of low efficiency induction of APLP2 clones, more 
clones expressing NS2 or NID only were present compared to coexpression with 
APLP2 (Fig. 3.9b). This result suggested that a part of the APLP2 expressing clonal 
cells are eliminated via apoptosis, leading to decreased clone numbers. In summary, 
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these data indicate a more complex mechanism of APLP2 action during wing 
development. 
3.2.4 APLP2 induces wing disc compartment shrinkage 
To further investigate the effect of APLP2 on compartmentalization of imaginal wing 
discs, expression of genes important for cell identity and compartmentalization were 
analyzed. Expression of apterous (ap), a Zink-finger protein essential for defining the 
dorsal compartment (Cohen et al. 1992), vestigial intron2 (vgI2), supposedly a direct 
target of Notch signaling (Neumann et al. 1996), and wingless (wg), a morphogen 
required for boundary formation and cell proliferation (Ng et al. 1996), were analyzed. 
Corresponding lines expressing lacZ under control of the endogenous promoters of 
ap, vgI2, and wg were crossed with eng-G4 APLP2 or eng-G4 only. 
Apterous visualized by LacZ was not perturbed by APLP2 expression in the posterior 
wing disc compartment, indicating that the dorsal identity of the cells was not 
affected. Similarly, vgI2 and also Wg expression marking the DVB was not 
interrupted by APLP2 expression (Fig. 3.10a-c).  
However, for all three LacZ lines, strong size reduction of the APLP2 expressing 
posterior compartment was observed compared to the anterior part or control 
(Fig. 3.10a-c). About 50 % reduction in size of the posterior compartment was 
evident upon APLP2 expression (see Fig. 3.10d), probably due to cell loss early in 
wing disc development. The observed phenomenon would correspond with a 
posterior wing notching phenotype due to compartment shrinkage. Moreover, this 
result further corroborates that APLP2 expression does not directly affect Notch 
signaling in the wing, but causes early cell loss, possibly via apoptosis, instead. 
Nevertheless, it still remains to be clarified, why Cut expression is lost upon APLP2 
expression early in development, even though the vgI2 pattern seems to be 
unchanged. 
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DVB, wing pouch, and notum. The width of anterior (A) and posterior (P) compartments is indicated by 
bars with double arrows. Scal bars equal 30 µm; (d) Schematic depiction of imaginal wing discs and 
size reduction of the posterior disc compartment upon APLP2 expression. Division into dorsal, ventral, 
anterior, and posterior is achieved by formation of dorsal-ventral and anterior-posterior boundaries 
respectively. The width of anterior (A) and posterior (P) compartments is indicated by bars with double 
arrows.  
 
Fig. 3.10: APLP2 expression in the posterior 
compartment affects its size. En-G4 and en-
G4 APLP2 flies were crossed with (a) ap-lacZ, (b) 
vgI2-LacZ, or (c) wg-LacZ, respectively. LacZ 
expression was visualized with an αLacZ 
antibody. Average projections of z-stack confocal 
sections are shown. Scale bar equals 30 µm. (a)
apterous expression in the dorsal compartment; 
(b) vgI2 as a direct target of Notch signalling, was 
expressed at the DVB;  (c) Wg  expression  at the
 Results 
 31
3.2.5 Enhancement of APLP2 induced wing notching 
A further aim of this study was to unveil the APLP2 domain responsible for induction 
of wing notches. Since no transgenic flies with APLP2 deletion constructs were 
available at that time, the ability of other APP family members to enhance the APLP2 
phenotype was investigated. Combinations of en-G4 APLP2 with APP, APLP1, the 
Drosophila orthologue APPL and APPLsd, a mutant thereof, were analyzed 
(Fig. 3.11 and data not shown). APPLsd is lacking 33 residues of the extracellular 
juxtamembrane region around the putative α-cleavage site and was described to be 
secretion deficient (Torroja et al. 1996). 
 
Fig. 3.11: Enhancing APLP2 induced wing notching. En-G4 APLP2 flies were crossed with w1118 
control, or different transgenic APPLsd lines, and analyzed in regard to wing notching. Phenotype 
enhancement was observed for all lines except APPLsd∆E2. 
The only line able to enhance the APLP2 wing notching phenotype was APPLsd 
(Fig. 3.11). While APPL overexpression induced no or only a marginal wing 
phenotype, APPLsd was far more potent and induced strong phenotypes with various 
Gal4 lines (data not shown). Since transgenic flies carrying extra- and intracellular 
deletion constructs of APPLsd were available, these lines were crossed with en-G4 
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APLP2 at 25 °C. Intracellular deletions of APPLsd, either of the NPTY motif 
(APPLsd∆NPTY) or the whole domain (APPLsd∆ID), did not abrogate phenotype 
enhancement (Fig. 3.11). Slight variations in phenotype enhancement were probably 
due to different expression levels. On the extracellular side, lines with APPLsd 
deletions covering the two major conserved domains of the APPL ectodomain 
showed differential effects. While deletion of the most N-terminal domain 
(APPLsd∆E1) still displayed phenotype enhancement, only a minor effect was 
present upon APPLsd∆E2 expression, where most of the Carbohydrate domain of 
APPL was deleted (Fig. 3.11). No major effect of the APPLsd lines on the APLP2 
induced wing vein phenotype was observed.  
Transferred to APLP2, these results suggest that the intracellular domain is 
dispensable for inducing wing notches, while there is a possible involvement of the 
APLP2 carbohydrate domain, since it is highly conserved in APPL as well. Similarly 
to sAPP, sAPLP2 expressing lines did not enhance wing notching (data not shown), 
corroborating that membrane anchoring is also important for efficient APLP2 
phenotype induction.  
3.2.6 Rescue of APLP2 induced wing notching 
In order to elucidate the mechanism of APLP2 induced wing notching, a search for 
genetic modifiers of the APLP2 phenotype should identify a possible mechanism and 
additional interacting factors. Enhancer-Promoter (EP) element lines are a very 
useful tool for such a purpose, since they were developed for screening gain of 
function mutants by miss-sense or overexpression (Rorth 1996). EP elements are 
preferentially integrated in the 5´ UTR region of genes and contain enhancer 
sequences and an Hsp70 promoter allowing Gal4 induced overexpression of the 
endogenous gene in a spatial and tissue specific manner. An EP-element 
enhancer/suppressor screen has already been conducted for the APP induced 
blistered wing, where several lines modulating the APP phenotype have been 
identified (G. Merdes, unpublished results). Additionally, EP lines from a screen for 
genetic modifiers of Drosophila bristles formation were also employed (Abdelilah-
Seyfried et al. 2000), since APLP2 is inducing bristles transformation as well (G. 
Merdes, pers. comm.). Overall, about 70 different EP-lines were crossed with 
en-G4 APLP2 and analyzed for modulation of the APLP2 phenotype. Although no 
enhancers of APLP2 induced wing notching were identified, four independent EP-
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lines were able to suppress the phenotype. Two of the identified suppressor lines 
carried P-element insertions in the 5´-UTR of the dally gene (E11-Dally), presumably 
leading to overexpression of Dally (G. Merdes, pers. comm.). Both lines showed 
strong suppression of the APLP2 phenotype and approx. 90 % of all hatched flies 
showed wild type wing morphology (Fig. 3.12). Dally belongs to a family of GPI-
anchored Proteoglycans homologous to mammalian Glypicans, which are involved in 
morphogen signaling and essential for tissue patterning (reviewed in Filmus et al. 
2001). 
Another EP-line identified as a suppressor carried an insertion within the perlecan 
gene (L11x-Perlecan) and has previously been shown to suppress APP induced wing 
blistering (G. Merdes, unpublished results). L11x-Perlecan line showed a rescue for 
about 50 % of the APLP2 notched wing flies (Fig. 3.12). Crossings of the EP-lines 
with en-G4 itself, did not exhibit a phenotype, besides weak vein abnormalities with 
E11-Dally (Fig. 3.12). 
 
Fig. 3.12: Rescue of APLP2 induced wing notching. EP-lines and w1118 control flies were crossed 
with eng-G4 or en-G4 APLP2 at 25 °C, respectively. Flies were analyzed for phenotype enhancement 
or suppression. The suppressing lines E11-Dally and L11x-Perlecan are shown. 
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Similarly, an EP line identified to overexpress an endogenous micro-RNA with anti-
apoptotic properties (bantam) (Brennecke et al. 2003), was also able to suppress 
APLP2 induced wing notching almost completely (data not shown).  
The combined data of the suppressor lines provides evidence for interference of 
APLP2 with morphogen signaling and cell matrix adhesion, thereby possibly leading 
to apoptosis. The wing notching effect of APLP2 was suppressed by these EP lines, 
suggesting that APLP2 is genetically interacting with Dally and Perlecan, while the 
anti-apoptotic bantam can also restore wild type wing morphology. 
3.2.7 Genetic interaction of APLP2 and E11-Dally 
Since APLP2 showed strong genetic interaction with the E11-Dally EP-line, this line 
was investigated in more detail. Dally is a GPI-anchored cell surface Proteoglycan 
known to participate in morphogen signaling, presumably by acting as a low affinity 
co-receptor and thereby shaping the morphogen gradient (Baeg et al. 2001). 
Moreover, Dally is supposed to be essential for uptake of Wingless by the Frizzled 
receptor (Lin et al. 1999). 
Since Dally EP-flies showed efficient APLP2 phenotype suppression, and due to its 
involvement in morphogen signaling, Wingless (Wg) distribution was analyzed in 
these lines. Imaginal wing discs from en-G4 control or en-G4 APLP2 flies, crossed 
either with E11-Dally or w1118 flies, were prepared from third instar larvae. 
Immunostaining of control imaginal discs displayed the expected wingless distribution 
at the notum, the DVB, and surrounding the wing pouch (Fig. 3.13a). In contrast, 
en-G4 APLP2 imaginal discs exhibited broadening of the Wg signal in the posterior 
compartment (Fig. 3.13a). This phenotype was partially suppressed by co-
expresssion of E11-Dally. However, the Wg distribution pattern was still enlarged at 
the DVB suggesting a more diffuse gradient (Fig. 3.13a). In order to investigate the 
extracellular Wg gradient only, the primary antibody against Wg was incubated with 
dissected imaginal discs before fixation, followed by post-fixation immunostaining of 
APLP2. The extracellular Wg (ec-Wg) gradient in the posterior section of 
en-G4 APLP2 imaginal discs was strongly disturbed, with ec-Wg being widely 
distributed in the whole compartment (Fig. 3.13b). In contrast, coexpression of 
E11-Dally largely restored normal ec-Wg distribution, although the gradient was still 
broadened compared to the unaffected, anterior compartment (Fig. 3.13b). 
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Nevertheless, restoration of the Wg gradient was apparently sufficient to regain 
normal wing morphology, as observed for hatched adult flies (see Fig. 3.12).  
 
Fig. 3.13: Distribution of total and extracellular Wg in imaginal wing discs expressing APLP2 
and E11-Dally. (a) Immunostaining of total Wg in control, en-G4 APLP2, and eng-G4 APLP2/E11-
Dally imaginal wing discs. Single channels and overlays with the transmission images are shown. (b) 
Immunostainings of extracellular Wg (ec-Wg) and APLP2 (CT-12) in en-G4 APLP2 and en-G4 
APLP2/E11-Dally imaginal wing discs. The affected regions with disturbed Wg distribution are 
indicated by arrowheads. Average projections of z-stacks of single channels and overlays with the 
transmission images are shown. Scale bars equal 30 µm. 
These results suggest that APLP2 disrupts normal Wg distribution, probably leading 
to increased diffusion. This might be caused by interference with endogenous Dally, 
possibly via direct interaction, and thus preventing Wg binding and signaling. 
Transgenic lines with UAS-Dally and with the Dally homologue, UAS-Dally-like (Dly) 
were also analyzed to confirm the results obtained with the EP-line. While 
overexpression of Dally alone led to strong margin defects similar to APLP2, no 
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rescue of the APLP2 phenotype could be observed (data not shown). This might be 
explained by Dally being overexpressed high above APLP2 levels, since quite 
probably a very sensitive equilibrium is needed to achieve a phenotype rescue. 
Interestingly, UAS-Dly expressed under the control of en-G4 led to embryonic 
lethality (data not shown). This might be due to the embryonic activity of the 
engrailed promoter, where Dly is critically involved in Hedgehog signaling 
(Desbordes et al. 2003). However, crossings with en-G4 APLP2 were able to rescue 
embryonic lethality of UAS-Dly flies (data not shown), strongly suggesting interaction 
of APLP2 with Dly as well. 
3.2.8 Influence of E11-Dally on APLP2 processing in vivo 
Since the results above indicated direct interaction of APLP2 and Drosophila 
Glypicans, and APP processing was already shown to influence phenotype strength, 
the effect of Dally on APLP2 processing in vivo was analyzed. Therefore, imaginal 
wing discs expressing E11-Dally, APLP2, or both, under the control of en-G4, were 
dissected together with control discs and analyzed by SDS-PAGE. Full length and 
CTFs of APLP2 were detected by immunoblotting with D2-II and CT-12, respectively. 
For comparison, APLP2 expressing COS-7 cells were analyzed in parallel. As shown 
in Fig. 3.14, Dally expression did not alter CTF or full length levels of APLP2 in 
imaginal wing discs. This demonstrates that the E11-Dally line is not affecting APLP2 
processing in vivo, clearly suggesting that suppression of the APLP2 phenotype is 
not due to altered proteolytic conversion.  
Taken together, these results support the view that APLP2 expression in the 
Drosophila wing induces wing notching by binding of APLP2 to Dally, and thereby 
disturbs Wg signaling. This presumably leads to apoptosis and size reduction of the 
expressing compartment. 
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Fig. 3.14: Influence of the E11-Dally line on APLP2 processing in vivo. Five dissected imaginal 
wing discs per crossed line (as indicated) from third instar larvae were denatured and subjected to 
SDS-PAGE and western blotting. For comparison, APLP2 expressing COS-7 cells were analyzed in 
parallel. Full length APLP2 was detected with D2-II, C-terminal fragments (CTFs) with CT-12. 
Asterisks indicate unspecific cross-reactive signals. 
3.3 Interaction partners of the APP intracellular domain 
3.3.1 APP binding to Drosophila PTB adaptor proteins 
In this work it has been shown that the intracellular domain of APP and APLP2 as 
well, is dispensable for wing phenotype transduction. Nevertheless, overexpression 
of APP family proteins can also induce phenotypes in other tissues during Drosophila 
development. Interestingly, APP, APLP1, or APLP2 expression interferes with 
mechano-sensory organ development, which is part of the peripheral nervous system 
(G. Merdes, pers. comm.). These so-called bristles are a well investigated system 
and their development is known to depend on Notch signaling (Guo et al. 1996). 
Upon overexpression of APP family proteins, a Notch gain of function phenotype 
could be observed in bristles, leading to cell fate transformation and increased 
numbers of extracellular cells (G. Merdes, pers. comm.). Surprisingly both, the N-and 
C-terminal domain of APP were shown to be necessary for phenotype induction, 
since deletion of the NPTY motif or the whole intra- or extracellular domain resulted 
in suppression of the APP induced phenotype (G. Merdes, pers. comm.). This 
suggests that extra- as well as intracellular interactions play a role in phenotype 
induction. It is known that several Phosphotyrosine binding (PTB) domain proteins 
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can interact with the NPTY motif of APP. Most of these ligands are also conserved in 
Drosophila. While there is no known protein with similarity to Fe65, homologues are 
described for X11 (Hase et al. 2002), JIP (Taru et al. 2002), Disabled (Liebl et al. 
2003), and Numb (Knoblich et al. 1995). Intriguingly, Numb is known to be a crucial 
player in bristles development required for asymmetric cell division (Knoblich et al. 
1995). During mitosis, Numb is asymmetrically localized to one cell, where it is able 
to suppress Notch signaling after cell division (Frise et al. 1996). Notch is active in 
the other cell lacking Numb, thereby creating two different daughter cell fates.  
 
Fig. 3.15: Schematic overview of the generated GST-APP fusion constructs. The APP wild type 
sequence of the intracellular domain (ID) is shown and deleted or exchanged residues are indicated. 
Deleted motifs are marked with lines and the generated APP constructs were named according to the 
deleted motif or point mutation. A TEV cleavage site was inserted in-between the GST and APPID 
sequences. The obtained GST-APLP1ID and GST-APLP2ID fusion constructs are shown below. 
Since APP family proteins interfere with cell fate decisions during bristle 
development, this observation made Numb a prime target. To analyze a possible 
interaction of APP family proteins to Drosophila Numb, in vitro pulldown assays were 
performed to dissect the binding properties. 
For this purpose, GST fusion constructs comprising the APP C-terminus 
(GST-APPID) and deletion or point mutants thereof, were generated and 
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recombinantly expressed in E. coli (Fig. 3.15). Additionally, GST fusions of APLP1 
and APLP2 C-terminal domains were obtained from Gunter Merdes and Tomas 
Grübl, respectively (Fig. 3.15). The recombinantly expressed fusion proteins were 
immobilized on Glutathion-Sepharose beads and tested for equal loading. 
3.3.2 In vitro pulldown of Drosophila Numb and Disabled with GST-APPID 
In order to analyze binding of Drosophila Numb (dNmb) to APP, the generated GST-
APPID coupled beads were incubated with 35S-Methionine labeled, in vitro translated 
dNmb and subjected to SDS-PAGE. Equal loading of GST fusion proteins was 
confirmed by Coomassie staining and the interaction was analyzed by 
autoradiography. Indeed, dNmb bound to APP, but not to GST only, and binding was 
partially, but not fully ablated by deletion or exchanges within the NPTY motif of APP 
(Fig. 3.16a). Particularly, the N684A exchange in APP displayed similarly diminished 
binding as the ∆NPTY deletion, while the Tyrosine exchanges (Y682A, Y687A) were 
less effective, suggesting N684 to be a crucial residue for interaction. Possibly, the 
APP BASS sequence also affected binding of dNmb, since it displayed a slightly 
weaker affinity. However, it is unclear whether dNmb can additionally bind to the 
BASS sequence, or if its contribution to binding is indirect.  
 
Fig. 3.16: In vitro binding of dNmb and dDab to APP. In vitro translated 35S-Methionine labeled (a) 
dNmb and (b) dDab were incubated with GST only, GST-APPID (AIDwt), or GST-APPID mutations (as 
indicated) and analyzed by SDS-PAGE and autoradiography. Comparable amounts of GST coupled 
Sepharose beads were detected by Coomassie staining. The asterisk in (a) indicates a shortened 
dNmb protein due to an internal start codon. 
Similarly, binding of Drosophila Disabled (dDab) to APP was also analyzed, since it is 
conserved in mammals, and mouse Disabled-1 has previously been shown to 
interact with APP family proteins (Trommsdorff et al. 1998; Homayouni et al. 1999; 
Howell et al. 1999). For this purpose, a C-terminally shortened dDab construct with 
45 kDa was used (kindly obtained from G. Merdes), since the full length protein was 
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too large to be in vitro translated. GST-APPID coupled beads were incubated with 
35S-Methionine labeled dDab. Autoradiographic analysis revealed specific interaction 
with the APPID strictly dependent on the presence of the NPTY motif (Fig. 3.16b). 
Some unspecific binding of dDab to GST was observed, which was nevertheless well 
below the specific binding signal. No major influence on binding was noted for the 
other deletion constructs. Unlike dNmb, dDab binding was completely abolished with 
single amino acid exchanges within the NPTY motif (Fig. 3.16b). 
 
Fig. 3.17: In vitro binding of dNmb and dDab to APP/APLPs. In vitro translated, 35S-Methionine 
labeled (a) dNmb and (b)dDab were incubated with GST-APPID (APP-ID), -APLP1ID (A1-ID), -APLP2ID 
(A2-ID) beads or GST only and analyzed by SDS-PAGE and autoradiography. Comparable amounts 
of GST-coupled Sepharose beads were detected by Coomassie staining. The asterisk in (a) indicates 
an additional, shortened dNmb protein, due to an internal start codon. 
To further compare binding affinities of dNmb and dDab to all APP family proteins, 
the in vitro translated, radio-labeled proteins were incubated with GST-APP, -APLP1, 
or -APLP2 beads, and processed as described above. Interestingly, APLP1 
displayed the highest affinity for dNmb, while APP and APLP2 showed moderate 
binding (Fig. 3.17a). Similarly, APLP1 also exhibited the strongest binding to dDab, 
although the differences between the APP family members in regard to dDab binding 
were lower compared to dNmb interaction (Fig. 3.17a). All GST fusion proteins were 
present in comparable amounts, as confirmed by Coomassie staining (Fig. 3.17). 
These results show that dNmb, and also dDab, can bind to APP family proteins in 
vitro by interaction of their PTB domain with the NPTY motif. For dNmb, the binding 
region to APP might be larger, since the 11 aa deletion of the NPTY motif did not 
suppress interaction completely. In vivo however, the corresponding deletion was 
sufficient to suppress the APP induced bristles phenotype and to act in a dominant 
negative fashion (G. Merdes, pers. comm.). This highly suggests that the NPTY motif 
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is the major binding region of dNumb, and that the interaction is responsible for the 
observed bristles transformation in vivo. A role for dDab in bristles formation is not 
clearly established yet, but possibly expression of APP family proteins interferes with 
the dDab pathway as well. Interestingly, APLP1 and APLP2 induced very strong 
bristles phenotypes, while APP showed only moderate effects. (G. Merdes, pers. 
comm.). Although the strength of APP, APLP1, or APLP2 induced phenotypes in vivo 
does not correlate with the in vitro binding affinities to dNmb, these results suggest 
that binding to dNmb is a prerequisite for the observed phenotype, but might not be 
the limiting factor. 
3.3.3 In vitro pulldown assays of human Numb and Disabled-2 with APP 
The results described above indicated that APP family proteins might be involved in 
signaling pathways depending on Numb and Disabled binding. A number of PTB 
domain proteins have been reported to bind to the NPTY motif of APP, and PTB 
domains are highly conserved from invertebrates to mammals, and therefore 
presumably serving similar purposes. In mammals, two conserved homologues of 
dNmb (Numb and Numb-like) and dDab (Dab1 and Dab2) are known. In vitro and in 
vivo binding of Disabled-1 to APP family proteins, but not for Dab2 and Numb, has 
been previously reported (Homayouni et al. 1999; Howell et al. 1999). Therefore 
interaction of Numb and Dab2 with APP was analyzed in detail.  
Four splice variants of human Numb (hNmb) are known (Verdi et al. 1999), and the 
shortest was used for the following pulldown assays. As already described above, 
GST-APPID coupled beads were incubated with 35S-Methionine labeled hNmb or 
Dab-2, respectively. Autoradiographic analysis revealed specific interaction of both 
proteins with the APPID (Fig. 3.18a, b). Moreover, the human proteins displayed 
similar binding properties as already observed for the Drosophila homologues. 
Accordingly, hNmb binding was not completely abolished with the NPTY deletion 
(GST-APP∆NPTY), while Dab-2 binding was reduced to GST background levels, 
suggesting complete loss of the interaction (Fig. 3.18a, b). 
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Fig. 3.18: In vitro binding of hNmb and Dab-2 to APP. In vitro translated, 35S-Methionine labeled (a) 
hNmb and (b) Dab-2 were incubated with GST only, GST-APPID (AIDwt), or GST-APPID mutations (as 
indicated) and analyzed by SDS-PAGE and autoradiography. Comparable amounts of GST coupled 
Sepharose beads were detected by Coomassie staining. The asterisk in (a) indicates a shortened 
Dab-2 protein due to an internal start codon. 
For hNmb, the tyrosine exchanges within the NPTY motif had a weak effect 
compared to N684A. Again, some minor influence of the BASS sequence on hNmb 
interaction was noted, while Dab2 binding only depended on the NPTY motif.  
These results reveal that binding properties of Numb and Dab to APP seem to be 
conserved between invertebrate and mammalian homologues. 
3.3.4 In vivo binding of Disabled-2 and APP 
The mammalian Disabled proteins have important, but separated functions during 
embryonic development. Dab-1 on the one hand, is mainly expressed in neurons and 
is crucially involved in transduction of the Reelin signal during cortical neuronal 
migration (Sheldon et al. 1997). Dab-2 on the other hand, is predominantly 
expressed in peripheral tissues, and possibly involved in endocytosis and TGFβ 
signal transduction (Mishra et al. 2002; Morris et al. 2002). Additionally, Dab2 was 
described as a proto-oncogene regulating cell proliferation (Xu et al. 1998). 
In order to investigate in vivo binding of APP to Dab-2, COS-7 cells were transiently 
cotransfected with APP695 and Dab2, or vector controls. As an additional control, the 
APP∆NPTY mutant construct was also cotransfected with Dab2. Subsequently, the 
cells were lysed and coimmunoprecipitation of APP and Dab-2 (22734) followed by 
SDS-PAGE were performed. Unfortunately, although endogenous Dab2 was present 
in COS-7 cells, it could not be efficiently overexpressed (Fig. 3.19). Similarly, stable 
transfection of Dab-2 could not be achieved, possibly because overexpression 
inhibited cellular proliferation (Xu et al. 1998). Nevertheless, specific binding of Dab2 
to APP was detected and enhanced upon APP overexpression, while no specific 
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interaction was noted, when precipitating APP/Dab2 transfected lysates with 
preimmune serum (P.I.). Cotransfection of APP∆NPTY and Dab-2 did not cause 
increased binding suggesting that the NPTY motif is necessary for in vivo interaction, 
too (Fig. 3.19). 
 
Fig. 3.19: Coimmunoprecipitation of Dab-2 with APP from COS-7 cells. Cells were double 
transfected with APP, Dab-2, APP/Dab-2, or vector only (as indicated). APP was immunoprecipitated 
from cell lysates with 22734 and submitted to SDS-PAGE and immunoblotting with an αDab2 
antibody. The membrane was reprobed with 22C11 against APP. Equal amounts of direct loads of all 
cell lysates are shown for comparison. 
Taken together, these results suggest that Dab-2 can interact with APP in vitro and in 
vivo, though presumably only small amounts of both proteins are associated in vivo, 
due to the weak overall affinity. 
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3.3.5 In vivo binding of human Numb and APP family proteins 
Numb and its homologue Numb-like (Nmbl), serve important functions during 
mammalian development, and its crucial role in asymmetric cell division and 
neurogenesis is conserved (Zhong et al. 2000; Shen et al. 2002). Furthermore, Numb 
is also expressed in mature neurons, though its function there is so far unknown. 
Interaction of Numb with APP family proteins would suggest a functional role in 
neurogenesis. In parallel to this study, it was shown by Roncarati and colleagues 
(Roncarati et al. 2002) that Nmb, and also Nmbl, can be coimmunoprecipitated with 
APP from mouse brain homogenates, but binding to APLP1 or APLP2 was not 
investigated in that study. 
 
Fig. 3.20: Coimmunoprecipitation of Numb with APP family proteins from mouse brain. APP, 
APLP1, or APLP2 were immunoprecipitated from mouse brain homogenates with 22734, 57, or D2-II, 
respectively. Immunoprecipitations with preimmune serum (P.I.) served as a control. The samples 
were submitted to SDS-PAGE and immunoblotting with an αNmb antibody. The direct load (DL) of the 
extract is shown for comparison. Asterisks indicate immunoprecipitation antibody signals. 
So far, in this work, only preliminary data could be obtained for in vivo binding of Nmb 
to APP family proteins. Nevertheless, when precipitating APP (22734), APLP1 (57), 
or APLP2 (D2-II) form mouse brain lysates, specific interaction with Numb was only 
detected for APLP1, but not for APP, APLP2 or when precipitating with preimmune 
serum only (Fig. 3.20). 
Though preliminary, this result substantiates the in vitro binding results and indicates 
that in vivo binding of Numb to APLP1 might be necessary for a common functional 
role. 
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3.4 Trans-interaction properties of APP family proteins in cell adhesion 
3.4.1 Processing dependent cell clustering induced by expression of APP 
family proteins 
Many studies have suggested a function for APP in cell adhesion. Likewise, as 
shown in this work, APP, APLP1, and APLP2 are able to induce cell adhesion 
defects upon expression in the Drosophila wing during development, although the 
mechanism remains elusive. To analyze, if phenotype induction of APP family 
proteins is a cause of their cell adhesion properties, a cell based assay would be 
helpful to address this question. Therefore, Drosophila Schneider (S2) cells were 
chosen again as a model system for several reasons: first, they do not have 
endogenous expression of the APP homologue APPL, generating a knockout 
situation for APP family proteins. Second, S2 cells lack strong cell adhesion 
properties and show only weak cell-cell interaction. Third, overexpressed 
transmembrane proteins are efficiently transported to the plasma membrane and 
show high cell surface expression. These properties make them an ideal model 
system to study cell adhesion proteins and receptor-ligand binding, as has been 
successfully done in previous studies (Tsiotra et al. 1996; Islam et al. 2004). 
Expression of two interacting proteins in two separated pools of S2 cells causes co-
clustering after mixing of both cell pools, like it has been shown for the Notch 
receptor and its ligand, Delta (Klueg et al. 1999). Thus, cell clustering gives a direct 
readout for an interaction of the two proteins. 
Since strong differences in the ability to interfere with cell adhesion in vivo were 
observed for the different APP family members, intrinsic properties of the proteins 
might in part account for it. Moreover, processing had a strong effect on phenotype 
strength. Therefore, the ability to modulate cell clustering in S2 cells was initially 
investigated for APPL and APPLsd due to their strong difference in phenotype 
strength and processing properties. The according pUAST plasmids were 
cotransfected with pMT-Gal4, and single cell suspensions were aggregated for 2h, 
and analyzed by immunocytochemistry.  
Interestingly, when comparing APPL and APPLsd expressing cells, a strong 
difference in cell clustering was observed. While APPL positive cells were randomly 
distributed, many APPLsd expressing cells formed homotypic cell clusters 
(Fig. 3.21a).  
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Fig. 3.21: Processing dependent homotypic clustering of APPL or APP expressing S2 cells. (a) 
Cells transfected either with APPL or APPLsd were aggregated and immunostained with an N-terminal 
APPL antibody. (b) APP, APP-D8, or SPA4CT expressing S2 cells were aggregated and 
immunostained with CT-13 or an anti-myc antibody, respectively. Scale bar equals 30 µm. (c) 
Quantification of aggregated cells expressing SPA4CT, APPwt, or APP-D8. Transfected cells were 
counted and the relative amount of clustered cells is shown (n≥3). ±SD and statistical significance are 
indicated. 
To further investigate the specificity of this observation, the corresponding 
experiment was also performed with APPwt and APP-D8, a secretion defective 
mutant construct, which has been characterized before (see Fig. 3.5). As a control, 
SPA4CT, a construct comprising only the Aβ, transmembrane and intracellular 
domain of APP, was also analyzed, since it was not inducing a phenotype in vivo. 
APPwt displayed a moderate tendency for homotypic cell cluster formation. In 
contrast, APP-D8 expressing homotypic aggregates were far more common 
(Fig. 3.21b). No cell clustering was observed for SPA4CT suggesting that the 
observed homotypic aggregation of APP cells is specifically mediated by its 
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ectodomain. Quantification of these results revealed that virtually no cell clusters 
containing three or more SPA4CT expressing cells were present, while about 6 % of 
all APP expressing cells formed homotypic aggregates (p<0.05) (Fig. 3.21c). For 
APP-D8, 22 % of all expressing cells were clustered, significantly more than with 
APPwt suggesting that processing affects APP mediated cell adhesion. 
These results allow two different conclusions. First, APP family proteins mediate cell-
cell adhesion in an ectodomain dependent fashion. Second, processing in S2 cells 
also strongly affects cell clustering, since both, APP-D8 and presumably also 
APPLsd, are cleaved to a lower extent than their wild type counterparts, thereby 
leading to stronger homophilic adhesion. These observations further indicated that 
cell clustering can be induced by direct homo-trans-interactions mediated by the APP 
ectodomain. 
3.4.2 Homophilic intercellular interaction of APP, APLP1, and APLP2  
In order to investigate trans-interaction properties of the APP family proteins in more 
detail, APP and its mammalian homologues APLP1 and APLP2 were analyzed in 
comparison. Accordingly, S2 cells were transfected with cDNAs encoding APP, 
APLP1, APLP2, and SPA4CT as a control and treated as described above. 
Immunocytochemical analysis revealed comparable transfection rates and all 
recombinant proteins were efficiently transported to the cell surface (Fig. 3.22a), 
which was confirmed by electron microscopy studies (data not shown). Cell 
clustering was observed with increasing strength for cells expressing APP, APLP1, or 
APLP2, whereas no clustering was observed with cells expressing SPA4CT 
(Fig. 3.22a). Additionally, recombinant expression of the full length Notch receptor did 
not lead to cell clustering (data not shown), confirming the specificity of the assay. As 
described before, quantification revealed that 6% of all APP expressing cells were 
clustered, showing statistically significant interaction compared to SPA4CT 
expressing control cells (p<0.05) (Fig. 3.22b). For APLP1 and APLP2, highly 
significant 32% and 36 % of all transfected cells were clustered, respectively 
(p<0.001). Consistent with this view, confocal microscopy studies of APLP1 
expressing clustered cells revealed that APLP1 accumulated at cell-cell contact sites 
of transfected cells, but not at contact sites of non-transfected cells, as observed 
when merging transmission and immunofluorescence images (Fig. 3.22c). 
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Fig. 3.22: Homophilic intercellular interactions of APP, APLP1, and APLP2. (a) Immunostainings 
of aggregated S2 cells expressing APP (40090), APLP1 (anti-myc), APLP2 (CT-12), or SPA4CT (CT-
13), respectively. Scale bar equals 30 µm. (b) Quantification of aggregated cells expressing SPA4CT, 
APP, APLP1, or APLP2. Transfected cells were counted and the relative amount of clustered cells is 
shown (n≥3). ±SD and statistical significance are indicated. (c) Confocal analysis of aggregated C-
terminally tagged APLP1 expressing S2 cells stained with an anti-myc antibody (APLP1). A single 
confocal section and the overlay with the transmission image are shown. Scale bar equals 3 µm. 
These data strongly suggest that cell surface expression of APP family proteins can 
stabilize cell-cell interactions by homophilic ectodomain mediated adhesion. 
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3.4.3 Heterophilic intercellular interaction of APP, APLP1, and APLP2  
It was further investigated whether heterophilic interaction between APP family 
proteins is occurring, since the homologues show high protein domain conservation. 
Again, Schneider cells were transiently transfected with SPA4CT, APP, APLP1, or 
APLP2. Pairs of differentially transfected single cell suspension pools were mixed, 
aggregated, and analyzed by immunocytochemistry as described above.  
Mixing of two different pools of either APP or APLP1 expressing cells showed on the 
one hand homophilic clusters of APP or APLP1 expressing cells comparable to the 
results described above, but in addition an enhanced tendency of heterotypic cluster 
formation (Fig. 3.23a). Similar results were obtained for mixed pools of APP and 
APLP2, or APLP1 and APLP2 expressing S2 cells. In contrast to APP and APLP1, 
homotypic cell clustering was still predominant in mixed populations of APLP1 and 
APLP2 expressing cells. No specific incorporation of SPA4CT in clusters of APLP1 or 
APLP2 expressing cells was observed (Fig. 3.23a, and data not shown). 
Quantification of heterotypic aggregates of mixed populations of APP or APLP1 
expressing cells showed that 28% had direct heterotypic cell contact compared to 
less than 3 % of mixed cell populations expressing SPA4CT or APLP1 (p<0.001) 
(Fig. 3.23b). A significant number of heterotypic clusters of APP and APLP2, or 
APLP1 and APLP2 expressing cells were counted showing 8 % and 12 % heterotypic 
cell contacts, respectively (p<0.05). Heterophilic interaction of APP and APLP2, or 
APLP1 and APLP2, was significantly weaker compared to APP and APLP1 
(p<0.001). Most interestingly, confocal microscopy studies revealed  that heterotypic 
aggregates of APP and APLP1 expressing cells displayed accumulated APLP1 
immunoreactivity at cell-cell contact sites (Fig. 3.23c), not only adjacent to APLP1 
expressing cells as observed for homotypic clusters, but also at contact sites of APP 
expressing cells. APP was also localized at cell contact sites and cellular protrusions 
framing adjacent APLP1 expressing cells, as evident from the merged images.  
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Fig. 3.23: Heterophilic intercellular interactions of APP, APLP1, and APLP2. (a) Immunostainings 
of aggregated S2 cells expressing mixed pools of APP/APLP1 (40090/anti-myc), APP/APLP2 (anti-
myc/CT-12), APLP1/APLP2 (anti-myc/CT-12), or SPA4CT/APLP1 (CT-13/anti-myc), respectively. 
Scale bar equals 30 µm. (b) Quantification of mixed aggregated cells expressing SPA4CT/APP, 
APP/APLP1, APP/APLP2, or APLP1/APLP2. Transfected cells were counted and the relative amount 
of cells with direct heterotypic contact is shown (n≥3). ±SD and statistical significance are indicated. 
(c) Confocal section of mixed pools of C-terminally tagged APLP1 (anti-myc) and APP (40090) 
expressing S2 cells. Single channel immunostainings and merged images are shown. Scale bar 
equals 3 µm.  
These findings show specific heterophilic trans-interaction of APP, APLP1, and 
APLP2. Interestingly, a strong tendency of APP and APLP1 for heterophilic 
interactions was observed, whereas APLP2 preferred homophilic interactions, 
suggesting distinct physiological functions. 
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3.4.4 APLP1 and APLP2 mediate cellular uptake of secreted fragments 
The S2-cell aggregation experiments described above provided evidence for homo- 
and heterophilic intercellular interaction of APP family members. These findings 
opened up the question, whether APP family proteins might function as receptors of 
their own secreted fragments (referred to as sAPP, sAPLP1, and sAPLP2, 
respectively) in a homo- or heterophilic manner. For this purpose, stable COS-7 cell 
lines transfected with APP, APLP1, APLP2, or vector only were generated. The cells 
were radio-labeled with 35S-Methionine and the medium of the different cell lines was 
conditioned for 3h to reach sufficient levels of labeled secreted proteins (referred to 
sAPP*, sAPLP1*, sAPLP2*). Afterwards, the media were collected, cleared from cell 
debris, and added to non-labeled APP, APLP1 and APLP2 expressing cells or vector 
transfected control cells for 1h. The media and cell lysates were analyzed afterwards 
by immunoprecipitation with antibodies specifically recognizing APP (22734), APLP1 
(42464) or APLP2 (42476). 
Autoradiographic analysis revealed that sAPLP1* and sAPLP2* medium levels were 
significantly reduced to approx. 60% and 70% when incubated with APLP1 or APLP2 
expressing cells, respectively (Fig. 3.24b, c), while no significant change in sAPP* 
levels was observed (Fig. 3.24a). Additionally, no difference in sAPLP1* medium 
levels before and after incubation with vector, APP, or APLP2 transfected cells was 
found (Fig. 3.24b, lane 1, 2, 6, and data not shown). Similarly, cellular uptake of 
sAPLP2* was only observed for APLP2 expressing COS-7 cells (Fig. 3.24c), 
indicating that APLP1 and APLP2 might interact with their own secreted fragments. 
No uptake of sAPP* was observed under our experimental conditions. 
In the extracts of incubated cells no accumulation of sAPP*, sAPLP1*, or sAPLP2* 
was detected (data not shown), which might be explained by fast endocytosis and 
subsequent degradation of the secreted forms. Therefore, an APLP1 mutant lacking 
the C-terminal NPTY internalization motif (APLP1∆NPTY) was used, which is 
expected to have a reduced endocytosis rate. Indeed, immunocytochemical analysis 
of APLP1∆NPTY expressed in COS-7 cells showed substantial accumulation 
proximal to the plasma membrane and additionally, extending lamellipodia and 
filopodia-like structures were stained with both antibodies used (see Fig. 3.25a).  
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Fig. 3.24: APLP1 and APLP2 mediate cellular uptake of secreted fragments. COS-7 cells 
expressing APP, APLP1, APLP2, or vector only (as indicated) were incubated with radio-labeled (a) 
sAPP*, (b) sAPLP1*, or (c) sAPLP2* conditioned media for 1h. Alternatively, labeled vector 
transfected control medium was used for incubation to confirm signal specificity ((a) APPctl, (b) 
APLP1ctl, APPctl, (c) APLP2ctl). Medium immunoprecipitation (M-IP) of the secreted fragments with 
22734 (α-sAPP*), 42464 (α-sAPLP1*), or 42476 (α-sAPLP2*) was followed by SDS-PAGE and 
autoradiography. (d-f) Chase experiment with sAPLP1* medium incubated either with (d) vector 
(pCEP), (e) APLP1wt, or (f) APLP1∆NPTY transfected COS-7 cells. Medium aliquots were taken at 
the indicated time points and immunoprecipitated with 42464, followed by SDS-PAGE and 
autoradiography. (g) Quantitative chase analysis of sAPLP1* uptake with vector, APLP1wt, or 
APLP1∆NPTY expressing COS-7 cells. The relative sAPLP1* medium contents were plotted against 
time with ±SD as indicated (n≥3). Statistical significance: **: p<0.001. (h) Normalized relative 
expression levels of APLP1wt and APLP1∆NPTY expressing COS-7 cells. 
Uptake of sAPLP1* by APLP1wt and APLP1∆NPTY expressing cells was analyzed 
over time, as described above. Autoradiography showed that sAPLP1* medium 
levels remained virtually unchanged with vector transfected cells (Fig. 3.24d). In 
contrast, sAPLP1* levels dropped over time when incubated with APLP1wt 
expressing cells (Fig. 3.24e). Even faster decline was observed for cells expressing 
APLP1∆NPTY (Fig. 3.24f), consistent with the marked increase in plasma membrane 
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localization. Quantitative analysis revealed that sAPLP1* levels in the medium 
dropped exponentially when incubated with APLP1wt or APLP1∆NPTY expressing 
cells (Fig. 3.24e). Although APLP1∆NPTY was expressed at lower levels compared 
to APLP1wt (Fig. 3.24f), these cells showed faster and more efficient sAPLP1* 
medium depletion. This suggests that sAPLP1* and possibly also sAPLP2* uptake is 
elevated when the surface expression of its presumed receptor, APLP1 or APLP2 
respectively, is enhanced.  
3.4.5 APLP1∆NPTY plasma membrane localization and intracellular 
accumulation of sAPLP1 
Although the APLP1∆NPTY expressing cells caused the strongest decline of 
secreted fragment levels, no substantial amounts of sAPLP1* in extracts of APLP1 
expressing cells could be detected. Therefore, immunocytochemical analysis of 
COS-7 cells expressing N-terminally myc-tagged APLP1wt or APLP1∆NPTY was 
performed.  
 
Fig. 3.25: APLP1∆NPTY localizes to the plasma membrane and causes intracellular 
accumulation of sAPLP1. COS-7 cells expressing N-terminally myc-tagged APLP1wt or 
APLP1∆NPTY were cultivated for (a) one or (b, c) four days and subsequently analyzed by 
immunocytochemistry using anti-myc and anti-150 (directed against the juxtamembrane region of 
APLP1) antibodies. Confocal sections of single channels (myc, 150) and merged images are shown. 
Note that only after four day incubation, accumulation of sAPLP1 in large intracellular granules (arrow 
heads) in APLP1∆NPTY expressing cells was observed. Scale bars equal 5 µm. 
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Since medium amounts of sAPLP1 are increasing over time due to constitutive 
secretion, APLP1wt and APLP1∆NPTY cells were cultured for four days without 
medium exchange and immunostained thereafter. 
Diffuse granular APLP1wt (Fig. 3.25b) and APLP1∆NPTY (Fig. 3.25c) 
immunoreactivity was widely distributed in the cells. The majority of N-terminal anti-
myc staining and juxtamembrane anti-150 staining of APLP1wt was co-localized. 
However, for APLP1∆NPTY additional sAPLP1 immunoreactivity was observed with 
the anti-myc antibody in form of large (∅1-3 µm) intracellular vesicular granules, 
which were devoid of anti-150 immunostaining, as evident from the merged images 
(Fig. 3.25c). This observation hinted to impaired intracellular transport of internalized 
sAPLP1, though this point would require a more detailed characterization.  
Together with the aggregation assay data these results strongly indicate that not only 
full length APP family members exhibit trans-interaction, but that they can also act in 
a receptor-like manner mediating uptake of their own secreted extracellular 
fragments. 
3.4.6 APP interacts with APLP1 in vivo and APLP1 protein levels are 
upregulated in APP -/- mouse brain 
It was further aimed to investigate whether heterophilic interactions between APP 
family members exist in vivo. Since APP and APLP1 exhibited strong hetero-trans-
interaction, these properties were analyzed in mouse brain.  
Therefore, immunoprecipitations from mouse brain extracts were performed with an 
antibody directed against the APLP1 intracellular domain (57). To verify specificity, 
equal protein amounts from APP -/-, APLP1 -/-, and APLP2 -/- mouse brain extracts 
were also immunoprecipitated with ab57 and immunoblotted for APP with 22C11 
(Fig. 3.26). APP was coimmunoprecipitated from WT and APLP2 -/-, but not from 
APP -/- and APLP1 -/- brain samples (Fig. 3.26) showing specific heterophilic 
interaction of APP and APLP1 in vivo. In mouse brain, at least three distinct forms of 
APP with a molecular weight of 100 kDa, 108 kDa and 120 kDa were detected, likely 
representing different post-translationally modified APP695 species (Sandbrink et al. 
1997). Interestingly, only the high molecular weight forms of APP with a molecular 
weight of 108 and 120 kDa were coimmunoprecipitated with APLP1 suggesting that a 
specific pool of APP exists in complex with APLP1 in vivo. 
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This indicates that APLP1 might interact only with a post translational modified APP 
that does not represent the major pool of APP in brain.  
 
Fig. 3.26: APP/APLP1 interaction in vivo and upregulated APLP1 protein levels in APP -/- 
mouse brain. Brain extracts from WT, APP -/-, APLP1 -/-, and APLP2 -/- mice were subjected to 
immunoprecipitation with a C-terminal APLP1 antibody (57) and analyzed by SDS-PAGE and 
immunoblotting with an anti-APP antibody (22C11). Direct loads (DL) with 20 µg of total protein are 
shown for comparison. The membrane was reprobed with anti-APLP1 (CT-11) and anti-β-TubulinIII 
(βTubIII) antibodies.  
Unexpectedly, far higher protein levels of APLP1 were detected in the direct load of 
APP -/- compared to WT or APLP2 -/- brain homogenates. Moreover, APLP1 was 
shifted to a higher apparent molecular weight in APP -/- extracts only (Fig. 3.26), 
while APLP2 levels were unchanged in all samples (data not shown). To verify these 
results, samples of three different APP -/- mice with an age of 6 to 12 months and 
age matched WT mice were analyzed and confirmed our initial observation. 
These data show that APLP1 specifically interacts with high molecular weight forms 
of APP in mouse brain. Additionally, so far not reported upregulation of APLP1 
protein levels in APP-/- mice underscores a functional interaction between APP and 
APLP1. 
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3.4.7 APP, APLP1, and APLP2 are enriched in synaptic plasma membranes 
and APP interacts with APLP1 synaptic compartments 
It has been shown previously that higher molecular weight forms of APP are enriched 
in synaptic compartments (Beher et al. 1999). Moreover, a postsynaptic enrichment 
has been reported for APLP1, while APP could not be detected in postsynaptic 
fractions (Kim et al. 1995). This set of data allowed the hypothesis that APLP1, 
localized to the postsynaptic density interacts with presynaptic APP, thus stabilizing 
the interaction of pre- and postsynaptic membranes. Therefore, we wanted to verify 
synaptic enrichment of APP family proteins and investigate whether APP and APLP1 
are in fact interacting in synaptic membrane compartments.  
A separation into crude synaptic membrane (RSM) and synaptic plasma membrane 
(SPM) fractions was obtained from brain homogenates of WT, APP -/-, APLP1 -/-, 
and APLP2 -/- mice as previously described (Beher et al. 1999). Accordingly, 
enrichment of 108 and 120 kDa forms of APP was found in SPMs, while levels of the 
major 100 kDa form were decreased (Fig. 3.27a). The synaptic enrichment of APP 
was comparable in samples of WT, APLP1 -/-, or APLP2 -/- fractions. APLP1 and 
APLP2 also accumulated in SPMs (Fig. 3.27a) and similarly to APP, synaptic 
enrichment only of the highest molecular weight form of APLP2 was shown. 
Enrichment of synaptic compartments in the purified fractions was confirmed by 
strongly increased Synaptophysin levels in SPMs compared to total brain 
(Fig. 3.27a).  
Since the APP species interacting with APLP1 were found to be enriched in synaptic 
preparations, total extracts and SPMs from WT mouse brains were 
immunoprecipitated either with preimmune serum (P.I.) or an anti-APLP1 antibody 
(57), respectively (Fig. 3.27b). APP was indeed specifically coimmunoprecipitated 
with APLP1 from total extracts and SPMs to similar amounts. This result 
corresponded with the observation that comparable amounts of higher molecular 
weight APP forms were present in direct loads of both fractions. 
Another intriguing observation was made, when enrichment of postsynaptic proteins 
in RSMs was confirmed. For this purpose, RSM samples were immunoblotted for 
PSD95, a protein selectively enriched in the postsynaptic density. It became evident 
that PSD95 protein levels were strongly upregulated in APLP1 -/- mice, but 
unchanged in WT, APP -/-, or APLP2 -/- fractions (Fig. 3.27c). 
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Fig. 3.27: APP, APLP1, and APLP2 are enriched in synaptic plasma membranes and APP 
interacts with APLP1 in synaptic compartments. (a) Crude synaptic membranes (RSMs) and 
synaptic plasma membranes (SPMs) were prepared from brain homogenates (BH) of WT, APP -/-, 
APLP1 -/-, and APLP2 -/- mice. 20 µg of total protein from each fraction were subjected to SDS-PAGE 
and immunoblotted with an anti-APP antibody (22C11). The membrane was subsequently reprobed 
with anti-APLP1 (CT-11) and anti-APLP2 (D2-II) antibodies. Enrichment of synaptic compartments 
was confirmed with an anti-Synaptophysin antibody (SynPh). (b) Total extracts (BH) and SPM 
preparations from WT mouse brains were immunoprecipitated either with preimmune serum (P.I.) or 
an anti-APLP1 antibody (ab57), subjected to SDS-PAGE and immunoblotted with an anti-APP 
antibody (22C11). Direct loads (DL) of BH and SPMs are shown for comparison. The same membrane 
was reprobed for APLP1 (CT-11) to confirm specific immunoprecipitation, and for Synaptophysin 
(SynPh). The asterisk indicates a non-specific antibody signal. (c) Crude synaptic membrane (RSMs) 
samples from WT, APP -/-, APLP1 -/-, and APLP2 -/- mice were immunoblotted for PSD95 and 
Synaptophysin (SynPh). 
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Taken together, these experiments confirm enrichment of all APP family proteins in 
synaptic plasma membranes and demonstrate that APP and APLP1, enriched in 
SPMs exist in a common complex. Together with the finding that APLP1 is 
specifically present in the post synaptic density and not at the presynaptic terminal, 
these data suggest a trans-cellular functional interaction of APP and APLP1 at the 
synapse. Moreover, a postsynaptic function is suggested for APLP1, since PSD95 
protein levels were specifically upregulated in APLP1 -/- mice indicating functional 
complementation. 
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4 Discussion 
4.1 APP interference with cell adhesion in vivo depends on membrane 
anchoring and processing 
Wing development of Drosophila melanogaster is well studied and many fundamental 
processes of wing patterning, like compartmentalization, boundary formation, and cell 
adhesion have already been elucidated in detail. Moreover, highly conserved 
signaling pathways also important for mammalian development, participate in wing 
patterning as well.  
In this work, the effect of APP expression on cell adhesion was studied using 
Drosophila wing development as a model system. Since the wing epithelium consists 
of only two cell layers held together by Integrin mediated adhesion, overexpression of 
proteins affecting Integrin signaling leads to cell adhesion defects visible as wing 
blisters. This phenotype represents an easy accessible feature to analyze genetic 
interaction with endogenous signaling pathways. 
It could be shown that APP expression induces wing blisters dependent on its 
ectodomain and membrane anchoring. The APP intracellular domain is not needed 
for phenotype induction, since all C-terminal deletion constructs generated and 
analyzed in this study were still able to generate cell adhesion defects. Surprisingly, 
the APP mutant construct lacking the intracellular domain (APP∆CT) used in the 
study of Fossgreen and colleagues (Fossgreen et al. 1998) was not able produce a 
blistered wing phenotype, while the corresponding deletion construct fused to GFP 
(APP∆CT-GFP) exhibited a phenotype comparable to APPwt. This obvious 
discrepancy might be explained by two observations. First, expression levels of 
APP∆CT transgenic lines seem to be significantly lower compared to APPwt 
(G. Merdes, pers. comm.), which might lead to marginal wing defects that were not 
observed. Second, improper membrane retention could be an additional factor 
lowering the amount of APP interfering with cell adhesion. Evidence for this notion 
comes from a study from Gunawardena et al., where the same APP∆CT line was 
used for expression in motorneurons (Gunawardena et al. 2001). Although APP∆CT 
is still transported along the axon, diffuse immunostaining was observed indicating 
that a significant amount of this mutant is released from vesicles. This phenomenon 
is not observed for APP∆CT-GFP (A. Szodorai, pers. comm.), since this construct is 
presumably completely membrane retained due to the large, barrel-like GFP tag. 
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Therefore, proper membrane anchoring of APP seems to be a crucial requirement for 
blistered wing induction, while the C-terminal domain is dispensable. 
A subtle influence on phenotype strength could be noted for the APP basolateral 
sorting signal (BASS), which has previously been shown to be required for 
basolateral sorting of APP in polarized MDCK cells (Haass et al. 1995). The BASS 
sequence could have a similar function in the polarized epithelial cells of the 
Drosophila wing. This might explain reduced phenotype strength for APP mutant 
constructs lacking the BASS sequence, since apically transported APP would not be 
present at cell adhesion sites. However, intracellular distribution of APP will have to 
be analyzed in more detail to confirm this hypothesis.   
Processing of APP is another important factor regulating its impact on cell adhesion. 
It could be shown in this study that the APP-M596I/F615P mutant construct is 
cleaved to a far lower extend than APPwt in vitro and in vivo. This concomitantly 
leads to stronger blistered wing phenotypes compared to APPwt suggesting that the 
potency of phenotype induction is regulated by proteolytic conversion. A simple 
explanation might be that more full length APP or APP having a longer half-life is 
accumulating at adhesion sites and is thus interfering with Integrin signaling to a 
higher extend. Interestingly, in primary neurons, APP was found to be colocalized 
with β1-Integrins (Storey et al. 1996; Yamazaki et al. 1997), and it was further 
reported to be associated with the adaptor protein Fe65 and β1-Integrins at dynamic 
adhesion sites (Sabo et al. 2001). Fe65 is also described to increase APP processing 
(Sabo et al. 1999), possibly exactly at these adhesion sites leading to increased cell 
motility (Sabo et al. 2001). Though there is no known Fe65 homologue in Drosophila, 
these findings indicate a relevance of processing at adhesion sites.  
However, overall proteolytic conversion of APP in epithelial wing cells seems to be 
low, since no γ-cleavage of SPA4CT could be observed in imaginal wing discs using 
a GFP reporter system (Loewer et al. 2004). In contrast, Notch is efficiently cleaved 
in wing discs, while APP seems to be mainly converted in developing neurons 
suggesting cell type specific processing. Although there is basal APP conversion in 
the wing as well, the findings in these studies argue against a mechanism were APP 
competes with endogenous substrates for α- or γ-secretase suggesting that 
processing per se is not causative for the blistered wing phenotype. 
On the contrary, an enhancer/suppressor screen for genetic modifiers of the APP 
induced blistered wing supports a ligand based mechanism of APP interference. In 
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this screen, Drosophila Perlecan, a large multidomain heparan sulfate proteoglycan 
important for Hedgehog and FGF signaling (Park et al. 2003), was found to suppress 
the APP phenotype (G. Merdes, pers. comm.). Intriguingly, APP interacts with 
Perlecan in mammals (Narindrasorasak et al. 1991) suggesting that the Drosophila 
homologue is suppressing APP induced wing blistering via direct interaction.  
4.2 APLP2 interferes with Wingless signaling via interaction with the 
Drosophila Glypican Dally 
Similarly to APP, the mammalian paralogues APLP1 and APLP2 are also inducing 
cell adhesion defects upon expression in the Drosophila wing. Moreover, these two 
family members exhibited far stronger phenotypes than APP. In the course of this 
study, APLP2 was shown to induce notched wings by interfering with Wingless, and 
possibly also Notch signaling. It was elucidated that wing notching depends on 
APLP2 membrane anchoring and its extracellular carbohydrate domain, similar as 
the APP induced blistered wing phenotype. Interestingly, size reduction of the APLP2 
expressing, posterior wing compartment in imaginal discs was observed suggesting 
that the wing notching phenotype is induced either by inhibited cellular proliferation or 
apoptosis. The low frequency of APLP2 expressing clones generated by mosaic 
analysis further suggests that these cells are eliminated very early, possibly via 
apoptosis. Additionally, overexpression of the anti-apoptotic micro-RNA bantam 
(Brennecke et al. 2003) reversed the wing notching effect of APLP2. Though 
experiments for a direct detection of apoptosis were not performed so far, the 
accumulated indirect evidence highly suggests apoptotic properties of APLP2 during 
wing development. 
This effect might be explained by interference with Wingless signaling in the 
developing wing disc, since APLP2 led to accumulation of extracellular Wingless and 
disruption of the normal Wg gradient. Wingless is a crucial, extracellular factor 
necessary for dorsoventral wing patterning (Neumann et al. 1997), cell proliferation 
(Giraldez et al. 2003), and survival (Johnston et al. 2003). However, APLP2 does not 
directly affect Wingless expression of the cells at the DVB, but interferes with its 
extracellular distribution, possibly leading to decreased Wg signaling and thus 
apoptosis.  
Intriguingly, the Drosophila Glypican Dally was found to genetically interact with 
APLP2, since overexpression of Dally suppressed the phenotype. Glypicans are GPI-
anchored Heparansulfate Proteoglycans, which are also conserved in mammals and 
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play a major role in tissue patterning during development (reviewed in Filmus et al. 
2001). In Drosophila, the two known Glypicans Dally and Dally-like (Dly) are reported 
to participate in morphogen signaling of Wingless (Lin et al. 1999; Tsuda et al. 1999; 
Khare et al. 2000; Baeg et al. 2001), Hedgehog (Hh) (Desbordes et al. 2003; Lum et 
al. 2003; Han et al. 2004), and Decapentaplegic (Dpp) (Jackson et al. 1997; Fujise et 
al. 2001; Fujise et al. 2003) by acting as low affinity coreceptors (Lin et al. 1999), 
thereby shaping the morphogen gradients. Dally (this work) or Dally-like 
overexpression (Baeg et al. 2001) lead to extracellular accumulation of Wg and a 
wing notching phenotype, while Dally hypomorphs induce wing notching as well (Lin 
et al. 1999). Therefore, it is quite feasible that APLP2 sequesters endogenous 
Glypicans by direct interaction and thus prevents Wingless gradient formation and 
uptake (see Fig. 4.1). Consistently, coexpression of Dally with APLP2 restores the 
extracellular Wingless gradient. Moreover, overexpression of Dally-like under the 
engrailed promoter leads to embryonic lethality due to its involvement in Hedgehog 
signaling (Han et al. 2004), but lethality could be rescued by coexpressing APLP2. 
Therefore, a model involving direct interaction of Drosophila Glypicans and APLP2 is 
so far the most likely explanation for the observed phenotype (Fig. 4.1). 
Surprisingly, APLP2 expression in the posterior wing compartment abrogated Cut 
expression of cells at the DVB. Cut is a homeobox-containing transcription factor and 
late-arising DVB-specific marker, whose expression is specifically induced by Notch 
signaling (Micchelli et al. 1997). In contrast, vestigial intron 2 (vgI2) and Wingless 
expression of DVB cells remained unaffected. Since expression of all three proteins 
is thought to be induced by Notch signaling (Neumann et al. 1996; de Celis et al. 
1997; Micchelli et al. 1997; Go et al. 1998), it is so far unclear why Wg and vgI2 
signals remain unaffected, while Cut expression is lost. It is described that Notch and 
Wg act synergistically on Cut expression (Neumann et al. 1996), but Wg is supposed 
to be only indirectly involved (Micchelli et al. 1997). For this reason, an effect of 
APLP2 on Notch signaling might also be present, but could not be shown directly. 
Further experiments are needed to address this question. 
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Fig. 4.1: Schematic model of APLP2 induced interference with Wingless signaling. APLP2 
expressed in the Drosophila wing interacts with the Drosophila Glypicans Dally and/or Dally-like. This 
interaction is possibly direct and involves the APLP2 carbohydrate domain. As Glypicans are 
responsible for shaping the Wingless gradient and act as corecepetors of Wingless, sequestration of 
Dally by APLP2 leads to loss of Wingless signaling. 
Notch signaling strictly depends on ligand regulated S2-cleavage (Lieber et al. 2002) 
and subsequent γ-secretase processing (Struhl et al. 2001), as interference with 
proteolysis leads to Notch loss of function phenotypes. Although APLP2 was shown 
to be processed in imaginal wing discs as well, substrate competition for γ-secretase 
does not play a major role. This could be verified by mosaic expression of APLP2 
together with S2-cleaved Notch. In this experiment, APLP2 did not abrogate Notch 
induced Cut expression suggesting that γ-secretase activity is not the limiting factor. 
Moreover, APLP2 does not seem to be a substrate for the Drosophila α-secretase 
Kuzbanian (G. Merdes, pers. comm.). Together with the result that Dally 
coexpression as well, did not affect APLP2 processing, while it was able to rescue 
the phenotype, these data argue against a direct involvement of processing in APLP2 
induced wing notching. 
It remains to be clarified if APLP2 is indeed interacting with Glypicans directly. 
However, this is quite likely, since APP is described to interact with Cerebroglycan 
(Glypican-2) in rat brain (Williamson et al. 1996). Therefore, it will be interesting to 
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analyze APLP2/Glypican interaction in the mammalian system, which might involve a 
role for APLP2 in tissue patterning. 
4.3 Numb and Disabled interact with the C-terminal NPTY motif of APP 
family proteins 
In this study, the C-terminal domain of APP family proteins was shown not to be 
directly involved in the cell adhesion phenotype of the Drosophila wing. Nevertheless, 
it comprises important features in regard to APP transport and function. A number of 
proteins has been reported to interact with the APP intracellular domain, most of 
them via the NPXY internalization motif (summarized in (De Strooper et al. 2000; 
Annaert et al. 2002). All adaptor proteins found to interact with the NPTY motif of 
APP so far, do so via their Phosphotyrosine binding domain (PTB). Besides Shc 
(Russo et al. 2002; Tarr et al. 2002), all of them are also reported to bind to non-
phosphorylated NPXY sequences. PTB domains are structurally highly conserved 
between mammals and invertebrates, and thereby presumably exhibit similar 
functional properties.  
Evidence for in vivo relevance of PTB domain protein binding to APP family proteins 
could be obtained from gain of function experiments in Drosophila mechano-sensory 
organ development. In this system, overexpression of APP family proteins leads to 
cell transformation reminiscent of Notch gain of function phenotypes (G. Merdes, 
pers. comm.). In contrast to the investigated wing phenotypes, this phenotype 
depended on both, the intra- and extracellular domain of APP (G. Merdes, pers. 
comm.). The PTB domain protein Numb is required for asymmetric cell division 
during bristle formation and regulates the cell fate decision via Notch signaling 
(Knoblich et al. 1995; Frise et al. 1996). 
Here, it was shown that the Drosophila PTB domain proteins Numb (dNmb) and 
Disabled (dDab) can interact with the APP intracellular domain in vitro. As described 
for mammalian PTB proteins, the NPTY motif is crucial for binding of both proteins. 
For dNmb however, deletion of the NPTY motif did not lead to a complete loss of 
binding in vitro. This suggests that a larger region is involved in the interaction, since 
deletion of the BASS sequence also resulted in some reduction in binding strength. 
In vivo however, NPTY motif deletion is sufficient to suppress APP induced bristles 
transformation in a dominant negative fashion (G. Merdes, pers. comm.). Moreover, 
coexpression of PTB proteins like human Fe65, which is not involved in bristles 
transformation, suppressed the APP induced phenotype (G. Merdes, pers. comm.), 
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probably by direct competitive binding to the NPTY motif. Intriguingly, APP family 
proteins are also recognized by the endogenous, Nmb dependent machinery and 
asymmetrically localized during cell division (G. Merdes, pers. comm.). Together, 
these results indicate that direct binding of Nmb to APP family proteins is necessary 
for their asymmetric localization and bristle transformation. Interestingly, the 
mammalian APP family proteins exhibited different in vitro binding affinities towards 
dNmb and dDab. In both cases, APLP1 showed the strongest interaction, while APP 
and APLP2 displayed only moderate binding, especially towards dNmb. Somehow 
surprising, APLP1 and APLP2 induced the strongest bristle phenotypes in vivo. 
These observations implicate that despite prerequisite binding of Nmb, which 
presumably is required for asymmetric localization of APP family proteins, phenotype 
induction is not due to sequestration of Nmb from endogenous target genes. 
Moreover, phenotype strength is supposedly determined by extracellular interactions, 
similar as already observed for the wing phenotypes induced by APP family proteins. 
This view allows the speculative hypothesis that phenotype induction in bristles and 
wing cell adhesion is triggered by the same mechanism, although this notion requires 
further investigation. 
A functional role of dDab in Drosophila has not been established yet  (Liebl et al. 
2003), but it might be involved in signal transduction events and endocytosis similar 
as its mammalian orthologues Dab1 (Sheldon et al. 1997) and Dab2, respectively 
(Hocevar et al. 2001; Morris et al. 2001; Mishra et al. 2002).  
In accordance with PTB domain conservation across species, human Numb and 
Dab2 could be shown to interact with mammalian APP family proteins as well. 
Intriguingly, binding specificities of these adaptor proteins in regard to APP are 
conserved between vertebrates and invertebrates, since a very similar binding 
behavior could be noted for Drosophila and human Nmb. Moreover, APLP1 interacts 
with Numb in mouse brain, which has previously been reported for APP (Roncarati et 
al. 2002). Although APP binding to Numb in mouse brain could not be confirmed in 
this work so far, these results imply a functional interaction of at least some APP 
family members with Numb in vivo. Since Numb is also required for asymmetric 
neuroblast division in mammals (Zhong et al. 2000; Shen et al. 2002), this interaction 
suggests a role for APP family members in neurogenesis.  
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These results confirm that functions and binding specificities of proteins can be 
conserved even between Drosophila and humans, and further underscore the 
feasibility of a heterologous approach in the search for an APP function. 
4.4 Trans-interaction of APP, APLP1, and APLP2 
4.4.1 Homo- and hetero-trans-dimerization of APP family proteins promotes 
cell adhesion 
Cell adhesion is an essential prerequisite for tissue and synapse formation and 
depends on cell-matrix and cell-cell interactions, mediated by so called cell adhesion 
molecules (CAMs). The cell adhesion function of CAMs like Cadherins is mediated 
by trans-dimerization of these proteins present at adjacent cells or at pre- and 
postsynaptic sites (Takai et al. 2003). Accumulating data, including the results 
obtained in this study for the Drosophila model system, are supporting the notion for 
an involvement of APP family proteins in cell adhesion. Consistently, homo-
dimerization of APP has previously been shown to occur by interaction of the 
Collagen binding domains, and possibly also by the Carbohydrate regions (Beher et 
al. 1996; Scheuermann et al. 2001). Moreover, recombinant sAPP is mainly 
recovered as a dimer, suggesting that homo-dimerization is an intrinsic property of 
APP (Beher et al. 1996; Scheuermann et al. 2001). The high degree of conservation 
of the Collagen binding domain and carbohydrate domain in all APP family members 
including APPL from Drosophila (Martin-Morris et al. 1990) and APL-1 from C. 
elegans (Daigle et al. 1993) is consistent with the notion that besides APP, also 
APLP1 and APLP2 can dimerize via their ectodomains. 
In this study, homophilic intercellular interactions of all APP family members were 
elucidated. This was shown by clustering of APP, APLP1, or APLP2 expressing S2-
cells in a cell aggregation assay, a system that has been used for similar 
experiments before (Tsiotra et al. 1996; Klueg et al. 1999; Islam et al. 2004). The 
results suggest that cell clustering is specifically mediated by trans-interaction of the 
corresponding ectodomains, since truncation of the APP ectodomain (SPA4CT) 
completely abolished clustering. This study further extend the previous finding for cis-
dimerization of APP (Scheuermann et al. 2001) and provide for the first time 
evidence that APP is also able to form trans-dimers, a property that is even more 
pronounced for APLP1 and APLP2. How can the observed differences in the 
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tendency to form trans-interactions be explained? For Cadherins, one of the best 
studied families of cell adhesion proteins, an equilibrium between lateral and 
adhesive dimers has been observed and both, cis- and trans-dimerization, occur via 
the same interfaces (Troyanovsky et al. 2003). Such a mechanism could hold true for 
APP family proteins as well, where steric properties of APLP1 and APLP2 might be 
the cause for stronger trans-interaction compared to APP. 
 
Fig. 4.2: Model of trans-interaction of APP family proteins. APP forms lateral intracellular, as well 
as adhesive intercellular dimers. The interaction of both might be mediated by the Collagen binding 
and Carbohydrate domains. Similar mechanisms might exist for APLP1 and APLP2. Hetero-trans-
dimerization of APP favors APLP1 over APLP2, an interaction that is limited to the nervous system 
and might take place at synaptic contacts. 
 
In addition to homophilic interaction, APP family proteins also exhibit heterophilic 
trans-dimerization properties. Heterotypic clustering was observed for all mixed 
combinations of cells expressing APP, APLP1, or APLP2. Again, SPA4CT was not 
coclustered, suggesting a specific ectodomain mediated interaction as observed for 
homotypic cell adhesion. However, significant differences in interaction efficiency 
were noted. Although APP has displayed a low tendency for homo-trans-dimerization 
before, profound hetero-complex formation with APLP1 was observed. In contrast, 
APLP2 exhibited a preference for homotypic over heterotypic interactions. Distinct 
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dimerization properties are also described for other CAMs, such as Nectins and 
Cadherins. While Nectin-1 and Nectin-3, members of the Immunoglobulin-like CAM 
family, preferentially show hetero-trans-dimerization (Satoh-Horikawa et al. 2000), 
Cadherins favor homophilic trans-interactions (Angst et al. 2001). 
Based on the observed heterophilic interaction preferences, a model for trans- 
interaction of APP family proteins would suggest preferential hetero-association of 
APP and APLP1 and homo-trans-dimerization of APLP2 (Fig. 4.2). This so far not 
described trans-association of APP family proteins sheds new light on functional 
properties of these proteins, suggesting a role in cell-cell adhesion by direct homo- 
and heterophilic trans-interaction. 
4.4.2 Trans-cellular interaction of APP family proteins is modulated by 
proteolysis and correlating with in vivo phenotype strength  
The trans-interaction properties observed for APP family proteins are also modulated 
by processing. This could be shown by analyzing cell clustering of APP or APPL 
expressing cells compared to APP-D8 or APPLsd, mutant constructs which are 
supposed to be less efficiently cleaved. Indeed, the processing deficient constructs 
displayed an increase in homotypic cell interactions indicating that elevated amounts 
of the full length proteins at the cell surface also mediate stronger cellular 
interactions. The other way round, this further suggests that trans-mediated 
interaction of APP family proteins might be regulated by processing. 
Bewilderingly, a correlation between in vitro cell clustering and in vivo phenotype 
strength can be deduced. All APP family members exhibiting strong trans-interaction 
properties are also inducing the strongest cell adhesion phenotypes in the Drosophila 
wing in vivo. This is especially evident when comparing APPLwt and APPLsd. While 
overexpression of APPL neither induced significant cell clustering nor a wing 
phenotype, APPLsd displayed both, strong cell clustering and wing blistering (see 
Table 1). Similarly, the other APP family members displayed consistent phenotype 
strength in vitro and in vivo (see Table 1). This observation suggests that trans-
dimerization of APP family proteins is involved in triggering cell adhesion defects in 
the Drosophila wing in vivo. Additionally, mosaic expression of APLP1 in imaginal 
wing discs also revealed rounding and detachment of expression clones from the 
surrounding tissue (A. Löwer, pers. comm.) supporting an involvement of homophilic 
trans-interaction in cell adhesion in vivo. This would also suggest that binding of 
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Glypicans might modulate dimerization of APLP2, since overexpression of Dally 
inhibited the APLP2 phenotype in vivo. 
Construct Wing phenotype Cell clustering 
APPL - - 
APPLsd +++ +++ 
APP + + 
APP-D8 ? ++ 
APP-M596I/F165P ++ (++) 
APLP1 +++ +++ 
APLP2 +++ +++ 
Table 1: Comparison of wing phenotype strength and cell clustering induced by APP family 
proteins. The effects of the expression of different APP family proteins, or mutants thereof, on the 
wing phenotype or homophilic cell clustering were classified: -, none or minor; +, clearly visible; ++, 
strong; +++, very strong. Brackets indicate preliminary observations. 
However, it is so far unclear, how processing influences the phenotype of APLP1 and 
APLP2 and why APPLsd is able to induce strong phenotypes and APPLwt not. 
Though it was published to be secretion deficient (Torroja et al. 1996), C-terminal 
fragments of APPLsd can still be detected if expressed in vivo (G. Merdes, pers. 
comm.) indicating that processing is still taking place. Nevertheless, proteolytic 
conversion of APPLsd might be reduced, leading to a similar effect as shown for APP 
secretion deficient mutants able to induce cell clustering and enhanced blistered wing 
phenotypes compared to APPwt. It remains to be investigated if cell clustering can 
also be modulated by applying α-secretase inhibitors (e.g. Batimastat), which would 
confirm the influence of processing on cell clustering properties of APP family 
proteins. 
4.4.3 APLP1 and APLP2 have a receptor-like function 
APP, APLP1, and APLP2 are highly dynamic proteins which are transported through 
the secretory pathway to the plasma membrane and subsequently internalized to 
lysosomal or endosomal compartments (Koo et al. 1994; Koo et al. 1996; Yamazaki 
et al. 1996). APLP1 and APLP2 were shown to mediate binding to sAPLP1 and 
sAPLP2 in a cellular context. As this property was enhanced with the APLP1∆NPTY 
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mutant, which is enriched in the plasma membrane, this interaction is proposed to 
take place at the cell surface. This observation is consistent with the results form the 
cellular aggregation assays, where full length APLP1 and APLP2 showed strong 
homophilic trans-interaction, suggesting that interaction between the full length 
proteins and their soluble ectodomains is also possible. However, no uptake of 
medium sAPP was observed in APP, APLP1, or APLP2 overexpressing cells. This 
result might be explained by the overall lower tendency of APP to form trans-
interactions compared to APLP1 and APLP2. Furthermore, APP binding proteins like 
Fibulin-1 could possibly be secreted by COS7 cells (Ohsawa et al. 2001), thereby 
preventing cellular sAPP uptake. 
 
Fig. 4.3: APLP1 and APLP2 mediated uptake of secreted fragments. APLP1 and APLP2 exhibited 
receptor-like properties in regard to their own secreted fragments, sAPLP1 and sAPLP2, respectively. 
Uptake of those fragments is presumably mediated by direct interaction with the full length proteins 
and subsequent internalization and transport to endosomal and lysosomal compartments. 
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Despite a clear decline of medium sAPLP1 or sAPLP2, no accumulation in cell 
extracts was observed. For APP, it has been shown that following internalization from 
the cell surface, the majority of the protein is rapidly sorted to lysosomal 
compartments for degradation (Koo et al. 1996). This possibly explains why no 
sAPLP1 or sAPLP2 was detected in cellular fractions after medium uptake (see 
Fig. 4.3). Preliminary evidence for this notion could be obtained with the lysosomal 
inhibitor Chloroquine, which resulted in accumulation of sAPLP1 in coculture 
experiments (unpublished observation). Without lysosomal inhibition, accumulation of 
intracellular sAPLP1 was only observed in APLP1∆NPTY expressing cells after 
cultivation for four days, since overexpression of APLP1 also leads to increased 
amounts of sAPLP1 in the medium over time. Under these conditions, sAPLP1 
accumulated in huge intracellular vesicle-like structures, possibly due to impaired 
internalization of APLP1∆NPTY. The observed phenomenon is reminiscent of 
accumulations of fused endosomal vesicles induced by overexpression of the 
constitutively active Rab5 mutant Q79L (Roberts et al. 1999). This Rab5 mutant is 
lacking its GTPase activity, which is thought to result in a higher rate of endocytosis, 
leading to giant endosomal accumulations. This would suggest that sAPLP1 is only 
incompletely internalized in APLP1∆NPTY expressing cells. However, the nature of 
the observed intracellular sAPLP1 accumulations remains to be clarified.  
It will further be interesting to analyze if APLP1 and APLP2 are transducing a cellular 
signal upon uptake of their extracellular fragments, and if this property is modulated 
by other ligands like Heparin or Glypicans. 
4.4.4 APP and APLP1 interact in synaptic compartments  
Cell adhesion molecules have been implicated in synaptogenesis and regulation of 
synaptic stability (Takai et al. 2003). Here, enrichment of APP, APLP1, and APLP2 in 
synaptic membranes is reported. Moreover, a hetero-complex of APP and APLP1 
was detected in synaptically enriched membrane fractions. The APP/APLP1 
interaction is highly specific, since only higher molecular weight forms of APP 
specifically enriched in synaptic compartments interact with APLP1. This strongly 
suggests a function of the APP family in the interaction of pre- and postsynaptic 
membranes. Consistent with this assumption, APP and APLP2 have been previously 
shown to be enriched at presynaptic terminals (Yamazaki et al. 1995; Lyckman et al. 
1998; Beher et al. 1999) and growth cones (Beher et al. 1999; Sabo et al. 2003), 
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while APLP1 is specifically localized to the postsynapse (Kim et al. 1995) and absent 
from presynaptic terminals (Lyckman et al. 1998). Additionally, all family members 
show developmentally increased expression levels correlating with postembryonic 
synaptogenesis (Moya et al. 1994; Sandbrink et al. 1994; Lorent et al. 1995). This 
intriguingly corroborates a role for APP family proteins in synaptic connectivity and 
adhesion, similarly as shown for other CAMs like Cadherins and Nectins (Takai et al. 
2003), which are involved in establishing and modulating synaptic contacts. 
These results also coincide with the functional redundancy of APP family proteins, 
which has nicely been shown by mouse knock out studies. While mice with single 
knockouts of APP, APLP1, or APLP2 are viable and show only mild phenotypes, 
combined APP-/- and APLP2-/-, or APLP1-/- and APLP2-/- knockout mice die shortly 
after birth with no obvious phenotype (von Koch et al. 1997; Heber et al. 2000). In 
contrast, APP-/- and APLP1-/- mice are viable and fairly normal, suggesting that 
APLP2 can functionally compensate for its homologues during embryonic 
development (Heber et al. 2000). The results from this study suggest that APP and 
APLP1 have closely interlinked functions, while APLP2 acts in a redundant, but 
possibly more independent manner. Due to the expression pattern of APLP1 (Lorent 
et al. 1995), APLP1 interaction with APP must be limited to the nervous system, quite 
probably to neurons. One might speculate that APLP2 is still able to compensate for 
the loss of APP and APLP1,  since it is expressed in neurons as well as in peripheral 
tissues in a similar pattern as APP (Slunt et al. 1994) and capable to mediate strong 
homophilic trans-interaction. On the other hand, loss of APLP2 and either APP or 
APLP1 might not be tolerated due to the inability of the remaining family member to 
mediate homophilic trans-interactions ubiquitously. Nevertheless, this tempting but 
speculative hypothesis remains to be proven in vivo. 
Besides the molecular interaction between APP and APLP1, a genetic 
interdependence of these two proteins was also observed, as APLP1 protein levels 
were upregulated in APP knock out mice. In former APP -/- mice studies no changes 
in mRNA levels of APLP1 were observed (Zheng et al. 1995), suggesting that APLP1 
is stabilized on the posttranscriptional level. Moreover, APLP1 is shifted to a higher 
apparent molecular weight in APP -/- compared to WT mice, indicating that 
posttranslational modification might lead to increased APLP1 protein stability. 
Preliminary results indicate that neither glycosylation nor sialylation are involved 
(unpublished observation). 
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4.5 Conclusions and outlook 
In summary, it was shown that APP, APLP1, and APLP2 exhibit properties of cell 
adhesion proteins. This is evident from cell adhesion phenotypes in Drosophila 
melanogaster and homo- and hetero-trans-dimerization observed for all APP family 
members. Moreover, APLP1 and APLP2 exhibit a receptor-like function for their 
corresponding secreted ectodomains, and APP and APLP1 are interacting in vivo in 
synaptic compartments. Additionally, the PTB domain proteins Numb and Disabled 
interact with the C-terminal NPTY motif of APP family proteins, possibly modulating 
the cell adhesion function and signal transduction properties. 
These data hint to a role for APP family proteins in cell adhesion, neurogenesis, and 
synaptic connectivity and modulation. Moreover, the data indicate that the interplay of 
the APP family members might be necessary for normal synaptic function. Genetic 
studies of APP, APLP1 and APLP2 knock out mice further support this view, since 
they propose functional redundancy and suggest a role for the APP family members 
in maturation of cortical synapses (Heber et al. 2000). Future studies should take into 
account that APP, APLP1, and APLP2 do not act exclusively on their own, but 
function in a complex interdependent manner. This might have implications for AD as 
well, especially as the APP/APLP1 hetero-complex presumably contributes to 
synaptic Aβ production, a process previously described to be modulated by neuronal 
activity (Kamenetz et al. 2003). Therefore, the functional interdependence of APP, 
APLP1, and APLP2 may further advance our understanding, not only of their role in 
normal physiology, but also pathogenesis. 
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5 Material and Methods 
5.1 Chemicals 
Agar Difco, Augsburg 
Agarose Invitrogen 
6-Aminohexane acid Merck-Schuchardt, Hohenbrunn 
Ampicillin Biomol, Hamburg 
Ammoniumperoxodisulfate Roth, Karlsruhe 
Bacto Tryptone Difco, Augsburg 
Bacto Yeast Extract Difco, Augsburg 
Benzonase Merck, Darmstadt 
Bicinchinonic acid Sigma, Deisenhofen 
Boric acid J.T.Baker, Deventer, Holland 
Bovine serum albumne (BSA) Roth, Karlsruhe 
Bromophenol-blue Serva, Heidelberg 
Calciumchloride J.T.Baker, Deventer, Holland 
Coppersulfate (CuSO4) Sigma, Deisenhofen 
CuSO4 solution (4%) Sigma, Deisenhofen 
DMSO (Dimethylsulfoxide) Sigma, Deisenhofen 
Disodiumhydrogenphosphate (Na2HPO4) Merck, Darmstadt 
DTT (Dithiothreitol) Serva, Heidelberg 
EDTA (Ethylendiaminetatracetate) Roth, Karlsruhe 
EGF (Epidermal growth factor) R&D Systems 
FGF-2 (Fibroblast growth factor 2) R&D Systems 
Ficoll P-400 Amersham 
Ethanol Riedel-de-Haen, Seelze 
Ethidiumbromide Sigma, Deisenhofen 
G418-sulfate PAA Laboratories  
L-Glutamine (200 mM) Sigma, Deisenhofen 
Glycerol Roth, Karlsruhe 
Heparin Sigma Deisenhofen 
Hydrochloric acid 37% Merck, Darmstadt 
Hygromycin B PAA Laboratories  
IPTG (Isopropylthiogalactoside) Biomol, Hamburg 
Isopropanol Roth,Karlsruhe 
Kanamycin Sigma, Deisenhofen 
β-Mercaptoethanol Sigma, Deisenhofen 
Methanol Merck, Darmstadt 
Milk powder Roth, Karlsruhe 
MOPS (3-(N-morpholine)propane sulfonic acid) Sigma, Deisenhofen 
Natriumchloride J.T.Baker, Deventer, Holland 
Nonidet P40  (NP-40) Fluka, Neu-Ulm   
Penicillin-Streptomycin Sigma, Deisenhofen 
PMSF (Phenylmethylsulfonylfluoride) Serva, Heidelberg 
Poly-L-Lysine (PLL) Sigma, Deisenhofen 
Polyoxyethylen-sorbitan-monolaurate( Tween20) Sigma, Deisenhofen 
Protogel (30 % (W/V) Acrylamide;   
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0,8 %(W/V) Bisacrylamide) National Diagnostics 
D(+)-Saccharose Roth, Karlsruhe 
Sodiumazide (NaN3) Sigma, Deisenhofen 
Sodiumdihydrogenphosphate (NaH2PO4) Merck, Darmstadt 
SDS (Sodiumdodecylsulfate) Sigma, Deisenhofen 
Sodiumpyruvate Sigma, Deisenhofen 
TMEDA (N,N,N’,N’-Tetramethylenediamine) Sigma, Deisenhofen 
Tricine Biomol, Hamburg 
Tris-HCl Sigma, Deisenhofen 
Urea Roth, Karlsruhe 
5.2 Materials 
1 kb (+) DNA-ladder Invitrogen 
B27 supplement Invitrogen  
Biomax MR single emulsion films Amersham (Kodak) 
Bis-Tris-Gels 4-12% Invitrogen 
BSA standard solution Pierce 
Complete Protease Inhibitor Cocktail Roche Molecular Diagnostics 
Dulbecco’s Modified Eagle’s Medium (DMEM) Sigma Deisenhofen 
DMEM/F-12 (1:1)  Invitrogen 
ECL solution Amersham 
Effectene Qiagen 
F-12/HAM nutrient mixture  Sigma, Deisenhofen 
Fetal calf serum (FCS) PAA Laboratories or  
Biochrom AG 
Freund’s Adjuvant complete or incomplete  Sigma, Deisenhofen 
Glutathione Sepharose 4 Fast Flow Amersham 
High Fidelity Polymerase Chain Reaction Mix Roche 
Hyperfilm ECL Amersham  
Lipofectamine Plus / Lipofectamine 2000 Invitrogen 
[35S]-L-Methionine >1000 Ci/mmol; Amersham 
Mimimum Essential Medium Eagle (MEM) Sigma, Deisenhofen 
N2-supplement  Invitrogen 
Nitrocellulose Protran 0,4 µm  Schleicher & Schuell 
Non-Essential Amino Acid Solution (100 x) Sigma, Deisenhofen 
Nucleobond  AX-Kit Macherey & Nagel 
OPTIMEM Invitrogen 
Pfu-DNA-Polymerase     Invitrogen 
Prestained Protein marker: Rainbow low Amersham 
Prestained Protein marker: Rainbow high   Amersham 
Prestained Protein Marker: Rainbow broad range Amersham 
[14C]-labeled Protein marker high Amersham 
[14C]-labeled Protein marker low Amersham 
Protein A-Sepharose Amersham 
Protein G-Sepharose  Sigma 
Qia Maxi Prep Kit Qiagen 
Qia Spin Mini Prep Kit Qiagen 
Qia Quick Gel Extraction Kit Qiagen 
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Quick Ligation Kit     New England Biolabs (NEB) 
T4-DNA-Ligase   Invitrogen 
Taq-DNA-Polymerase Invitrogen 
TNT-Coupled In Vitro Transcription/translation Kit Promega 
TOPO-cloning kit Invitrogen 
Trypsin-EDTA Sigma, Deisenhofen 
Restriction enzymes were purchased from Roche Molecular Diagnostics or New 
England Biolabs (NEB). 
Cell culture dishes and flasks purchased from Sarstedt, Falcon, Costar, or Greiner 
were used. 
Plasticware was purchased from Sarstedt, Falcon, or Eppendorf. 
5.3 Cell lines 
DH5α: E. coli supE44 ∆lacU169 (80 lacZ∆M15) hsdR17 recA1 endA1 gyrA96, thi-1 
relA1; (Hanahan et al. 1983) 
BL21 (DE3): E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal (DE3) endA Hte 
TKB1 (Stratagene): E. coli B F– dcm ompT hsdS(rB–mB–) gal λ(DE3) [pTK Tetr] 
Lysogenic for lambda DE3, which carries the T7 polymerase gene under lacUV5 
control. 
 
COS-7: African green monkey kidney epithelial cell line (Gluzman 1981) 
SH-SY5Y: human neuroblastoma (Ross et al. 1983) 
HEK 293: Human embryonic kidney tumor, SV40-transformed  
HeLa: human epithelial adenocarcinoma cells from cervix 
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5.4 Antibodies 
Name Protein(Epitope) WB IP (µl) IC/IH Reference 
57 hAPLP1           
(642-650/604-614 
aa) 
- 5 - Eggert et al. 2004
150 hAPLP1           
(553-592 aa) 
1:2.000 5 1:100 
(5%BS
A) 
Eggert et al. 2004
158 hAPLP2           
(672-696 aa) 
1:2.000 5 - Eggert et al. 2004
22734 hAPP695 
(ectodomain) 
- 5 - obtained from 
G. Multhaup 
40090 hAPP695  
(ectodomain) 
- - 1:100 obtained from 
G. Multhaup 
42464 hAPLP1           
(499-557 aa) 
1:2.000 5 - (Paliga et al. 
1997) 
42476 hAPLP2           
(608-662 aa) 
1:2.000 5 - Eggert et al. 2004
CT-11 hAPLP1           
(640-650 aa) 
1:10.000 3 1:2.000 Calbiochem 
CT-12 hAPLP2           
(752-763 aa) 
1:5.000 3 1:2.000 Calbiochem 
CT-13 
(2213) 
hAPP             
(682-695 aa) 
1:5.000 5 1:100 (Grziwa et al. 
2003) 
D2-II hAPLP2-751 1:10.000 3 1:2.000 Calbiochem 
WO2 Aβ (1-16 aa) 1 µg/ml 5 µg/ml - (Ida et al. 1996) 
22C11 hAPP             
(66-81aa) 
1:10.000 - - (Weidemann et 
al. 1989) 
3F10 rat αHA 1:5.000 - 1:100 Roche 
9E10 mouse αmyc 1:1.000 - 1:80 Roche 
JAC6  rat αmyc  - - 1:100 Serotec 
SVP-38 Synaptophysin 1:1.000 - - Sigma 
SDL.3D10 β-Tubulin III 1:1.000 - - Sigma 
TUB 2.1 β-Tubulin 1:1.000 - - Sigma 
K28/43 PSD-95 1:1.000 - - Upstate 
 LacZ - - 1:500 Roche 
 dWingless - - 1:100 DSHB 
2B10 dCut - - 1:100 DSHB 
C594.9B dDelta 1:10.000 - 1:100 DSHB 
 dNotch 1:1.000 - 1:100 DSHB 
9F8A9 dELAV 1:1.000 - - DSHB 
 
For Enhanced Chemical Luminescence (ECL) detection after Western blotting, 
appropriate Horseradish-Peroxidase (HRP) coupled anti-mouse (Promega), anti-
rabbit (Promega), or anti-rat (DAKO) antibodies were used as a 1:10.000 dilution. 
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For immunocytochemistry, corresponding Alexa488, Alexa568, Alexa594, or 
Alexa633 fluorescent dye-coupled, goat secondary antibodies were purchased from 
Molecular Probes and used as a 1:200 dilution. 
All experiments in this study were performed at least three times. 
5.5 Oligonucleotides 
All oligonucleotides were purchased from MWG Biotech. 
Primer name Sequence (5´→3´) Description 
M13rev CAGGAAACAGCTATGAC 
M13for GTAAAACGACGGCCAGT 
Sequencing and PCR of 
pSK(+) constructs 
s-APP695-2 GTGGCCGAGGAGATTCAGGA 
s-APP695-3 GAAGTTGAGCCTGTTGATGCC 
Sequencing and PCR of 
APP constructs 
s-APP695-Y682A GATGCAGCAGAACGGCGCCGAAAATCCAACCTAC 
s-APP695-N684A GCAGAACGGCTACGAAGCTCCAACCTACAAGTTC 
s-APP695-Y687A GAAAATCCAACCGCCAAGTTCTTTGAGCAGATGC 
APP mutagenesis PCR  
 
 
s-APP∆BASS GATGCTGAAGAAGAAACATCATGGTGTGGTG 
s-APP∆PEER GTTGACGCCGCTGTCACCCAGAACGGCTAC 
s-APP∆NPTY CCAAGATGCAGCAGCAGATGCAGAACTAG 
s-BASS-∆CT GTACACATCCATTCATTAGGGTGTGGTGGAGG 
APP mutagenesis PCR  
 
 
 
s-APP-∆CTGFP GCTGAAGAAGAAACAGATGGTGAGCAAGGGCGA 
as-GFP-APP-3´UTR CTGCTGTGGCGGGGGTTTACTTGTACAGCTCG 
for APP∆CT and GFP 
fusion preserving the 
APP 3´UTR 
 
BamHI-TEV-εAPP 
GCGGATCCGAGAACCTGTACTTCC
AAGGCGTGATGCTGAAGAAGAAA
C 
as-APP-ct-XhoI CGCCTCGAGCTAGTTCTGCATCTGC 
PCR amplification of 
εAPP (APPID) with 5´ TEV 
cleavage site 
s-APP-V614G CATCATCAAAAATTGGGGTTCTTTGCAGAAGATGTGGG 
s-APP-F615P CATCATCAAAAATTGGTGCCCTTTGCAGAAGATGTGGG 
s-APP-V614G/F615P CATCATCAAAAATTGGGGCCCTTTGCAGAAGATGTGGG 
APP mutagenesis PCR  
 
 
s-APP-M596I GATCTCTGAAGTGAAGATCGATGCAG 
as-APPM596I AATTCTGCATCGATCTTCACTTCAGA 
phosphorylated with  
BglII/EcoRI compatible 
ends for cassette cloning 
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Primer name Sequence (5´→3´) Description 
s-BglII-APP∆F616 GGCGAGATCTTTGCAGAGGATGTGGGTTCAAAC 
s-BglII-APP∆S622 GGCCAGATCTCAAACAAAGGTGCAATC 
s-APPsd CGCCCTGCTGCCGACTATGAAGTTCATCATC 
s-EcoRI-APP-D8 
GCCGAATTCCGACATGACTCAGGA
GACGATGACGATGACGATGACGA
TGGTTCAAACAAAGGTGC 
APP mutagenesis PCR  
 
 
 
Gal4 5´ TGGATTACAATGAAGCTACTGTCTTCTATCGAACAAGC 
Gal4 3´ CACCAAACCCAAAAAAAGAGTAAAATG 
Gal4 amplification  
 
s-Kozak-ATG-Nmb GCCACCATGAACAAATTACGGCAAAG 
as-Nmb-TAA-TOPO GCTTAAAGTTCAATTTCAAACGTC 
Human Numb PCR  
 
s-Nmb-1593 CCGATGGTTAGAAGAGGTGTC  
Human Numb 
sequencing 
s-Nmb-393 CCGTGATGGCACCACTCGTCG  
Human Numb 
sequencing  
s-∆NPTY-APLP1 GCGAACTGCAGCGGGAACGACCCTGACC 
s-APLP1-BamHI 
 
CGTGGATCCCGAGAAGGCAC 
 
 
APLP1∆NPTY 
mutagenesis PCR 
5.6 Plasmids 
pBluescript SK+      Stratagene 
pCEP4       Invitrogen 
pCDNA 3.1(+)-Hygro    Invitrogen 
pUAST      obtained from G. Merdes  
pCR II-TOPO     Invitrogen 
pMT-V5/HIS6-TOPO    Invitrogen 
pCEP4-APP695, -APLP1, and -APLP2 constructs have been previously described 
(Eggert et al. 2004) and have been kindly provided by S. Eggert. The pUAST-
SPA4CT-DA construct based on SPA4CT-DA, which has been previously described 
(Lichtenthaler et al. 1999), was kindly obtained from G. Merdes. pUAST-APP695 and 
the pUAST-APP/APLP2 chimeric construct have been described previously 
(Fossgreen et al. 1998). pGEX-4T2-GST-APLP1ID, pCRII-TOPO-dNumb and -dDab 
constructs were kindly obtained from G. Merdes. The pUAST-APP∆G0 constructs 
was kindly obtained from S. Scheuermann. The pGEX-4T1-GST-APLP2ID construct 
was kindly obtained from T. Grübl. 
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5.7 Cloning of constructs 
5.7.1 Cloning of APP nt-myc into pUAST 
APP nt-myc was cloned from a pSK(+)-APP695ntmyc plasmid by ligating the 
NotI/EcoRI (APP 5´) and EcoRI/XhoI (APP 3´) digested APP fragments with the 
corresponding NotI/XhoI digested pUAST vector. 
5.7.2 Cloning of APLP1 ct-myc into pUAST 
APLP1 ct-myc was cloned from the corresponding pSK(+)-APLP1 ct-myc plasmid by 
ligating the EcoRI/XhoI digested APLP1 cDNA with an EcoRI /XhoI digested pUAST 
vector. 
5.7.3 Cloning of APLP2 into pUAST 
pUAST-APLP2 without a myc-tag was cloned from the corresponding 
pSK(+)APLP2 ct-myc and pSK(+)APLP2 nt-myc plasmids. The EcoRI/BglII APLP2 
fragment from pSK(+)APLP2 ct-myc (APLP2 5´) and the BglII/SalI APLP2 fragment 
from pSK(+)APLP2 nt-myc (APLP2 3´) were ligated into an EcoRI/XhoI digested 
pUAST vector. 
5.7.4 Cloning of APP-Y682A, -N684A, and –Y687A 
pSK(+)-APP695 was used as a template and the constructs were generated by 
nested PCR with Pfu polymerase and appropriate primers. An initial PCR product 
was generated using sense mutagenesis primers and M13for under the following 
conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  1 min  72 °C 
25 cycles, approx. 300 bp 
One third of the PCR product was used as a primer, together with the sense primer 
s-APP695-3, and 100 ng of the XhoI/ClaI fragment of APP from pSK(+)APP695 as a 
template. 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
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Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
25 cycles, approx. 900 bp 
The PCR product was digested with EcoRI and SalI and ligated into an EcoRI/SalI 
digested pSK(+)-APP695 vector. The identity of the constructs was confirmed by 
sequencing. The constructs were further subcloned into pUAST and pCEP4 vectors 
by ligating the NotI/EcoRI and EcoRI/XhoI digested fragments with the corresponding 
NotI/XhoI digested vectors. 
5.7.5 Cloning of APP-BASS∆CT, -∆BASS, -∆PEER, and –∆NPTY 
pSK(+)-APP695 ntmyc was used as a template and the constructs were generated 
by nested PCR with Pfu polymerase and appropriate primers. APP-BASS∆CT was 
generated by introducing a stop codon at the desired site. An initial PCR product was 
generated using sense mutagenesis primers and M13for under the following 
conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  1 min  72 °C 
25 cycles, approx. 300 bp 
One third of the PCR product was used as a primer, together with the sense primer 
APP695-3, and 100 ng of the XhoI/ClaI fragment of APP from pSK(+)APP695 ntmyc 
as a template. 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  57 °C 
Elongation  2 min  72 °C 
25 cycles, approx. 900 bp 
The PCR product was digested with EcoRI and SalI and ligated into an EcoRI/SalI 
digested pSK(+)-APP695 nt-myc vector. The identity of the constructs was confirmed 
by sequencing. The constructs were further subcloned into pUAST and pCEP4 
vectors by ligating the NotI/EcoRI and EcoRI/XhoI digested fragments with the 
corresponding NotI/XhoI digested vectors. 
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5.7.6 Cloning of APP- ∆CT-GFP 
Green fluorescent Protein (GFP) was amplified by PCR from pEGFP-N1 with s-APP-
∆CT-GFP and as-GFP-APP-3´UTR primers as follows: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
25 cycles, approx. 700 bp 
One third of the PCR product was used as a primer, together with M13for as a sense 
primer and 20 ng of pSK(+)APP695 ntmyc as a template, to amplifiy the 3´UTR of  
the APP cDNA fused to GFP. 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
25 cycles, approx. 1.000 bp 
One third of the PCR product was again used as a primer, together with the sense 
primer s-APP695-3, and 100 ng of the XhoI/ClaI fragment of APP from 
pSK(+)APP695 ntmyc as a template. 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  95 °C 
Elongation  2 min  72 °C 
25 cycles, approx. 1.200 bp 
The PCR product was digested with EcoRI and SalI, and ligated into an EcoRI/SalI 
digested pSK(+) vector. The identity of the fragment was confirmed by sequencing. 
The EcoRI/SalI fragment containing the truncated APP∆CT-GFP construct was 
completed with the NotI/EcoRI fragment of APP nt-myc and subcloned into pUAST 
and pCEP4 vectors via NotI. 
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5.7.7 Cloning of Gal4 into pMT-TOPO 
The yeast Gal4 cDNA was amplified by PCR with the High Fidelity PCR Kit (Roche) 
and appropriate primers from a vector template under the following conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  3 min  72 °C 
30 cycles 
The 2643 bp product was cloned into the pMT/V5-His-TOPO vector (Invitrogen) 
according to the manufacturer’s protocol. 
5.7.8 Cloning of APP-V614G, -F615P, and –V614G/F615P 
pSK(+)-APP695 nt-myc was used as a template and the constructs were generated 
by nested PCR with Pfu polymerase and appropriate primers. An initial PCR product 
was generated using sense mutagenesis primers and M13for under the following 
conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
30 cycles, approx. 700 bp 
One third of the PCR product was used as a primer, together with the sense primer 
s-APP695-3, and 100 ng of the XhoI/ClaI fragment of APP from 
pSK(+)APP695 nt-myc as a template. 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
30 cycles, approx. 900 bp 
The PCR product was digested with EcoRI and SalI and ligated into an EcoRI/SalI 
digested pSK(+)-APP695ntmyc vector. The identity of the constructs was confirmed 
by sequencing. The constructs were further subcloned into pUAST and pCEP4 
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vectors by ligating the NotI/BglII and BglII/XhoI digested fragments with the 
corresponding NotI/XhoI digested vectors. 
5.7.9 Cloning of APP-M596I/V614G, - M596I/F615P, and – M596I/V614G/F615P 
The constructs described above were used as templates for cassette cloning of the 
M596I exchange. Phosphorylated sense and antisense oligonucleotides carrying the 
mutation and BglII/EcoRI compatible ends were annealed by heating to 95 °C, 
followed by slow cooling to room temperature. The template plasmids 
pSK(+)-APPntmyc -V614G, -F615P, and –V614G/F615P were digested with BglII 
and EcoRI and ligated with the phosphorylated oligonucleotide. The identity of the 
constructs was confirmed by sequencing. The constructs were further subcloned into 
pUAST and pCEP4 vectors by ligating the NotI/BglII and BglII/XhoI digested 
fragments with the corresponding NotI/XhoI digested vectors. 
5.7.10 Cloning of APP-∆F616 and -∆S622 
pSK(+)-APP695ntmyc was used as a template and the constructs were generated by 
PCR amplification with Pfu polymerase and appropriate primers containing a BglII 
site. The PCR product was generated using sense mutagenesis primers and M13for 
under the following conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
30 cycles, approx. 700 bp 
The PCR product was digested with BglII and SalI, and ligated into a BglII/SalI 
digested pSK(+)-APP695ntmyc vector preserving the 5´ region of APP. The identity 
of the constructs was confirmed by sequencing. The constructs were further 
subcloned into pUAST and pCEP4 vectors by ligating the NotI/EcoRI and EcoRI/XhoI 
digested fragments with the corresponding NotI/XhoI digested vectors. 
5.7.11 Cloning of APPsd 
pSK(+)-APP695ntmyc was used as a template and the construct was generated by 
nested PCR with Pfu polymerase and appropriate primers. An initial PCR product 
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was generated using the sense mutagenesis primer and M13for under the following 
conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
30 cycles, approx. 900 bp 
One third of the PCR product was used as a primer, together with the sense primer 
s-APP695-2, and 100 ng of the EcoRI/XhoI fragment of APP from 
pSK(+)-APP695ntmyc as a template. 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  3 min  72 °C 
30 cycles, approx. 1.300 bp 
The PCR product was digested with AatII and SalI and ligated into an AatII/SalI 
digested pSK(+)-APP695ntmyc vector. The identity of the construct was confirmed by 
sequencing. The construct was further subcloned into pUAST and pCEP4 vectors by 
ligating the NotI/AatII and AatII/XhoI digested APP sd fragments with the 
corresponding NotI/XhoI digested vectors. 
5.7.12 Cloning of APP-D8 
pSK(+)-APP695 ntmyc was used as a template and the construct was generated by 
PCR amplification with Pfu polymerase and an appropriate sense primer containing 
the internal APP EcoRI site. The PCR product was generated using the sense 
mutagenesis primer and M13for under the following conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
30 cycles, approx. 700 bp 
The PCR product was digested with EcoRI and XhoI, and ligated into an EcoRI/XhoI 
digested pSK(+) vector. The identity of the construct was confirmed by sequencing. 
The EcoRI/XhoI APP-D8 fragment was further subcloned into pUAST and pCEP4 
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vectors, together with an NotI/EcoRI digested APP ntmyc fragment, by ligation with 
the corresponding NotI/XhoI digested vectors. 
5.7.13 Cloning of GST fusions of the APP intracellular domain 
pSK(+)-APP695, -∆BASS, -∆G0, -∆PEER,–∆NPTY, -Y682A, -N684A, and –Y687A 
were used as templates to amplify the corresponding wild type or mutant APP 
intracellular domain. The constructs were generated by PCR with Pfu polymerase 
introducing 5´ BamHI (s-BamHI-TEV-εAPP) and 3´ XhoI (as-APPct-XhoI) restriction 
sites, and a 5´ TEV cleavage site into the amplified εAPP fragment under the 
following conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  30 s  72 °C 
30 cycles, approx. 150 bp 
The PCR product was digested with BamHI and XhoI and ligated into a BamHI/XhoI 
digested pGEX-4T2 vector. The identity of the constructs was confirmed by 
sequencing.  
5.7.14 Cloning of APPL and APPLsd into pUAST 
APPL and APPLsd were cloned from a pSL plasmid (kindly obtained from A. Löwer) 
by digesting with EcoRI and ligation into an EcoRI digested pUAST vector treated 
with calf intestinal phosphatase (CIP). The correct orientation of the insert was 
confirmed by digesting with ApaI. 
5.7.15 Cloning of pCDNA3.1 APLP1 nt-myc 
APLP1 nt-myc was subcloned from pSK(+)-APLP1 nt-myc into pCDNA 3.1 via 
NotI/XhoI. 
5.7.16 Cloning of APLP1∆NPTY nt-myc 
pSK(+)-APLP1 nt-myc was used as a template and the construct was generated by 
nested PCR with Pfu polymerase and appropriate primers. An initial PCR product 
  Material and Methods 
 87
was generated using a sense mutagenesis primer and M13for under the following 
conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  1 min  72 °C 
25 cycles, approx. 300 bp 
One third of the PCR product was used as a primer, together with the sense primer 
s-APLP1-BamHI, and 100 ng of the NotII/ClaI fragment of APLP1 nt-myc from 
pSK(+)-APLP1 nt-myc as a template. 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  2 min  72 °C 
30 cycles, approx. 1000 bp 
The PCR product was digested with BamHI and ClaI and ligated into an BamHI/ClaI 
digested pSK(+)-vector. The identity of the APLP1∆NPTY fragment was confirmed by 
sequencing. To complete the APLP1 nt-myc CDS, a NotI/StuI and StuI/BamHI 
fragment of APLP1 nt-myc from pSK(+)-APLP1 nt-myc was ligated into a NotI/BamHI 
digested pSK(+)-vector containing the APLP1∆NPTY fragment. The 
APLP1∆NPTY nt-myc construct was further subcloned into the pCEP4 vector via 
NotI/XhoI. Amino acids 635 to 646 (RHGYENPTYRFL) of the APLP1 C-terminus are 
deleted in APLP1∆NPTY. 
5.7.17 Cloning of human Numb 
Human Numb was cloned from genomic Drosophila DNA containing a P-element 
insert with the hNmb cDNA. The hNmb cDNA was amplified by PCR with Pfu 
polymerase and appropriate primers under the following conditions: 
Initial denaturizing 2 min  95 °C 
Denaturizing  30 s  95 °C 
Annealing  30 s  55 °C 
Elongation  4 min  72 °C 
30 cycles, approx. 1.800 bp 
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The PCR product was cloned into the pCRII-TOPO-TA vector (Invitrogen) according 
to the manufacturer’s protocol. The identity of the construct was confirmed by 
sequencing. hNmb was further subcloned into pCDNA3.1 via HindIII/XhoI. 
5.7.18 Cloning of human Dab2 
A pRK5-Dab2 plasmid was kindly obtained from G. Merdes.  
The Dab2 cDNA was subcloned into pSK(+) via ClaI and HindIII, and further into 
pCDNA3.1 via KpnI/NotI 
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5.8 DNA methods 
5.8.1 Ethanol precipitation of DNA 
Solutions: 3 M Sodium acetate pH 5.2 
100 % Ethanol 
70 % Ethanol 
TE-buffer (pH 8.0): 10 mM Tris/HCl pH 8.0 
1 mM EDTA pH 8.0 
1/10 Vol. of 3 M Sodium acetate, pH 5.2 and 2.5 Vol. 100 % Ethanol (-20 °C) was 
added to the DNA sample, mixed well, and incubated for 30 min at -20°C. The 
precipitated DNA was centrifuged for 20 min at 4 °C/13.000 rpm, washed with icecold 
70 % Ethanol, and centrifuged for 5 min at 4 °C/13.000 rpm. The supernatant was 
removed, and the precipitated DNA was air-dried and diluted in TE-buffer or H2O. 
5.8.2 PCR (Polymerase chain reaction) 
DNA was amplified by PCR using Taq, Pfu, or High Fidelity Taq/Pwo (Roche), as 
appropriate. Specific sense and antisense oligonucleotide primers flanking the 
desired target sequence were used. 
A typical PCR reaction was prepared as follows: 
10-100 ng DNA template 
1 µl Polymerase (1 U) 
5 µl 10 x reaction buffer 
1 µl 10 mM dNTP (Desoxy-Nucleotide-Triphosphate)-Mix: (dATP, dTTP, 
dGTP, dCTP) 
2 µl sense-Primer, 10 pM 
2 µl anti-sense-Primer, 10 pM 
ad 50   µl H2O 
PCR parameters were adjusted to the appropriate conditions. Generally, 25-35 
cycles were used for amplification. 
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5.8.3 Colony PCR  
Colony PCR allows screening of a large number of transformed E. coli colonies for 
positive clones before isolation from small scale cultures of these cells.  
Colonies were picked with a sterile toothpick and dipped three times in 25 µl dd H2O. 
To break the cell walls and release plasmid DNA, the mixture was boiled at 95°C for 
5 min prior to the PCR. Taq-Polymerase, dNTPs, MgCl2, and buffer were added, 
together with specific primers for the transformed plasmid. The PCR products were 
analyzed on an agarose gel.  
In parallel, small scale liquid cultures were inoculated with the colonies for isolation of 
plasmid DNA, and incubated on a shaker at 37° in LB-medium containing the 
appropriate antibiotic for selection.  
5.8.4 Restriction digestion of DNA 
A typical reaction was prepared as follows: 
1.0 µg DNA plasmid 
3 µl 10x reaction buffer 
0.5 – 1.0 µl Restriction enzyme (5-10 U) 
ad 30 µl  H2O 
The reaction was incubated at the appropriate temperature (generally 37 °C) for 
1-2 h. 
5.8.5 Analysis of DNA fragments on Agarose gels (Meyers et al. 1976)  
Solutions: 1 x TAE buffer:  40 mM Tris-acetate 
1 mM EDTA pH 8.0 
Ethidiumbromide stock:  10 mg/ml (use 1:10.000)   
6 x DNA sample buffer:  0.25 % (w/v) Bromophenol-blue 
60 % Glycerol (w/v) 
0.1 mM EDTA pH 8.0 
Depending on the size of the DNA fragments, appropriate 0.8-2 % (w/v) Agarose gels 
were used for separation. The Agarose was dissolved in 1xTAE buffer by boiling in a 
microvave oven. Ethidiumbromide was added to a final concentration of 1 µg/ml, and 
the solution was poured into a gel chamber. Samples supplemented with DNA 
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sample buffer and, for comparison, a 1 kb DNA ladder were loaded, and 
electrophoresis was performed at 100-200 V. 
After separation, the gels were photographed and printed with a RAYTEST IDA 
(Image and Documentation analysis) gel documentation device. The DNA fragments 
were cut out from the gel under UV light (254 nm) and transferred into an Eppendorf 
tube. 
To purify DNA fragments from agarose, the QIAquick gel extraction kit (Qiagen) was 
used according to the manufacturer’s protocol. The DNA was eluted in 30 µl H2O 
pH 8.4. 
5.8.6 Ligation 
A typical ligation reaction was prepared as follows: 
300 ng DNA insert fragment 
30 ng DNA vector fragment 
4 µl 5x T4-DNA-Ligase buffer 
1 µl T4-DNA-Ligase 
ad 20 µl  H2O 
Insert DNA was generally used in a 5-10 fold excess of vector DNA. The ligation 
reaction was incubated for 2-3 h at 16 °C. 
Alternatively, the Quick Ligation kit was used according to the manufacturers protocol 
(NEB). The ligation reaction was then incubated for 15-30 min at room temperature. 
5.8.7 Preparation of bactrial agar plates (Sambrook 1989)  
Solutions: LB-(Luria-Bertani) Medium:  0,5 % (w/v) NaCl 
        1 % (w/v) Bacto-Tryptone 
                          0.5 % (w/v) yeast extract 
                             20 mM Tris/HCl pH 7.5 
The pH value was adjusted to 7.0 with NaOH. 
 
2x YT-Medium:   1% (w/v) NaCl 
               1.6 % (w/v) Bacto-Tryptone 
               1% (w/v) yeast extract 
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               20 mM Tris/HCl pH 7.5  
The pH value was adjusted to 7.0 with NaOH. 
 
Bacto-Agar 
Ampicillin stock (100 mg/ml): use 1:1.000 
Kanamycin stock (50 mg/ml): use 1:1.000 
 
For agar plates, 7.5 g bacto-agar was added to 500 ml LB or 2xYT medium, and 
autoclaved. After cooling to 60 °C, the appropriate antibiotic was added to a final 
concentration of 100 µg/ml for Ampicillin or 50 µg/ml for Kanamycin, respectively. 
The liquid medium was poured into 10 cm culture dishes and allowed to cool to room 
temperature. The agar plates were stored upside down at 4°C and covered from 
light.  
5.8.8 Chemo-competent E. coli generated with the RbCl method 
RFI buffer:    100 mM RbCl  
  50 mM MnCl2 x 4 H2O  
30 mM Potassium acetate 
10 mM CaCl2 x 2 H2O  
  15 % Glycerol (w/v)  
The pH value was adjusted to 5.8 with acidic acid. The buffer was 
sterile filtered, and 50 ml aliquots were stored at -20 °C. 
RFII buffer: 10 mM MOPS (3-(N-Morpholino)-propanesulfonic acid) 
  10 mM RbCl  
75 mM CaCl2 x 2 H2O  
15 % Glycerol (w/v)  
The pH value was adjusted to 6.8 with NaOH. The buffer was sterile 
filtered, and 15 ml aliquots were stored at -20 °C. 
SOB-Med.: 20 g Bacto-Tryptone 
5 g Bacto-yeast extract 
0.5 g NaCl 
  ad 1 l dd H2O 
The components were dissolved and 10 ml of a 250 mM KCl solution 
were added. The pH value was adjusted to 7.0 with NaOH and the 
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water was added to a final volume of 1 l. Immediately before use, 5 ml 
of a 2 M MgCl2 solution were added. 
SOC-medium: identical to SOB-medium; additionally, 20 ml of a 1 M sterile filtered 
Glucose solution were added before use. 
A single colony (E. coli DH5α) was inoculated into 2 ml SOC-medium and incubated 
for 2 h at 37 °C under vigorous shaking. Afterwards, 500 µl were inoculated into 
50 ml SOB-medium and incubated at 37 °C, until an OD (600 nm) ~0.5-0.6 was 
reached. The following steps were conducted at 4 °C with pre-cooled material. The 
culture was transferred to 50 ml Falcon tubes and incubated for 15 min at 4 °C, and 
centrifuged at 3000 rpm/4 °C (Heraeus centrifuge) for 10 min. The sedimented cells 
were resuspended in 17 ml RFI buffer and incubated on ice for 30 min. The cells 
were again centrifuged at 3000 rpm/4 °C (Heraeus centrifuge) for 10 min, 
resuspended in 4 ml RFII buffer, and incubated on ice for 15 min. Aliquots of 200 µl 
were transferred into Eppendorf tubes and shock frozen in liquid nitrogen. Competent 
DH5α were stored at -80 °C. 
5.8.9 Transformation of chemo-competent E. coli  
LB-medium     
Chemo-competent DH5α 
Bacterial agar plates 
Chemo-competent cells were treated according to (Hanahan 1985). Cells were 
thawed on ice, and DNA (5-200 ng) was added to a 100 µl cell aliquot, and incubated 
for 15 min on ice. Cells were heat shocked for 45-60 s at 42 °C, and cooled on ice for 
5 min. 900 µl LB medium were added and cells were incubated for 45-60 min at 
37 °C on a roller shaker. Afterwards, different aliquots were plated on bacterial agar 
plates (50-500 µl) and incubated over night at 37 °C. 
5.8.10 Liquid cultures of bacteria 
LB-medium     
Small scale liquid cultures 
A single colony was inoculated into 2-3 ml LB medium supplemented with the 
appropriate antibiotic, and incubated over night at 37 °C under vigorous shaking. The 
bacterial culture was used for small scale DNA preparation (Mini Prep).  
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Large scale liquid cultures 
For large scale DNA preparation (MaxiPrep), a 1 ml pre-culture was inoculated into 
200 ml LB-medium supplemented with the appropriate antibiotic, and incubated over 
night at 37 °C under vigorous shaking. 
5.8.11 Small scale DNA preparation (Mini Prep) 
For small scale DNA preparation (1-5 µg), the Qiagen MiniPrep Kit was used. 
Buffers were supplied by Qiagen  
S1: 50 mM Tris/HCl, 10 mM EDTA, 100 µg RNase A / ml, pH 8.0 
S2: 200 mM NaOH, 1% SDS 
S3: 2.80 M Potassium acetate pH 5.1 
70 % Ethanol 
TE-buffer pH 8.0: 10 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.0 
 
Small scale liquid cultures (1-2 ml) were transferred into an Eppendorf tube and 
centrifuged at 6.000 rpm for 5 min. Cells were resuspended in 100 µl S1 buffer and 
further processed according to the manufacturer’s protocol. 
5.8.12 Large scale DNA preparation (Maxi Prep) 
For large scale DNA preparation (200-500 µg), the Qiagen Maxi Prep kit, or the 
Nucleobond AX-500 kit (Macherey & Nagel) were used. 
  S1: 50 mM Tris/HCl, 10 mM EDTA, 100 µg RNase A/ml pH 8.0 
   S2: 200 mM NaOH, 1% SDS 
S3: 2.80 M Potassium acetate pH 5.1 
N2: 100 mM Tris, 15 % Ethanol and 900 mM KCl pH 6.3  
N3: 100 mM Tris, 15 % Ethanol und 1150 mM KCl pH 6.3 
N5: 100 mM Tris, 15 % Ethanol und 1000 mM KCl pH 8.5  
Isopropanol p.a. 
3 M Sodium acetate pH 5.2  
100 % Ethanol p.a. (-20°C) 
70 % Ethanol p.a. (-20°C) 
TE-buffer pH 8.0: 10 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.0 
A large scale bacterial culture was centrifuged for 10 min at 6.000 rpm/4°C 
(Beckmann JA-2, rotor JA 10-158). Cells were resuspended in 12 ml S1 buffer and 
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further processed according to the manufacturer’s protocol. For low copy plasmids, 
double buffer amounts were used.  
Further, the DNA precipitated with Isopropanol was dissolved in 500 µl H2O and 
precipitated again with Ethanol as described. After centrifugation, the precipitated 
DNA was washed with 70 % Ethanol once and centrifuged for 5 min at 13.000 rpm. 
The DNA pellet was air-dried and dissolved in TE-buffer or H2O. 
5.8.13 Photometric analysis of DNA concentrations 
Concentrations of DNA were measured with a spectral photometer (Biorad Smart 
Spec 3000) at a wavelength of 260 nm. Generally, the DNA was diluted to 1:100 in 
H2O for measurement. 
A rule of thumb: 
ssDNA or ssRNA:  A260nm(1cm)= 1 c ~ 40 µg/ml 
dsDNA:   A260nm(1cm)= 1 c ~ 50 µg/ml 
 
The purity of the DNA samples was determined by measuring the A280nm and A310nm, 
which correspond to the absorption maxima of proteins and polysaccharides. For 
pure DNA, the A260nm/A280nm ratio is supposed to be between 1.8 and 2.0, with no 
absorption at A310nm.  
5.8.14 Phenol-chloroform extraction of DNA 
An equivalent volume of Phenol-Chloroform-Isoamylalcohol (25:24:1) was added to a 
DNA solution in TE buffer or H2O, and thoroughly vortexed for at least 1 min. The 
emulsion was centrifuged for 10 min at 14.000xg to achieve a separation of the 
phases. The aquatic, DNA containing phase on top was carefully transferred into a 
new Eppendorf tube. The procedure was repeated once, and the DNA was 
precipitated with Ethanol as described and dissolved in TE-buffer or H2O. 
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5.9 Biochemical protein methods 
5.9.1 Coupled in vitro transcription and translation 
The TNT Coupled-Transcription/Translations system (Promega) was used for direct in 
vitro translation of proteins. 1 µg of a plasmid encoding the desired protein under 
control of a T3 or T7 promotor was added to the provided reticulocyte lysate and 
buffers, which was further supplemented with the appropriate Polymerase according 
to the manufacturer’s protocol.  
A typical reaction was prepared on ice as follows: 
1 µg DNA template 
2 µl [35S]-Methionine (eq. to 20 µCi) 
40 µl Reticulocyte lysate 
1 µl T3 or T7 Polymerase 
ad 50 µl  nuclease-free H2O 
The reaction was incubated for 90 min at 30 °C. The sample was either used 
immediately or stored at -80 °C.  
5.9.2 Recombinant expression and purification of GST fusion proteins 
LB-medium 
10 x PBS (Phosphate buffered saline): 10 mM Na2HPO4 
2 mM KH2PO4 
137 mM NaCl 
2.7 mM KCl 
The pH value was adjusted to 7.4 with hydrochloric acid. 
IPTG stock:   1 M in H2O  
Ampicillin stock:  100 mg/ml 
Lysozyme stock: 50 mg/ml 
PMSF stock:  100  
Pulldown buffer: 20 mM Tris pH 7.4 
   150 mM NaCl 
   2 mM EDTA 
   0.2 % Triton X-100 
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For recombinant expression of GST fusion proteins, pGEX4 vectors (Amersham) and 
BL21 (DE3) bacteria were used. 20 ng of the plasmid was transformed into chemo-
competent BL21 cells as described and plated on Ampicillin (100 µg/ml) containing 
agar plates. A single colony was picked, inoculated into 50 ml LB-medium 
supplemented with Ampicillin (100 µg/ml), and grown at 37 °C over night with 
vigorous shaking. The next day, cells were centrifuged at 6000 rpm for 10 min, and 
resuspended in 200 ml LB-medium supplemented with Ampicillin (100 µg/ml). Cells 
were grown at 37 °C with vigorous shaking, until an OD600nm of ~1 was reached. 
Expression of the fusion proteins was then induced by adding IPTG to a final 
concentration of 1 mM. After 2-3 h of expression, cells were harvested by 
centrifugation at 6000 rpm for 10 min, and resuspended in 30 ml PBS on ice. 
Lysozyme was added to a final concentration of 50 µg/ml and incubated for 30 min 
on ice. PMSF was added and cells were disrupted by sonification (Branson sonifier 
tip) with 30 bursts (1 per second) at 50 % of the maximum output. The cell lysate was 
supplemented with Triton X-100 to a final concentration of 1 % and centrifuged at 
5000 rpm for 10 min (Heraeus Minifuge RF). The supernatant was recovered and 
incubated with an appropriate amount (100-1000 µl 50 % slurry) of Glutathione 
Sepharose (Amersham) for 1 h at room temperature. The Sepharose with bound 
GST fusion proteins was sedimented at 5000 rpm for 5 min (Heraeus Minifuge RF), 
and washed three times with PBS containing 1 % Triton X-100. The Sepharose 
beads were resuspended as a 50 % slurry in pulldown buffer, supplemented with 
0.02 % NaN3, and stored at 4 °C. For verification of loaded GST fusion protein 
amounts, 10 µl of the Sepharose bead suspension were denatured in SDS sample 
buffer for 10 min at 70 °C and analyzed by SDS-PAGE and Coomassie staining. 
5.9.3 In vitro pulldown assays 
Pulldown buffer 
2x SDS sample buffer:  0.125 M Tris/HCl pH 6.8 
20 % (w/v) Glycerin 
4 % SDS 
      10% β-Mercaptoethanol 
0.01 % Bromophenol-blue 
Coomassie staining solution: 0.1 % (w/v) Coomassie Brilliant Blue R-250 
     45 % (v/v) Methanol 
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     45 % (v/v) dd H2O 
     10 % (v/v) Acetic acid 
Destaining/fixation solution: 30 % (v/v) Methanol 
     60 % (v/v) dd H2O 
     10 % (v/v) Acetic acid 
 
To analyze in vitro interaction of two proteins, binding of in vitro translated 35S-
Methionine labeled proteins to GST fusion proteins coupled to Glutathione-
Sepharose beads was utilized.  
Typically, 10 µl of an in vitro translated protein were added to 30 µl of GST fusion 
proteins coupled to Glutathione-Sepharose beads (50 % slurry) in 500 µl pulldown 
buffer, and incubated for 2-3 h at room temperature on an overhead shaker. The 
Sepharose beads were washed three times with pulldown buffer and recovered by 
centrifugation at 10.000x g for 30 s. The buffer was completely removed from the 
beads with a Hamilton syringe, and the Sepharose beads were denatured in 2x SDS 
sample buffer for 10 min at 70 °C. The samples were analyzed by SDS-PAGE, and 
the gel was stained with Coomassie staining solution for 30 min on a horizontal 
shaker. Afterwards, the gel was incubated several times with destaining solution, until 
the nonspecific Coomassie background has been completely washed out. The gel 
was rehydrated in ddH2O and dried on a gel dryer for 1 h at 70 °C. The presence of 
in vitro translated labeled proteins interacting with the GST fusion proteins was 
analyzed by autoradiography with 35S-Methionie sensitive MR-films (Kodak). 
5.9.4 Cell lysis 
1x PBS 
Lysis buffer: 50 mM Tris pH 7.4 
  150 mM NaCl 
  2 mM EDTA 
  1 % NP-40 
Complete Protease Inhibitor Mix (Roche) 
2x SDS sample buffer 
 
Cells were washed once with cold PBS, scraped in 500 µl 1x PBS, and transferred 
into an Eppendorf tube. Residual cells in the dish were scraped again in 500 µl 
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1x PBS, and transferred into the same tube. Cells were centrifuged at 300x g for 
5 min, the PBS was removed, and an appropriate amount (50-500 µl) of cell lysis 
buffer supplemented with Complete Protease Inhibitors was added. Cells were 
resuspended in the lysis buffer and incubated for 20 min on ice. The lysate was 
cleared from debris and nuclei by centrifugation at 16.000x g for 10 min. The 
supernatant was used immediately for immunoprecipitation, or denatured with the 
appropriate amount of 2x SDS sample buffer. Alternatively, cell lysates were stored 
at -80 °C for later use. 
5.9.5 Immunoprecipitation of medium samples and cell lysates 
Washing buffer A (Wash A):  10 mM Tris/ HCl pH 7.5 
     150 mM NaCl 
2 mM EDTA 
0.2 % NP40 
Washing buffer B (Wash B):  like Wash A, but with 500 mM NaCl instead 
Washing buffer C (Wash C):  10 mM Tris/HCl pH 7.5 
2x SDS sample buffer  
Protein A sepharose (Amersham) as a 50 % slurry in Wash A, 0.02 % NaN3 
Protein G sepharose (Sigma) as a 50 % slurry in Wash A, 0.02 % NaN3 
If not stated otherwise, proteins from medium samples or cell lysates were 
precipitated with appropriate antibodies and 30 µl Protein A (for polyclonal 
antibodies) or Protein G (for monoclonal mouse antibodies). Medium aliquots were 
cleared from cell debris by centrifugation at 15.000x g for 10 min. Cell lysates 
(minimum sample volume was 500 µl) were generally preincubated for 1 h at 4 °C 
with 10 µl of Protein A/G sepharose to reduce unspecific binding. Equally, antibodies 
were prebound to 30 µl of Protein A/G sepharose in 500 µl Wash A by incubating on 
an overhead shaker for 1 h at room temperature. The sepharose beads were 
sedimented at 15.000x g for 30 s, and the cell lysate supernatant was transferred to 
the prebound antibody beads. The samples were incubated for 2-3 h at room 
temperature, or over night at 4 °C. The sepharose beads were centrifuged at 
15.000x g for 30 s, and washed three times with Wash A buffer. In case of unspecific 
binding, additional washing steps with Wash B and Wash C were performed. The 
buffer was completely removed with a Hamilton syringe, and the Sepharose beads 
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were denatured in 2x SDS sample buffer for 10 min at 70 °C. The samples were 
further analyzed by SDS-PAGE and Western blotting. 
5.9.6 Preparation of brain extracts and coimmunoprecipitation  
TBS buffer: 50 mM Tris pH 7.4 
150 mM NaCl 
5 mM EDTA   
Whole mouse brain extracts were prepared from age matched wild type (CG/BL6), 
APP -/-, APLP1 -/-, and APLP2 -/- mice by homogenization in TBS supplemented 
with Complete (Roche Molecular Diagnostics) in a Teflon tissue homogenizer at 
800 rpm with 12 up and down passes. The homogenates were adjusted to 1 % NP-
40 and incubated for 1 h at 4 °C. Afterwards non-solubilized tissue was removed by 
centrifugation at 2.000x g for 15 min and subsequently at 16.000x g for 10 min. Total 
protein levels were determined by a BCA protein assay (Sigma). For 
coimmunoprecipitation, brain extracts containing equal protein levels were 
preincubated with Protein A-Sepharose (Amersham Pharmacia) for 1h at 4 °C. 
Afterwards, supernatants were precipitated with an anti-APLP1 antibody (57) and 
Protein A-Sepharose overnight at 4 °C. Sepharose-beads were washed three times 
with lysis buffer, denatured in SDS sample buffer, and analyzed on 8% Tris-Glycin 
gels.  
5.9.7 Synaptic plasma membrane preparation 
Sol A:    5 mM HEPES/HCl pH 7.4 
     320 mM Sucrose 
Krebs buffer:   145 mM NaCl 5mM KCl 
     1.2 ml Ca2Cl  1.3 mM MgCl2  
     1.2 mM NaH2PO4 10 mM Glucose 
     20 mM HEPES/HCl pH 7.4  
Hypotonic lysis buffer: 5 mM Tris/HCl pH 8.0 
Ficoll solution:  7.5 % (w/v) and 12.5 % (w/v) Ficoll 400 in Sol A 
Sucrose solution:  10 % (w/w), 28.5 % (w/w), and 48 % (w/w) in H2O 
Preparation of synaptic plasma membranes was performed as previously described 
(Gordon Weeks 1987). If not stated otherwise, all steps were performed on ice. Two 
mouse brains were placed in 10x Vol. Sol A buffer and homogenized with a Teflon 
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tissue homogenizer at 800 rpm with 12 up and down passes. The homogenate was 
centrifuged at 1.000x gmax (2400 rpm Heraeus RF2) for 5 min, and the supernatant 
was recovered. The sediment was resuspended in 10x Vol. Sol A buffer, and 
centrifuged again at 1.000x gmax (2.400 rpm, Heraeus RF2) for 5 min. Both 
supernatants were centrifuged at 12.000x gmax (9.340 rpm, Beckmann JA-17) for 
20 min, and the supernatant containing soluble proteins was discarded. The crude 
membrane fraction (RSM) was resuspended in 5 ml Sol A buffer. A Ficoll step 
gradient was made by layering 4.5 ml 12 % (w/v) Ficoll  in Sol A underneath 4,5 ml 
7.5 % (w/v) Ficoll in Sol A  in an  SW40 (Beckmann) polyallomer tube. 2.5 ml of the 
RSM fraction were carefully layered onto the Ficoll gradient and centrifuged at 
68.000x gav (23200 rpm, SW40 Beckmann) for 1 h. Synaptosomes were recovered 
from the 7.5 %/12.5 % Ficoll-interphase and transferred into a small beaker. With 
slow stirring, Krebs buffer was added dropwise at room temperature to a total volume 
of 15 ml to rehydrate the Synaptosomes. The renatured synaptosomes were 
centrifuged at 12.000x gmax (9340 rpm, JA-17) for 20 min, and the sediment was 
resuspended with a Dounce homogenisator in 1.5 ml Krebs buffer. The 
synaptosomes were incubated at 37 °C for 10 min, centrifuged at 10.000x gmax for 
15 s, and resuspended with a Dounce homogenisator in 12.5 ml hypotonic lysis 
buffer. Synaptosomes were incubated at 4 °C for 30 min and resuspended with a 
tight-fitting Dounce homogenisator. The lysed synaptosomes were centrifuged at 
100.000x gmax (23700 rpm, SW40) for 30 min, and resuspended in 1.6 ml hypotonic 
lysis buffer. The synaptosome fraction was mixed with 10 ml 48 % (w/w) Sucrose in 
dd H2O (34 % (w/w) final Sucrose  concentration) and 5.5 ml were layered 
underneath 5.5 ml 28.5 % (w/w) Sucrose, which was again layered underneath 
1.5 ml 10 % (w/w) Sucrose. The Sucrose gradient was centrifuged at 60.000x gav 
(21800 rpm, SW40) for 110 min and synaptic plasma membranes (SPMs) were 
recovered from the 34 %/28.5 % Sucrose-interphase. The SPMs were diluted 1:10 in 
hypotonic lysis buffer and centrifuged at 100.000x gmax (23.700 rpm, SW40) for 
30 min. The SPMs were either resuspended in hypotonic lysis buffer and shock 
frozen, or extracted with 1 % NP-40 lysis buffer for coimmunoprecipitation 
experiments. 
For coimmunoprecipitation of APP and APLP1 from SPMs and wild type mouse brain 
homogenates, equal amounts were incubated with either preimmune serum or 
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antibody 57 overnight at 4 °C, and further analyzed by SDS-PAGE and 
immunoblotted with 22C11 against APP. 
5.9.8 Quantitative chase analysis of APP, APLP1, and APLP2 expressing 
cells 
Washing buffer A (Wash A):  10 mM Tris/ HCl pH 7.5 
     150 mM NaCl 
2 mM EDTA 
0.2 % NP40 
COS-7 cell lines expressing APLP1, APLP2, or vector only were labelled with 
200 µCi [35S]-Methionine in MEM w/o Methionine (Sigma) and 5 % dialyzed FCS 
(Sigma) for 1h, and rinsed twice with 1x PBS. Fresh medium (Methionine free MEM 
and 5% dialyzed FCS) was added and conditioned for 3h. Media (containing labeled 
proteins depicted as sAPP*, sAPLP1*, and sAPLP2*) were collected and centrifuged 
at 5.000x g for 15 min, and cold Methionine was added to a final concentration of 10 
mM to prevent further labeling.  
Non-labeled cell lines expressing APP, APLP1, APLP2, or vector only, were rinsed 
with 1x PBS twice and incubated with the collected labeled medium containing either 
sAPLP1, sAPLP2, or control for 1h. Medium levels of sAPLP1* or sAPLP2* were 
analyzed after 0h and 1h. Therefore, the media were centrifuged at 10.000 g for 
10 min and 1 ml aliquots of the supernatants were subjected to immunoprecipitation 
with 42464 (sAPLP1) or 42476 (sAPLP2) over night at 4 °C, washed three times with 
Wash A, and denatured in 2x SDS sample buffer at 95 °C for 5 min, followed by 
SDS-PAGE analysis, and autoradiography. Equally, the incubated cells were 
collected in PBS and centrifuged at 5.000 g for 3 min on a 20% Sucrose cushion to 
prevent contamination with sAPLP1* and sAPLP2* not associated with the cells. 
Cells were resuspended in lysis buffer supplemented with Complete (Roche 
Molecular Diagnostics), lysed on ice for 20 min, and centrifuged at 6.000 g/4 °C for 
10 min. Supernatants were analyzed by immunoprecipitating sAPLP1* and sAPLP2*, 
as described for medium fractions, and autoradiography. Chase experiments of 
APLP1 or APLP1∆NPTY expressing cells incubated with sAPLP1* containing 
medium were performed as described above, except that medium aliquots were 
taken after 0, 1, 3, 5, and 7 h. The collected medium aliquots were then centrifuged 
at 10.000x g for 10 min and immunoprecipitated with 42464, subjected to SDS-PAGE 
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and autoradiography. All autoradiographs were scanned and signals were quantified 
using Image Gauge (Fuji Systems). Expression of all cell lines was confirmed by 
Western blotting. For APLP1 and APLP1∆NPTY, relative expression levels were 
determined by immunoblotting with ab42464 and normalized to β-Tubulin (Sigma).  
5.9.9 Determination of protein concentrations 
BioRad DC protein assay (Biorad) 
Bicinchoninic acid (BCA) (Sigma) 
4% CuSO4 solution (Sigma) 
BSA (Bovine Serum Albumin) standard solutions (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 
1.0 mg/ml). 
ELISA 96-well plate (Greiner) 
The protein concentration of lysate supernatants was determined using the BioRad 
DC protein assay (Biorad) or a BCA assay (Sigma) according to the manufacturer´s 
protocol.  
The BioRad DC protein assay is based on a Lowry assay (Lowry et al. 1951), where 
proteins react with an alkaline copper tartrate solution and reduce the added folin 
reagent. The reduced folin species have a characteristic blue color with an 
absorption maximum of 750 nm.  
The BCA assay is based on a quantitatively catalyzed reaction of the BCA-Cu2+-
complex to the reduced BCA-Cu+-complex, which is accompanied by a color change 
with an absorption maximum at 550 nm. 
For the BCA assay, 20 µl of each BSA standard solution and cell lysate (1:10 
dilution) were pippeted into the ELISA plate in triplicates. The 4 % CuSO4 solution 
was diluted 1:40 with the BCA solution, and 200 µl of the mixture were added to the 
standards and lysates. The plate was incubated for 15 min at 37 °C, and further 
15 min at room temperature on a horizontal shaker. 
Absorption was measured with a microplate-reader (BIO-RAD, model 450) at 
550 nm, and protein concentrations were calculated with the BSA standard curve. 
5.9.10 Discontinous SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)  
Tris-Tricine gels were prepared according to (Laemmli 1970). 
Buffers: 30 % (w/v) Acrylamide; 0.8 % (w/v) Bisacrylamide (Protogel) 
separation gel buffer: 2 M Tris/HCl, pH 8.8 
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Stacking gel buffer: 1 M Tris/HCl, pH 6.8 
20 % (w/v) SDS (Sodium dodecylsulfate) 
10 % (w/v) APS (Ammoniumperoxodisulfate) 
TMEDA 
1 x running buffer: 25 mM Tris-base, 192 mM Glycine, 0.1 % SDS 
Separating gel: 
Gel 
percentage 
Protogel 
(ml) 
2 M Tris, 
pH 8.8 
(ml) 
20 % 
SDS 
(ml) 
ddH2O
(ml) 
10 % APS
(ml) 
TMEDA 
(ml) 
Final 
volume
 (ml) 
15 % 15 5.6 0.15 9.1 0.1 0.02 30 
8 % 8 5.6 0.15 16.1 0.1 0.02 30 
Stacking gel: 
Protogel 
(ml) 
1 M Tris, 
pH 6.8 
(ml) 
20 % SDS
(ml) 
ddH2O 
(ml) 
10 % APS
(ml) 
TMEDA 
(ml) 
Final 
volume 
 (ml) 
1.67 1.25 0.05 7.00 0.05 0.015 10.035 
Elektrophoresis was performed over night at 70-90 V. 
Precut glass plates (20 x 20 cm) were assembled with Teflon spacers (1 mm) and a 
silicon tube and used for casting the gel. 
5.9.11 Tris-Tricine-PAGE 
Tris-Tricine gels were prepared according to (Schagger et al. 1987). 
Cathode buffer: 0.1 M Tris, 0.1 M Tricin, 0.1% SDS 
Anode buffer:  0.2 M Tris/HCl pH 8.9 
Gel buffer: 3 M Tris, 0.3 % SDS, pH 8.45  
 Stacking 
gel 
4% T 
3 % C 
Separating 
gel 
10 % T 
3 %C 
Separating 
gel 
16.5 % T 
3 % C 
Separating 
gel 
16.5 % T 
6 % C 
49,5 % T solution 
3 % C solution 1 ml 6.1 ml 10 ml - 
49,5 % T solution 
 6 % C solution - - - 10 ml 
Gel buffer 3.1 ml 10 ml 10 ml 10 ml 
Glycerol - 4 g 4 g 4 g 
ad H2O  12.5 ml 30 ml 30 ml 30 ml 
10 % (w/v) APS 150 µl 150 µl 150 µl 150 µl 
TMEDA 20 µl 20 µl 20 µl 20 µl 
[T = Acrylamide; C = Bisacrylamide] 
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Alternatively, for separation of small molecular weight proteins, precast 10-20 % Tris-
Tricine gels (Invitrogen) were run with 1x cathode buffer for 90 min at 140 V. 
5.9.12 Bis-Tris-HCl polyacrylamide gel electrophoresis 
Separation of proteins by electrophoresis was also carried out using precast 4-12 % 
Bis-Tris gels (Invitrogen). 
20 x MES buffer:  1 M MES, 1 M Tris base, 69.3 mM SDS, 20.5 mM EDTA 
20x MOPS buffer:  1 M MOPS, 1 M Tris base, 69.3 mM SDS, 20.5mM EDTA. 
Depending on the molecular weight of the protein of interest, 1x MOPS (50-100 kDa) 
or 1x MES (10-50 kDa) running buffer were used due to different separation 
properties. 
5.9.13 Western blotting (semi-dry) 
Proteins separated by SDS-PAGE were transferred from the gel to a nitrocellulose 
membrane by electrophoresis (Western blotting).  
Cathode buffer:  25 mM Tris base, 40 mM 6-Aminohexane acid, 20 % Methanol 
Anode buffer I:  30 mM Tris base, 20 % Methanol 
Anoden buffer II:  300 mM Tris base, 20 % Methanol 
Nine sheets of Whatman paper were cut according to the gel size and three sheets 
were soaked with each buffer. A nitrocellulose membrane was also presoaked in 
Anode I buffer. The blot was assembled on a semi-dry apperature as follows: 
Cathode (-) 
3 Whatman sheets soaked with cathode buffer 
SDS gel 
Nitrocellulose soaked with Anode I buffer 
3 Whatman sheets soaked with anode I buffer 
3 Whatman sheets soaked with anode II buffer 
Anode (+) 
The proteins were blotted for 1-1.5 h at 1 mA/cm2. 
5.9.14 Western blotting (wet blot) 
Transfer buffer: 192 mM Glycin, 25 mM Tris-Base, 20 % Methanol 
Following SDS-PAGE, the gel was equilibrated in transfer buffer for 5 min. Whatman 
sheets and a nitrocellulose membrane were cut to the size of the gel and soaked in 
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transfer buffer. The gel and the membrane were sandwiched between soaked pieces 
of sponge pads, Whatman paper, and perforated plastic plates as follows: 
Anode (+) 
Sponge pad 
2 Whatman sheets 
Nitrocellulose 
SDS gel 
2 Whatman sheets 
Sponge pad 
Cathode (-) 
The transfer was performed in a blotting tank (Biorad) for 1-3 h at 380 mA at 4°C. 
5.9.15 Ponceau S-staining  
Ponceau S-solution:  0.2 % (w/v) Ponceau-S red,  
3 % (w/v) sulfonic acid 
0.1 % (v/v) glacial acid. 
Proteins immobilized on a membrane can be reversibly stained with the Ponceau S-
dye to evaluate the efficiency of protein transfer after western blotting. The 
nitrocellulose membrane was incubated in Ponceau S-solution on a horizontal shaker 
for 5 min. The staining solution was recovered, and unspecifically bound dye was 
removed by incubation with dd H2O. The membrane staining could be completely 
removed by incubation with 1x PBS.  
5.9.16 Western blot detection 
10x PBS 
10x TBST (Tris buffered saline Tween): 100 mM Tris/HCl 
1.5 M NaCl 
0.5 % Tween 20  
ECL-Kit (Amersham) 
After western blot transfer of the proteins to the nitrocellulose membrane, the 
membrane was blocked for 1 h in 1x TBST/5 % (w/v) skimmed milk. The primary 
antibody was diluted in 1x TBST to an appropriate concentration and the blot was 
incubated either for 2-4 h at room temperature or overnight at 4 °C. The membrane 
was washed twice with 1x TBST, and further incubated two times in 1x TBST for 
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10 min. Incubation of the blot with the secondary antibody conjugated to horseradish 
peroxidase (HRP, dilution 1:10.000) was carried out for 1 h at room temperature. The 
membrane was again washed twice with 1x TBST, and further incubated two times in 
1x TBST for 10 min. The protein of interest was detected by enhanced chemical 
luminescence (ECL) utilizing the reaction of Luminol and H2O2, which is catalyzed by 
HRP. For this purpose, the membrane was incubated with the ECL (Amersham) 
reagent for 1 min and the chemifluorescent signal was visualized by exposure of 
Hyperfilm ECL (Amersham) films.  
5.9.17 Reprobing of Western blot membranes 
Stripping buffer:  62.5 mM Tris/HCl pH 6.7 
100 mM β-Mercaptoethanol  
2 % SDS  
For reprobing the membrane with different antibodies, the previously applied 
antibodies had to be removed first. For this purpose, stripping buffer was preheated 
to 80 °C. The membrane was incubated with 100-200 ml preheated stripping buffer 
on a horizontal shaker until room temperature was reached (30-45 min). The 
membrane was further incubated several times with 1x TBST, until no residual 
β-Mercaptoethanol could be detected (3-5 times). The blot was again blocked in 
1x TBST/5 % (w/v) skimmed milk for 1 h, and a new primary antibody could be 
applied as described. 
5.9.18 Coomassie staining of proteins 
Coomassie staining solution: 0.1 % (w/v) Coomassie Brilliant Blue R-250 
     45 % (v/v) Methanol 
     45 % (v/v) dd H2O 
     10 % (v/v) Acetic acid 
Destaining/fixation solution: 30 % (v/v) Methanol 
     60 % (v/v) dd H2O 
     10 % (v/v) Acetic acid 
After SDS-PAGE, the gel was incubated with Coomassie staining solution on a 
horizontal shaker for 30 min. Afterwards, the gel was washed several times with 
destaining solution on a horizontal shaker, until the nonspecific Coomassie 
background has been removed. The gel was rehydrated in ddH2O for 1-3 h. Two 
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sheets of Whatman paper were soaked with dd H2O and the gel was put on top of the 
Whatman papers and covered with cling film. The gel was then dried on a vacuum 
gel dryer for 1-1.5 h at 70 °C. 
5.9.19 Autoradiography of gels with radioactive samples 
Fixation solution: 30 % (v/v) Methanol 
   60 % (v/v) dd H2O 
   10 % (v/v) Acetic acid 
After gel electrophoresis, the proteins were immobilized by incubating the gel in 
fixation buffer on a horizontal shaker for 30 min. Two sheets of Whatman paper were 
soaked with dd H2O and the gel was put on top of the Whatman papers and covered 
with cling film. The gel was dried on a vacuum gel dryer for 1-1.5 h at 70 °C and later 
analyzed by autoradiography with 35S-Methionine sensitive MR-films (Kodak) in a 
light tight film cassette. 
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5.10 Cell culture methods 
5.10.1 Cultivation of adherent cells 
Culture medium for COS-7, HeLa, and HEK 293 cells: 
DMEM (4500 mg/l Glucose; 0.11 g/l Sodium pyruvate)  
1 % Penicillin/Streptomycin (10000 U Penicillin, 10 mg Streptomycin/ml in 
0.9 % NaCl)  
10% FCS 
Culture medium for SH-SY5Y cells: 
50 % MEM (Minimum Essential Medium Eagle) w/o L-Glutamine  
50 % Nutrient Mixture F-12; HAM  
1 % MEM Non-essential amino acid solution (100x stock)  
1 % L-Glutamin-Lösung (200 mM stock) 
1 % Penicillin/Streptomycin (10000 U Penicillin, 10 mg Streptomycin/ml in 0,9 
% NaCl)  
10 % FCS 
For stably transfected cells, Hygromycin B or G418-sulfate was used as appropriate 
at final concentrations of 300 µg/ml (Hygromycin B) or 500 µg/ml (G418). 
The cells were cultivated in 10 cm cell culture dishes (Sarstedt) and passaged with 
Trypsin-EDTA at 90-100 % confluency. If not passaged, cell medium was exchanged 
every 3-5 days. For SH-SY5Y cells, only half of the medium was replaced 3 days. 
For passaging, cells were washed with sterile 1x PBS once, and trypsinized with 
1.5 ml of Trypsin-EDTA for 3-5 min at 37 °C. The detached cells were resuspended 
in 4.5 ml fresh growth medium until a single cell suspension was present. Aliquots 
(1/20-1/3) of the resuspended cells were plated in dishes containing 10 ml fresh 
medium and equally distributed with gentle shaking. Cells were cultivated at 37 °C 
and 5 % CO2. 
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5.10.2 Cultivation of semi-adherent Schneider (S2) cells 
Culture Medium for Schneider (S2) cells: 
Schneider´s Medium (Invitrogen) 
1 % Penicillin/Streptomycin (10000 U Penicillin, 10 mg Streptomycin/ml in 
0.9 % NaCl)  
10 % FCS 
The cells were cultivated in T-75 cell culture flasks (Costar) with 20 ml growth 
medium. S2 cells stayed adherent until 80-90 % confluency was reached, after which 
they detached and proliferated in suspension. At this time point, cells were passaged 
by resuspending until a single cell suspension was present. An aliquot (1/40-1/20) of 
the resuspended cells was transferred into a new flask containing 20 ml fresh 
medium, and equally distributed with gentle shaking. Cells were cultivated at 25 °C 
under a normal atmosphere. 
5.10.3 Freezing of cells for long term storage 
Freezing medium: 10 % (v/v) DMSO in growth medium with 20 % FCS and w/o 
antibiotics 
Cells at 70-90 % confluency were used for freezing. Cells from a 10 cm dish were 
trypsinized as described and transferred into 15 ml tubes with 10 ml of fresh medium. 
The cells were sedimented at 300x g for 5 min and resuspended in 3-4.5 ml freezing 
medium. 1.5 ml aliquots were transferred into cryovials (Nunc), and incubated on ice 
for 1-1.5 h. The vials were then stored at -80 °C over night, and then transferred into 
a liquid nitrogen tank for long term storage.  
Alternatively, vials were directly incubated in a cryobox (Nunc) containing 
Isopropanol at -80 °C over night, and afterwards transferred into a liquid nitrogen 
tank as well. 
5.10.4 Thawing of frozen cells 
Cells frozen in liquid nitrogen were quickly thawed at 37 °C in a water bath. Cells 
were then transferred into a 10 cm dish with 10 ml fresh growth medium and equally 
distributed with gentle shaking. The medium was replaced the next day to remove 
residual DMSO.  
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Alternatively, thawed cells were transferred into 15 ml tubes with 10 ml of fresh 
medium and centrifuged at 300x g for 5 min. The cells were resuspended in 5 ml 
normal growth medium, and transferred to 10 cm culture dishes with 10 ml of fresh 
growth medium. Cells were further cultured as described. 
5.10.5 Transfection of adherent cells with the Ca3(PO4)2 method 
2 x HBS:  50 mM HEPES pH 7.12-7.13 
280 mM NaCl 
1.5 mM Na2HPO4 
10 mM Tris/HCl pH 7.5 
2 M CaCl2 
Glycerol/HBS: 30 % Glycerol : 2 x HBS = 1:1 
DMEM 
A typical reagent was prepared as follows: 
5 µg DNA 
62 µl 2 M CaCl2 
ad 440 µl Tris/HCl pH 7.5 
In a 15 ml tube, 500 µl 2 x HBS were permanently vortexed at half maximum speed 
and the prepared DNA/Tris/CaCl2 solution was added dropwise. The mixture was 
added dropwise to cells at 70-80 % confluency (6 cm dish, 2 ml growth medium) and 
incubated for 3 h at 37 °C and 5 % CO2. The medium was completely removed, and 
1.5 ml Glycerol/HBS was added for 140 s to facilitate DNA uptake. The cells were 
washed with DMEM twice, and supplemented with 4 ml normal growth medium. Cells 
were cultivated for 24-48 h at 37 °C and 5 % CO2 and then harvested for further 
analysis.  
5.10.6 Transfection of SH-SY5Y cells with Lipofectamine Plus 
OptiMEM (Invitrogen) 
Lipofectamine (Invitrogen) 
Plus-reagent (Invitrogen) 
In an Eppendorf tube, 5 µg DNA were mixed with 750 µl OptiMEM and 20 µl Plus –
reagent. After 15 min incubation, 30 µl Lipofectamine in 750 µl OptiMEM were added, 
inverted several times, and incubated for 15 min. A 10 cm dish with SH-SY5Y cells at 
70-80 % confluency was washed with 1x PBS twice and 5 ml OptiMEM were added. 
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The Lipofectamine/DNA mixture was added dropwise to the cells and incubated for 
3 h at 37 °C and 5 % CO2. Afterwards, 5 ml OptiMEM and FCS to a final 
concentration of 10 % were added. The next day, appropriate growth medium 
containing either 500 µg/ml G418 or 250 µg/ml Hygromycin, depending on the 
transfected plasmid, was added to select transfected cells for stable expression. The 
cells were further cultivated as described. 
5.10.7 Transfection of COS-7 and HeLa cells with Lipofectamine Plus 
OptiMEM (Invitrogen) 
Lipofectamine Plus (Invitrogen) 
FCS 
Generally, 6 cm dishes with cells at 80-90 % confluency were transfected. 
In an Eppendorf tube, 2 µg DNA were mixed with 250 µl OptiMEM and 15 µl Plus 
reagent. After 15 min incubation, 5 µl Lipofectamine in 250 µl OptiMEM were added, 
inverted several times, and incubated for 15 min.  
Cells were washed with OptiMEM once and 2 ml OptiMEM were added. The 
Lipofectamine/DNA mixture was added dropwise to the cells and incubated for 3-4 h 
at 37 °C and 5 % CO2. Afterwards, the reagent was removed and fresh normal 
growth serum was added. After 24 h, the cells were either harvested for analysis or 
passaged and selected for stable expression. For this purpose, the growth medium 
was supplemented either with 500 µg/ml G418 or 250 µg/ml Hygromycin, depending 
on the transfected plasmid. The cells were further cultivated as described. 
5.10.8 Transient transfection of Schneider cells with Effectene 
S2 cells were plated in 12 well dishes at 30-50 % confluency the day before 
transfection. 2-3 h before transfection, the growth medium was replaced with 800 µl 
fresh medium, and cells were double transfected with Effectene (Qiagen) according 
to the manufacturer´s protocol as follows: 
0.5 µg pMT-Gal4 
0.5 µg pUAST-DNA 
ad 100 µl Enhancer buffer 
8 µl Enhancer 
The mixture was vortexed for 1 s and incubated for 3-5 min at room temperature. 
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Effectene (12.5 µl) was added by pippeting up and down five times and incubated for 
10 min at room temperature. Afterwards, 290 µl S2 growth medium were added by 
pippeting up and down twice. The mixture was directly added dropwise to the cells 
and incubated for 48 h at 25 °C. Expression was induced by adding CuSO4 (0.5 M 
stock in dd H2O) to a final concentration of 500 µM. Cells were generally analyzed 
16h later. 
5.10.9 APP medium secretion in Schneider cells  
S2-cells were transiently cotransfected with pMT-Gal4 and the corresponding pUAST 
constructs using Effectene as described. Expression was induced with 500 µM 
CuSO4 48h post-transfection for 16h. The cells were carefully washed with 1x PBS 
once and 2 ml fresh growth medium were added and conditioned for 3 h. The 
medium was cleared from cell debris by centrifugation at 15.000x g for 10 min. sAPP 
was immunoprecipitated  from 1 ml medium aliquots with 22734 (5 µl) and Protein A 
sepharose over night at 4 °C. The cells were directly lysed in 50 µl 2x SDS sample 
buffer supplemented with Benzonase (Merck) and denatured at 95 °C for 5 min. 
Medium-IP and cell lysates samples were analyzed by SDS-PAGE and 
immunoblotted with 22C11 against APP. All APP secretion deficient mutant 
constructs were analyzed in comparison to APP wt at least three times. Films were 
digitized and signals were quantified densitometrically using Image Gauge (Fuji 
Systems). Relative ratios of sAPP to cellular APP were calculated for all tested 
constructs. 
5.10.10 Schneider cell aggregation assay 
S2-cells were transiently cotransfected with pMT-Gal4 and the corresponding pUAST 
construct using Effectene as described. Expression was induced with 500 µM CuSO4 
48h post-transfection for 16h. In all experiments, comparable transfection efficiencies 
of about 20% for all analyzed constructs were achieved. For analysis of homotypic 
interactions, 4x105 cells in single cell suspension were aggregated in a 24-well for 2 h 
at 80 rpm on a horizontal shaker. For heterotypic aggregation, two separately 
transfected pools of Schneider cells were mixed (2x105 cells each) as single cell 
suspensions and aggregated accordingly. Afterwards, cells were transferred to poly-
L-Lysine coated cover slips and fixed in 4% Paraformaldehyde/PBS for 10 min. Cells 
were blocked with 5% normal goat serum in PBS for 1h and stained over night at 
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4 °C with antibodies against APPL/APPLsd (αAPPLnt), SPA4CT (2213), APP 
(40090), APP-D8 (anti-myc), APLP1 (anti-myc JAC6), or APLP2 (CT-12), 
respectively. For double labeling in heterotypic aggregation experiments, following 
antibody combinations were used: SPA4CT/APLP1 (2213/JAC6), APP/APLP1 
(40090/JAC6), APPmyc/APLP2 (JAC6/CT-12), and APLP1/APLP2 (JAC6/CT-12). 
Appropriate fluorescent secondary antibodies were incubated for 1h at room 
temperature and cells were afterwards embedded in Mowiol. For quantification of 
aggregated cells, clusters of three or more transfected cells were scored as positive. 
For heterotypic aggregation experiments, transfected cells with direct heterophilic cell 
contact were scored as positive. In total, 600-1.000 transfected cells from at least 
three independent experiments were counted for each experimental setup. Statistical 
significance of all quantified experiments was tested with an U-test for n<10. p<0.05 
was designated as significant, p<0.001 as highly significant. 
5.10.11 Immunocytochemistry of COS-7 cells 
COS-7 cells expressing myc-tagged APLP1 or APLP1∆NPTY were grown on cover 
slips and fixed with 4% Paraformaldehyde in 1x PBS for 10-30 min. Cells were 
permeabilized in 1x PBS + 0.1% Triton X-100 for 15 min and blocked with 5% normal 
goat serum in 1x PBS for 1 h. Incubation with a rat anti-myc (1:100, JAC6, Serrotec) 
and rabbit 150 (1:100) antibodies against the juxtamembrane region of APLP1 
followed over night at 4 °C. The next day, cells were incubated with the appropriate 
goat secondary antibodies coupled to Alexa 488 and Alexa 594 fluorescent dyes 
(Molecular Probes) for 1 h at room temperature, and mounted in Mowiol. Omission of 
primary antibodies was used as a control to verify specificity and showed only very 
low background staining. Embedded cells were examined on a Leica laser scanning 
confocal microscope with a 63x water immersion objective. 
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5.11 Drosophila strains and handling 
Standard fly food: 10 l Water  
80 g Agar 
180 g Dry yeast 
100 g Soy-flour 
220 g Honey 
800 g Cornmeal 
24 g Nipagin (Methyl-4-hydroxybenzoate, Merck) 
62.5 ml propionic acid (Sigma) 
Fly stocks were raised on standard fly food and maintained at 25°C with 60-70% 
relative humidity, except when stated otherwise. Embryos of the strain w1118 were 
used for generating transgenic lines. 
5.11.1 Fly stocks 
Line Genotype/Insert Reference 
Apterous-Gal4 Y1 w1118;P{w+mW.hs=GawB}apmd544/CyO (Milan et al. 2001) 
Glass-Gal4 P{w+mCScer\GAL4[GMR.PF]===GAL4
-ninaE.GMR} 
(Ye et al. 1999) 
Engrailed-Gal4 P{en2.4-GAL4}e16E (Ye et al. 1999) 
Distalless-Gal4 P{w+mW.hs=GawB}Dll.MD23 (Baena-Lopez et al. 
2003) 
hs-Flip P{Scer\FLP1[hs.PG].ry+t7.2===hsFLP} (Golic et al. 1989) 
Ay-Gal4 P{w+mC Scer\GAL4[Scer\FRT.Act5C],   
  <==FRT Hsp70AbpolyA,     y+t7.7 
<==FRT===AyGAL4} 
(Goto et al. 1999) 
Vg-Gal4 P{vg-GAL4.B} (Huang et al. 2000) 
Ap-LacZ P{lacZ-un4}aprK568, (Cohen et al. 1992) 
Wingless-LacZ Inserterted on the CyO chromosome obtained from G. 
Merdes 
UAS-GFP P{UAS-EGFP} (Weihe et al. 2001) 
Vestigial(In2.1)-LacZ P{w+mC Ecol\lacZ[vg.int2.1] 
===vg(D/V)-lacZ} 
(Ye et al. 1999) 
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5.11.2 Transformation of w1118 with pUAST constructs 
Injection buffer: 5 mM KCl 
   0.1 NaH2PO4 pH 6.8 
Bleach solution: 14 % (v/v) HOCl (Roth) in dd H2O 
agar plates:  500 ml dd H2O 
   13 g Bacto agar 
   2-3 ml propionic acid 
Transgenic flies carrying the gene of interest were generated by P-element mediated 
germ line transformation (Rubin et al. 1982; Spradling et al. 1982). The appropriate 
pUAST constructs (300 ng/µl) and helper DNA pUChs∆2-3 (75 ng/µl), dissolved in 
injection buffer, were coinjected into the treated w1118 embryos. Adult w1118 flies were 
allowed to lay eggs for 20-30 min at 25 °C. The embryos were recovered, 
dechorionized with bleach solution for 2 min, and then extensively washed with 
water. About 70-100 embryos were arranged and lined on an agar stripe and 
transferred onto a double-sided sticky tape (3M) mounted on a coverslip. The 
embryos were dehydrated in a closed chamber containing Silica gel for 7-8 minutes, 
and covered with Voltalef 10S oil (Lehmann & Voss & Co.). The appropriate pUAST 
constructs (300 ng/µl) and helper DNA pUChs∆2-3 (75 ng/µl), dissolved in injection 
buffer, were coinjected into the treated w1118 embryos. Microinjection was performed 
using an Eppendorf FemtoJet microinjector, with a Femtotip needle (Eppendorf) and 
200-300 hPa injection pressure. Larvae from injected embryos were transferred onto 
standard fly food and allowed to hatch. The founder generation flies were crossed to 
w1118 virgins or males and progenies were then screened for pigmented eyes. 
Positive transformed flies were backcrossed to w1118 flies twice and stable 
homozygous lines were established. Chromosomal integration of the transgene was 
mapped. At least 5 different independent transformants per construct were kept as 
stocks. 
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5.11.3 Generated transgenic fly lines 
Transgenic lines were kept at at 25°C with 60-70% relative humidity. 
 
Line Comment 
UAS-APP-Y687A  
UAS-APP-N684A  
UAS-APP-Y682A  
UAS-APP∆BASS nt myc  
UAS-APP∆G0 nt myc  
UAS-APP∆PEER nt myc  
UAS-APP-NPTY nt myc  
UAS-APP-BASS∆CT nt myc  
UAS-APP∆CT-GFP nt myc  
UAS-APP∆F616 nt myc  
UAS-APP∆S622 nt myc  
UAS-APP-M596I/F615P nt myc 
UAS-APPsd nt myc 
Lines established by G. Merdes 
UAS-APLP1 (human) 
UAS-APLP1∆NPTY (human) 
UAS-APLP2 (human) 
 
Lines established by A. Löwer 
UAS-Disabled-1 (murine)  
UAS-Fe65 (human)  
UAS-Dps-DADA Drosophila Presenilin with exchange of the critical Aspartates to Alanine 
5.11.4 Preparation of fly heads for Western blot analysis 
Freshly hatched, adult flies were collected in an Eppendorf tube and frozen in liquid 
nitrogen. Fly heads were separated from the cell body by flipping the tube several 
times, and heads were transferred into a new Eppendorf tube. Fly heads were 
homgenized with a micropestle (Eppendorf) in 50-100 µl 1x SDS sample buffer 
supplemented with Benzonase (Merck) and denatured at 95 °C for 10 min. 
5.11.5 Dissection and immunostaining of imaginal discs 
Dissection was done in PBS. Using foreceps, the larvae were cut in two parts by 
pulling out from the middle of the body. The cuticle of the larvae was inverted “inside-
out” along the forceps by keeping on holding the head. Salivary glands and the fat 
tissue were carefully removed, and the preserved imaginal discs stuck to the cuticle 
were fixed in PBS/3 %PFA for 30 min. Afterwards, cuticles were rinsed twice in 
1x PBS and washed in 1x PBS for 5 min. The preparations were then incubated 
three times in 1x PBS containing 0.3 %Triton X-100 and 5 % BSA for 10 min. 
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Incubation with the primary antibodies at the appropriate concentration in 1x PBS 
containing 0.3 %Triton X-100 and 5 % BSA, followed overnight at 4°C, in a 
humidified chamber on a horizontal shaker. The next day, cuticles were rinsed twice 
in 1x PBS/0.1 % Triton X-100, and incubated three times in PBS containing 
0.3 %Triton X-100 and 5 % BSA for 15 min each. Afterwards, appropriate fluorescent 
secondary antibodies in 1x PBS containing 0.3 %Triton X-100, 1 % BSA, and 2% 
goat serum were incubated for 1 h at room temperature on a horizontal shaker. The 
preparation was rinsed twice in 1x PBS/0.1 % Triton X-100, and then washed three 
times in 1x PBS/0.1 % Triton X-100 for 15 min each. The cuticles were rinsed in 
1x PBS, and imaginal discs were completely separated from the cuticles and 
tracheae with needles, on a slide containing a drop of 1x PBS. Cuticles and not 
required discs were removed from the slide and imaginal discs were mounted with 
Mowiol on a cover slip. Immunostained imaginal wing discs were analyzed by 
confocal microscopy (Leica) and average projections of z-stacks were used to depict 
the whole imaginal disc. 
5.11.6 Immunostaining of extracellular Wingless 
Staining of extracellular Wingless was essentially performed as described (Strigini et 
al. 2000). Larvae were dissected in ice-cold Schneider’s M3 medium (Sigma) and 
incubated with the Wingless antibody (1:10 dilution) for 60 min on ice. Larvae were 
then rinsed three times with ice-cold PBS/3 %PFA for 30 min. Subsequent 
processing was the same as for the conventional antibody labeling. 
5.11.7 Gain of function clones of APLP2 with the Flp/FRT system 
Mosaic expression of APLP2 in wing discs was used to analyze if APLP2 expression 
at the dorsal-ventral boundary inhibits its formation and thus Notch signaling at later 
time points.  
The FLP/FRT-recombination system allows statistical production of “gain of function” 
clones in a wild type environment (Struhl et al. 1993; Duffy et al. 1998). In addition, 
GFP was expressed as a clonal marker. A line carrying UAS-APLP2 and heat shock 
inducible Flp-Recombinase (hs-Flp) 


 −−
y
Flp;APLP2UAS hs  (kindly obtained from A. 
Löwer), was crossed to ay-G4 


 >><<−
GFP-CyO
FRTGal4ac  containing an actin 5a-Gal4-
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FRT module. Flies were allowed to lay eggs for 12h at 25 °C. Expression of Flip was 
induced 24 h after egg deposition by a 90 min heat shock at 37 °C, leading to 
statistical excision of the FRT element by Flp induced homologous recombination, 
thus generating APLP2 expressing clones. Third instar larvae were collected and 
checked for GFP expressing clones under a fluorescence stereoscope (Leica). 
Imaginal discs of positive larvae were dissected and stained with αCut and αAPLP2 
(CT-12) antibodies.  
For analyzing, if APLP2 competes with Notch for γ-Secretase processing, mosaic 
coexpression of APLP2 and S2-precleaved Notch (NS2), or the Notch intracellular 
domain (NID), was used. Lines carrying ay-Gal and UAS-NS2 or UAS-NID (kindly 
obtained from A. Löwer), were crossed to the UAS-APLP2; hs-Flp line 





 −−
y
Flp;APLP2UAS hs X 




 ><−
TM3
N-UAS;
GFP-CyO
FRTGal4 S2/IDac  or hs-Flp only. Flies 
were allowed to lay eggs for 12h at 25 °C, and expression of Flip was induced 48 h 
after egg deposition by a 90 min heat shock at 37 °C. Third instar larvae were 
collected and checked for GFP expressing clones under a fluorescence stereoscope 
(Leica). Imaginal discs of positive larvae were again dissected and stained with αCut 
and αAPLP2 (CT-12) antibodies. 
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 pUAST nt-myc APP  
    APP∆BASS  
APP∆G0  
  APP∆PEER  
  APP∆NPTY 
  APP-V614G  
APP-F614P  
APP-M596I/V614G/F614P  
APP-V614G/F614P 
APP-M596I/V614G 
APP-M596I/ F614P  
APP-D8 
APP  
nt myc 
 Appendix: plasmid maps 
 
 
 
pUAST  APP-Y687A 
   APP-N684A 
APP-Y682A 
APP 
 Appendix: plasmid maps 
 
 
pUAST  APP-BASS∆CT nt myc 
 
APP-BASS∆CT 
nt myc 
 Appendix: plasmid maps 
 
 
 
APP ∆CT-GFP  
nt myc 
pUAST  APP∆CT-GFP nt myc 
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APP∆F616  
nt myc 
pUAST  APP∆F616 nt myc 
 APP∆S622 nt myc 
 Appendix: plasmid maps 
 
 
 
 
APPsd  
nt myc 
pUAST  APPsd nt myc 
  
 Appendix: plasmid maps 
 
 
 
pUAST  APLP1 ct myc
 
APLP1  
ct myc 
 Appendix: plasmid maps 
 
 
 
pUAST APLP2 
 
APLP2  
 
 Appendix: plasmid maps 
 
 
 
APPL 
pUAST  APPL 
 APPLsd 
 Appendix: plasmid maps 
 
 
 
 pCEP nt-myc APP  
    APP-Y687A 
    APP-N684A 
APP-Y682A 
APP∆BASS  
APP∆G0  
  APP∆PEER  
  APP∆NPTY 
  APP-BASS∆CT 
  APP∆CT-GFP 
APP-V614G  
APP-F614P  
APP-M596I/V614G/F614P  
APP-V614G/F614P 
APP-M596I/V614G 
APP-M596I/ F614P  
APP-D8 
APPsd 
APP  
nt myc 
 Appendix: plasmid maps 
 
 
 
APLP1 
nt myc 
pCDNA 3.1 APLP1 nt myc 
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APLP1∆NPTY 
nt myc 
pCEP APLP1∆NPTY nt myc 
 Appendix: plasmid maps 
 
 
 
APPID 
pGEX-4T2 APPIDwt 
 Y687A 
   N684A 
Y682A 
∆BASS  
∆G0  
 ∆PEER  
∆NPTY 
 
    
GST 
 Appendix: plasmid maps 
 
 
 
hNumb 
pCDNA 3.1 hNumb 
 
 Appendix: plasmid maps 
 
 
 
hDab2 
pCDNA 3.1 hDab2
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